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Abstract 
Transcription factors play multiple and important roles during embryonic 
development. The Pax gene family have been shown to be essential in these 
processes, and mutations which abrogate their function disrupt the development of a 
range of embryonic tissues. One member of this family, Pax3, is characterised by a 
semidominant mutant phenotype and is involved in the proper formation of the brain, 
central and peripheral nervous system, hypaxial musculature, and cardiac outflow 
vessels. Pax3 is a transcription factor and its biological role involves the binding of 
specific sequences in genomic DNA to regulate the expression of a set of target genes. 
Defects observed in animals harbouring a mutation in Pax3 are assumed to arise from 
the misregulation of the transcriptional targets of this gene. 
In dissecting the precise biological function of Pax3, it is important to differentiate 
between primary and secondary phenotypes in the mutant animal; specifically, 
between defects caused by the direct misregulation of Pax3 targets and those 
generated by the compounded knock -on effects of a dysfunctional master -regulator 
such as Pax3. A simple comparison of expression profiles between wild type and 
mutant animals, using microarray or differential display based methodologies, would 
not achieve this aim. To date, no attempt to perform a comprehensive screen for direct 
Pax3 targets in development has been performed. 
This thesis presents a development of the tools necessary to perform the task of 
identifying direct targets of Pax3 in vivo. Firstly, two candidate genes for direct Pax3 
regulation are considered, Wntl and Pax7. These candidates are implicated from 
previous work on Pax3 although no direct transcriptional link has ever been 
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established. Firstly, differences in the expression of these genes between the Pax3 
mutant and wild type embryos is quantitatively analysed. In the case of Pax7, little 
work had been performed to identify the regulatory elements controlling its 
expression in the mouse. Described here is a series of experiments mapping the 5' end 
of the transcript, the delineation of a putative promoter region and the identification 
and cloning of a highly conserved enhancer element within the first intron. The Wntl 
regulatory elements have been well described elsewhere. A series of experiments are 
then performed to confirm the interaction between these regulatory regions and Pax3 
and the identification and testing of specific Pax3 binding sites is reported. 
To confirm these interactions in vivo, chromatin immunoprecipitation, using a novel 
mono -specific anti -Pax3 antibody designed for the purposes of this thesis, is used. 
This technique, having been verified on these two direct Pax3 targets in this way, 
could then be used to screen for novel direct targets of Pax3 regulation in vivo and in 
the wild type; expanding our understanding of the pathways and developmental 
function of this gene in future. 
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Chapter One: Introduction 
The transcription factor Pax3 is involved in a range of developmental and 
pathological processes, ranging from the patterning and specification of the central 
nervous system to the progression of cancer (Chi and Epstein, 2002). In animal 
models where the function of the Pax3 gene has been ablated or modified, a number 
of interesting phenotypes have been observed. These include neural tube closure 
defects, which are similar to the condition spina bifida in humans, severe brain 
defects, such as anencephaly and exencephaly, problems in a range of tissues which 
are normally populated by a migratory population of stem cells originating from the 
embryonic spinal cord known as the neural crest (in humans these defects are 
categorised under the umbrella term neurocristopathies) and defects in the proper 
septation and morphology of the heart. In humans the condition Waardenburg's 
Syndrome has been attributed to mutations in Pax3 (Epstein, 1996). Patients suffering 
from this congenital disorder have a heterozygous mutation in the Pax3 gene (only 
one Pax3 homozygous mutant human has been reported at term (Zlogotara, 1995)) 
and exhibit characteristic pigmentation defects (including a white forelock 
reminiscent of the white belly spot found on Pax3 heterozygous mice), deafness, 
craniofacial abnormalities, and even defects in limb musculature. 
Understanding such developmental processes, and using the Pax3 gene as a tool to 
probe these further, should ultimately enable the better understanding and more 
appropriate treatment of a range of diseases in future. 
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The Pax3 protein acts as a transcription factor, binding to DNA and regulating the 
expression of other genes (Epstein et al., 1991). Whilst much work has been done to 
describe the role Pax3 plays in different developmental processes, relatively few 
direct targets of Pax3 have been established and no comprehensive screen for Pax3 
target genes has been performed. This is important since, without an understanding of 
the direct targets of Pax3, any appreciation of the specific pathways this gene 
modulates is difficult. Furthermore, the interpretation of data obtained from 
manipulations of the Pax3 gene, whether knockouts, overexpressions, or even the use 
of Pax3 as a developmental marker, will be enhanced by a comprehensive 
understanding of the gene's transcriptional function. 
This thesis therefore aims to identify novel targets of direct regulation by Pax3 and 
defines the specific elements through which Pax3 is acting. These targets are then 
confirmed in vivo through the optimisation of a technique which can then be used as a 
tool for performing a more comprehensive screen for Pax3 target genes in future. 
Pax3 Biochemistry 
The paired DNA binding domain is found in several Drosophila genes, such as 
Paired, gooseberry - proximal /distal (Mansouri, 1996). These are involved in the 
segmentation patterning and development of the embryo. The paired domain is found 
throughout evolution, and represents a highly conserved 128 amino acid motif that 
forms a helix- turn -helix structure to contact DNA. In vertebrates, the first paired 
domain containing proteins identified were the Pax family. 
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The Pax Gene Family 
Pax genes encode a family of DNA binding proteins. These proteins are expressed in 
a temporally and spatially dynamic manner in the mammalian embryo. The disruption 
or misregulation of these factors has been shown to have serious consequences for the 
process of development and ultimate function of many tissues. Pax genes are 9 in 
number in the mouse and are all thought to bind DNA and act as transcription factors, 
regulating the expression of downstream target genes. These proteins are thought to 
bind to specific sequences in the promoters and enhancers (cis -regulatory sequences) 
of their targets and regulate their expression via the recruitment of either inhibitory or 
activatory transcriptional complexes (for general reviews, see (Chi and Epstein, 2002; 
Epstein, 1996; Mansouri, 1996)). The known roles of the Pax genes in mouse 
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Figure 1.1 : The roles of Pax genes in development, reviewed in (Chi and Epstein, 
2002; Eccles, 2002; Mansouri, 1996). Numbers in roman numerals denote the 
subfamily to which the factor belongs; i.e. Pax1 and Pax9 are within sub family I 
(classification from (JacksonLabs)) 
The Pax genes are divided into subfamilies on the basis of their domain composition, 
as shown in Figure 1.1. Members of the same subfamily have highly conserved DNA 
binding domains, with sequence divergence occurring towards the 3' end of the gene 
(C- terminus of the protein). This implies similar DNA sequence recognition by 
members of the same sub -family and may account for functional redundancy between 
family members in vivo. It is important to note that Pax proteins may also have other 
functions, aside from their roles as transcription factors, which are not highlighted in 
these studies. 
The Pax3 gene and its isoforms 
Pax3 was first identified in 1991 in the mouse and was shown to have a dynamic 
expression pattern during embryogenesis. Clones were isolated from a cDNA library 
using the Paxl paired box as a probe. The Pax3 gene was shown to be expressed from 
the onset of neurulation (E8.5) in the developing CNS (Goulding et al., 1991). This 
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has since been confirmed in several other studies (Bang et al., 1999; Natoli et al., 
1997) and Pax3 is further expressed in the adult hair follicle (Lang, 2005). The Pax3 
gene maps to mouse chromosome 1 (Epstein et al., 1991) and encodes a protein 
product of 479 amino acids (53 KDa). The Pax3 locus spans 95kb (ensembl) in the 
mouse and homologous loci have been identified in humans, Xenopus, Fugu and rat. 
A schematic of the Pax3 protein, highlighting the major domains, is illustrated in 
Figure 1.2. 
The Pax3 locus encodes up to 10 exons (Barber et al., 1999) with transcripts varying 
in length from 900 bp (Tsukamoto et al., 1994) to 3.6 kb (Goulding et al., 1991). Six 
exon splice variants (named PAX3a to Pax3f, respectively) were originally reported 
between human and mice (Barber et al., 1999). A recent study has identified a new 
isoform generated through the use of a novel splice site formed at the junction of 
exons 7 and 8 (Pax3 (48)) in the mouse. This isoform removes part of the 
transactivation site of Pax3 (encoded by exon 8) and has been shown to result in a 
transcriptionally dominant negative protein in vitro (Pritchard, 2003). 
The biological importance of many of these isoforms has yet to be determined 
experimentally. Indeed PAX3a and PAX3b, whilst thought to potentially also encode 
dominant negative forms of Pax3 (Tsukamoto et al., 1994), have yet to be confirmed 
as biologically functional at the protein level or even existant in the mouse. Similarly, 
Pax3e and Pax3f have not been characterised in any 
Figure 1.2: 
Scale drawing of mouse Pax3 protein illustrating 
major domains and features. NT = Amino -terminus, 
CT = Carboxy- terminus 
Paired Domain 








more detail than the sequencing of RTPCR clones (Barber et al., 1999). Pax3c was 
the original full length transcript reported for the mouse by (Goulding et al., 1991). 
Pax3d is identical to Pax3c, but has an extra C- terminal coding exon (exon 9). 
Because no functional difference between Pax3c and Pax3d could be detected, 
(Barber et al., 1999), the major Pax3c isoform has been used throughout this thesis. 
Another major source of transcript variation for this gene is the inclusion or exclusion 
of a glutamine (Q) codon generated by an alternative splicing event at the exon 2 - 
exon 3 junction, see Figure 1.3E (Vogan et al., 1996). All 8 of the Pax3 transcripts 
denoted above also therefore have a Q± status, bringing the total number of splice 
variants to 16 recorded so far. 
The inclusion of a glutamine residue at position 76 in the Pax3 protein was first 
identified by (Vogan et al., 1996). This glutamine residue is positioned between the 
two DNA binding sub - domains of the paired domain, see ( Czerny, 1993). This places 
the splice variation in the C- terminal sub -domain of the Pax3 paired domain in a 
similar position to exon 5a in the Pax6 -5a isoform (shown to be important in 
changing the sequence specificity of Pax6 see (Kozmik, 1997) and below). The 
inclusion of the Pax3 Q residue was shown in vitro to mediate changes in binding 
affinity of the paired domain to artificial consensus sites (the Q- isoform binding with 
around 5 times greater affinity to specific sequences as the Q +). In vivo the Q+ 
isoform is by far the most abundant of the isoforms (Vogan et al., 1996) and no 




Genomic Pax3 locus, from www.ensembl.org. 
A) Pax3 in context of mouse chromosome 1 
B) expanded contig view 
C) exon / intron schematic 
D) protein domain structure of transcript 
E) illustration of Q± alternative splicing between exon 2 
and exon 3 in Pax3. Blue = exon sequence, green = splice 
donor / acceptor sites, red = glutamate codon, arrows = 
alternative splice acceptor sites 
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studies have revealed that, when selected for using in vitro Selex* based 
methodologies, Pax3Q+ and Pax3Q- may also have affinities for slightly different 
sequences (Vogan and Gros, 1997). 
It is plausible that the two isoforms are generated by stochastic splicing events in the 
cell due to the existence of similarly high affinity splice acceptor sites. Since both 
isoforms do recognise identical sequences, it is possible that the difference generates 
such a minor change in functionality (and target sequence specificity (Vogan and 
Gros, 1997; Vogan et al., 1996)) that evolution has not selected for one or the other 
isoform and hence both are observed. This view may be supported by the fact that, to 
date, no differences in transcriptional targets have been observed for these isoforms in 
vivo. In this thesis the most abundant, Q +, isoform has been used for all experiments. 
The Pax3 Protein 
The Pax3 protein has been studied extensively and its functional domains mapped in 
detail. The N- terminus of the protein holds the paired and homeodomain, separated by 
an octapeptide motif, and the transactivating domain is found towards the C- terminal 
end of the protein (Figure 1.2). The functional significance of the conserved 
octapeptide motif is unclear, in spite of its presence in most Pax family proteins (with 
the exception of Pax4 /6). 
* Selex is an in vitro method for selecting oligonucleotides which bind to a protein 
with high affinity using several rounds of PCR amplification 
1? 
One group (Ziman and Kay, 1998) has proposed that this region is of regulatory 
importance at the DNA level, and that the octapeptide motif is in fact a site directing 
methyltransferase activity to regulate the transcription of Pax3 (i.e. DNA sequence is 
conserved over codon use between species). In Pax5, however, the octapeptide has 
been shown to interact with the Groucho family of co- repressors (Chi and Epstein, 
2002) and Ets co- regulators (Wheat, 1999). Similarly the ability of Pax3 to interact 
with the hDaxx repressor protein has been shown to be partially compromised on 
deletion of an N- terminally extended octapeptide domain (Hollenbach et al., 1999). 
The functional significance of this in vivo was not investigated by this group, 
however. 
The binding by the N terminal domains of the protein to specific sequences in 
genomic DNA during development is thought to represent the core biochemical 
function of the Pax3 protein *. Structural studies on the related human Pax6 and 
Drosophila paired proteins indicate a common mechanism for DNA interaction by 
this domain family (Xu, 1995; Xu, 1999). Much work has been done in vitro to 
dissect the precise components of these domains and how they interact with one 
another. It is generally accepted that, in Pax3, the paired domain imparts much of the 
sequence specificity of the protein and indeed plays an important role in modulating 
the DNA binding affinity of the homeodomain and its ability to dimerise on 
palindromic DNA sequences (Fortin et al., 1998; Underhill, 1997). This finding is 
reinforced by the Splotch delayed (Sp") mutant, a missense Pax3 mutant harbouring a 
* Interestingly, the regulation of p53 by Pax3 may be post- transcriptional since 
differences in p53 protein and not mRNA can be observed between a Sp2H -I- and 
wild type background, see Pani, L., Horal, M. and Loeken, M. R. (2002). Rescue of 
neural tube defects in Pax -3- deficient embryos by p53 loss of function: implications 
for Pax -3- dependent development and tumorigenesis. Genes Dev 16, 676 -80. 
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glycine to alanine substitution within position 9 of the paired domain. This mutation 
abrogates DNA binding by both domains and confers a null phenotype in vivo. 
Therefore, correct DNA - paired domain interactions are essential for the proper 
selection of Pax3 targets during development. 
The role of the homeodomain of Pax3 in binding DNA is also complex. (Underhill, 
1997) demonstrate that the paired domain of Pax3 affects the sequence specificity of 
the homeodomain and the spacing of the ATTA palindromic recognition sequence for 
this part of the protein. Spacing between the homeodomain and paired domain 
recognition sequences has been shown to affect the DNA binding affinity of the Pax3 
protein (Phelan and Loeken, 1998). The DNA binding of the paired and 
homeodomain are also reciprocally related, and abrogation of DNA binding in one 
can lead to loss of DNA binding in both (Apuzzo, 2004; Apuzzo and Gros, 2002). 
The paired and homeodomain of Pax3 are therefore considered functionally 
interdependent. 
The C- terminal portion of the Pax3 protein is responsible for the transactivatory 
functions (Chalepakis et al., 1994) and is not thought to be directly involved in DNA 
binding. The postulated role for this part of the protein in mediating transactivation of 
target genes has been borne out by functional dissections of the Pax3 protein in vitro 
(Chalepakis et al., 1994). Pax3 has clearly been shown to be able to up- regulate as 
well as down -regulate target genes, presumably depending on the transcriptional 
context within a particular cell type and target locus. Examples of Pax3 having both 
transactivatory and transrepressive functions in vitro (Chalepakis et al., 1994; Lang, 
2005) and in vivo (Kwang et al., 2002; Lang and Epstein, 2003) can be found in the 
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literature. The C terminal domain of Pax3 has also been shown to modulate the 
binding activity of the N terminal domains of the protein (Cao and Wang, 2000). This 
is supported by the in vivo observation that the Pax3 protein, and the Pax3 -FKHR 
fusion oncogene product (generated by a chromosomal translocation mutation 
common in alveolar rabdomyosarcoma (Lam et al., 1999) replacing the Pax3 C- 
terminus with the transactivation domain of one of the forkhead family of 
transcription factors) have the potential to transactivate different target genes in spite 
of their identical DNA binding protein domains (Barber et al., 2002; Begum, 2005; 
Du, 2005). The phenomenon of long -range structural alterations affecting the 
functionality of transcription factors has also been observed in a completely 
heterogenous context; the glucocorticoid nuclear receptors undergo similar long -range 
conformational changes on DNA binding (Pearce, 1998; van Tilborg, 2000). 
Pax3 Target Sequences 
The root functionality of a transcription factor comes from its ability to bind to cis - 
regulatory sequences of target genes and hence mediate either up- or down- regulation 
of their expression. To understand the role Pax3 plays during vertebrate development, 
it is therefore necessary to identify the target sequences to which it binds. Several 
attempts have been made using in vitro techniques to identify the consensus 
sequences recognised by Pax3. This was first performed by Chalepakis et al 
(Chalepakis and Gruss, 1995) using a PCR selection based Selex analysis of the Pax3 
paired domain to generate a 13bp consensus sequence. One of the most interesting 
results of this early work was the observation that, with the exception of the four 5' 
nucleotides, the Pax3 consensus sequence obtained was extremely similar to other 
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binding consensus sites derived for Pax2 and Pax6. Furthermore, the sequences of 
previously described high affinity paired domain binding oligo sequences CD 19 -2A 
and PRS9 (from the Drosophila e5 promoter) were conserved to the 3' end of the 
consensus sequence. These data were interpreted as meaning that the 3' end of this 
recognition sequence represented a high affinity Paired domain binding site (hence 
the homology to both other Pax sites and high affinity oligo sequences), and the 5' 
nucleotides may impart the actual sequence specificity to the Pax3 protein. Recent 
software designed to identify transcription factor binding sites (MatInspector) cites 
these first four base pairs as the core binding motif for Pax3. Some published Pax3 
consensus sites are summarised in Figure 1.4. 
This consensus sequence is thought to represent binding of the N- terminal sub - 
domain of the Pax3 protein only. In the Pax6 protein, an alternative splicing event in 
the DNA encoding the paired domain acts a molecular "toggle" to shift binding 
preference from the N to C- terminal sub -domain of the Pax6 paired domain, through 
the inclusion of the 5a exon (Kozmik, 1997). This dramatically alters the sequence 
specificity of the Pax6 protein. The presence of an alternatively spliced glutamine 
residue between the N and C terminal sub -domains of the paired domain in Pax3 
obviously represents an attractive model for a similar post -transcriptional level of 
regulation. Several papers have addressed this in vitro (Vogan and Gros, 1997; Vogan 
et al., 1996) and have obtained target sequences with a higher affinity for one or other 
isoforms. No absolute changes in binding specificity or in vivo target selection has yet 
been identified for these isoforms, however. 
Figure 1.4 : 
Comparison of Pax3 paired domain consensus sites previously 
reported in the literature. Predicted core consensus sites are 






in vitro, Selex 
methodology 
TCGTCACRCHYHA Chalepakis and 
Gruss, 1995 
in vitro, Selex 
methodology 
GTCACGCTT Vogan et al, 
1996 
in vitro, Selex 
methodology 
TCGTCACSCTT -A Vogan and 
Gross, 1997 
in vivo, c -RET 
enhancer 
TGTCACACTGCC Lang and 
Epstein, 2003 
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The above studies enable the identification of putative Pax3 DNA binding sites in 
vivo' via sequence analysis. As pointed out by many authors, however (Wasserman 
and Sandelin, 2004), the presence of a Pax3 consensus does not automatically imply a 
Pax3 responsive site in vivo. Functional studies are always essential to confirm the 
significance of any potential Pax3 binding site. Indeed, (Phelan and Loeken, 1998), 
observed that many of the Pax3 responsive genes confirmed so far actually contain 
low affinity Pax3 consensus sites, and not the high affinity sites identified by in vitro 
methodologies. This suggests that a simple sequence based approach to identifying 
new Pax3 targets may not be appropriate and that a more direct method for 
identifying Pax3 target genes in vivo may be required. 
Pax3 also interacts with other proteins in vivo. These interactions can occur via both 
the paired domain (Hollenbach et al., 2002; Lang and Epstein, 2003; Wheat, 1999) 
and homeodomain (Hollenbach et al., 1999; Stamataki et al., 2001) and can elicit both 
negative and positive transcriptional responses from the target genes in question. Thus 
it is important to appreciate that, whichever sequences the Pax3 protein binds to 
during development, the binding of co- factors and ultimately the recruitment of the 
RNA polymerase machinery is core to the function of this transcription factor. 
Pax3 In Neural Tube and Neural Crest Development 
The induction of neural tube from ectoderm occurs early in the development of the 
mouse and involves a complex array of signals. The formation of the neural tube and 
neural crest cells probably represents one of the earliest events in the evolution of 
vertebrates and therefore a high degree of conservation in the mechanisms and signals 
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used between species is thought to exist (Meuletnans and Bronner- Fraser, 2004). 
After gastrulation, the ectoderm is organised into neuroectodermal and ectodermal 
regions through the action of the Spemann's Organiser (in amphibians) or equivalent 
(the node in mice and chick). These structures secrete neural inducers, such as 
chordin and noggin, which enable the establishment of neural cell fates from non - 
neural ectoderm through the inhibition of the high levels of BMP signalling (LaBonne 
and Bronner- Fraser, 1998; LaBonne and Bronner- Fraser, 1999). Once the 
neuroectoderm has been specified in this manner, the tissue invaginates to form the 
neural fold and ultimately closes completely to generate the neural tube (Figure 1.5). 
It is the interface between neural and non -neural ectoderm which stimulates the 
generation of the neural crest population (Selleck and Bronner- Fraser, 1995). In mice, 
noggin mutants are still able to express many of the dorsal neural tube markers by 
E10.5, and some migratory neural crest cells are still observed (McMahon, 1998), 
implying that other signals must be involved in this process, such as Wnt and FGF 
(Monsoro -Burq, 2003). 
Intermediate levels of BMP signals from the ectoderm are however essential in the 
early stages of this process, and help to induce the expression of Msxl at the neural 
plate boundary (LaBonne and Bronner- Fraser, 1999; Liem, 1997; Monsoro -Burq, 
2004). Msxl and a Wnt8 signal from the underlying non -axial mesoderm (Bang, 1997; 
Bang et al., 1999) then induce Pax3 expression in the lateral edges of the neural plate. 
This is then restricted dorsally by Shh signals from the notochord and floor plate 
(Goulding, 1993) as neural tube closure proceeds, generating a Pax3 expression 
pattern restricted to the dorsal half of the developing neural tube. Another important 
gene, Zicl, is expressed in the dorsal neural tube after induction by BMP4 and BMP7 
Figure 1.5: 
Schematic of neural tube closure and neural crest 
induction highlighting the expression domains of the 
major genes outlined in the text. (Source image taken 













(Pax3, FoxD3, etc) 
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from adjacent ectoderm and is restricted to dorsal neural tube by Shh in a manner 
analogous to Pax3 (Aruga, 2002). The activities of these genes converge to stimulate 
the expression of neural crest markers such as Slug, Snail and Foxd3 which are 
important in establishing the neural crest lineage ( Dottori et al., 2001; Kos, 2001; 
LaBonne and Bronner- Fraser, 1999; Mennerich and Braun, 2001). One interesting 
study has proposed that a major function of Pax3 is the inhibition of p53 mediated 
apoptosis (Pani et al., 2002). This is based on the rescue of neural tube defects on a 
Sp2H -/- p53 -I- double mutant background due to reduced cell death. It is important to 
consider the role of Pax3 as a cell survival signal therefore, in addition to the 
regulation of developmental target genes. 
The precise role of Pax3 in the process of switching on the genes specifying the 
neural crest lineage is still unclear. Whilst Pax3 is genetically upstream of Foxd3 
( Dottori et al., 2001), direct interaction between Pax3 and the regulatory elements of 
Foxd3 has not been shown. Furthermore, the induction of Slug by the combined 
activities of Zici and Pax3 (Monsoro -Burq, 2004) have been shown to be mediated 
by Wnt signalling. These observations are in keeping with those made on Pax3 
chimeras (Mansouri et al., 2001) that, whilst Pax3 null cells cannot be rescued by 
wild type counterparts in somites, a non -cell autonomous role exists for the gene in 
the development of the neural crest. If Pax3 requires a non -cell autonomous signal to 
enable the instruction of downstream target genes involved in neural crest 
development, suitable candidate factors should be considered. 
Wnts are attractive signals to facilitate this role of Pax3. In Xenopus, the induction of 
neural crest cell fates in the dorsal neural tube has been shown to be dependent upon 
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Wntl and Wnt3a, synergising with neuralising factors such as noggin (Saint -Jeannet 
et al., 1997). This activity could not be replaced with Wnt5a or Wnt8, implying that 
the Wnt signal responsible for inducing Pax3 expression and that involved in neural 
crest specification are different (Bang et al., 1999; Saint -Jeannet et al., 1997). 
Similarly in Zebrafish, Wnt signalling has been shown to be essential during neural 
crest induction from underlying mesoderm (Lewis, 2003) (in Xenopus neural crest 
(Bang et al., 1999) this mesodermal signal has been shown to be Wnt8) but this signal 
is distinct from a second Wnt activity, however, which specifies a neural crest 
lineage. Both the "two signal" model of neural crest induction (where the induction of 
neuroectoderm by chordin and noggin requires a second signal to express neural crest 
specific markers (LaBonne and Bronner- Fraser, 1998)) and the "double gradient" 
model (where default anterior neural tissue is patterned combined lateralising and 
posteriorising gradients (Villanueva, 2002)) in Xenopus depend upon canonical Wnt 
signalling. In chick, inhibition of Wnt signalling similarly perturbs the expression of 
neural crest marker genes (Garcia- Castro, 2002). 
Other Wnt genes that are expressed in this tissue at this stage are Wntl and Wnt3a. 
Compound knockouts of these genes (Ikeya et al., 1997) show major defects in their 
neural crest populations and neural crest derived structures but not in the overall 
dorsoventral patterning of the neural tube, suggesting these factors act after the 
establishment of patterning within the neural tube itself. Further experiments 
investigating the expression and function of Wnt receptors in Xenopus neural crest, 
the frizzled protein family, have revealed that the Wntl specific receptor Frz3 is 
necessary for the induction of neural crest in the developing Xenopus embryo in 
association with the Kermit co- receptor (Deardorff, 2001; Tan, 2001). 
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The expression of Wntl and Wnt3a in the Pax3 mutant has been investigated, and 
whilst the expression of Wnt3a did not change, in situ data for Wntl did imply a 
significant downregulation in the neural tube of Sp2H homozygotes (Conway et al., 
2000). Wntl therefore represents an attractive candidate gene for direct regulation by 
Pax3 in this system. 
Wntl and Wntl Regulation 
Much work has been done on Wntl and the regulation of this gene, and will be briefly 
dealt with here (for a comprehensive, review of Wnt biology in this and other systems 
see (Logan, 2004; Miller, 2001)). Wntl was the first of the Wnt genes to be 
discovered, and was originally identified as the site of a mouse mammary tumour 
viral insertion into the 5' and 3' regulatory regions of the gene (Van Ooyen, 1984). 
Later sequence alignments revealed that the gene was the mammalian homologue of 
the Drosophila Wingless (Wg) gene, and the ability of Wntl to transform mammary 
cells when inappropriately expressed led to its categorisation as a proto -oncogene and 
suggested a biological role in proliferation (Dickinson et al., 1994; Nusse et al., 
1990). Knockout strategies (McMahon and Bradley, 1990; Thomas, 1990) revealed an 
essential role for Wntl in the development of midbrain and cerebellar structures. 
Neither of these studies illustrated defects in neural tube development in spite of the 
strong dynamic expression of this gene. Similarly, Wnt3a knockout mice (Takada, 
1994) displayed defects in somitogenesis but not in the neural tube or neural crest 
derivatives. A redundancy in Wnt signalling in the neural tube was therefore 
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postulated and Wntl / Wnt3a double mutant embryos exhibit a severe neural crest 
phenotype (Ikeya et al., 1997). 
If Wntl represents a direct target of Pax3 regulation in the developing embryo, an 
elucidation of the cis -regulatory elements driving the expression of this gene is 
required. Due to the insertion of the provirus into the region 5' proximal to the gene 
causing inappropriate Wntl regulation (Nusse et al., 1990; Van Ooyen, 1984), initial 
analysis of the Xenopus Wntl 5' proximal promoter was performed to delineate a 
functional promoter with luciferase reporter genes (Gao et al., 1994). Attempts in 
mouse to generate LacZ transgenics which recapitulate the expression pattern of Wntl 
using 5' proximal regions of the Wntl genomic locus failed to show a repeatable or 
faithful pattern of expression (J. Mason, unpublished data and (Echelard et al., 1994)). 
In the mouse, a 5.5kb 3' distal element has been shown to direct the expression of 
Wntl in the developing CNS ( Echelard et al., 1994) which was later remarkably 
reduced to a highly conserved 110bp element sufficient for driving expression of a 
reporter in the midbrain and even rescuing the knockout phenotype in this region of 
the Wntl mutant embryo (Rowitch et al., 1998). This 110 bp element does not drive 
expression in the developing neural tube, however. The 3' distal enhancer is generally 
considered the region of major regulatory importance controlling the expression of 
Wntl. 
It should be noted that some studies (Lagutin et al., 2003; St -Arnaud and Moir, 1993) 
have demonstrated the importance of the Wntl promoter in regulating expression of 
the gene in forebrain and RA differentiated P19 cells, respectively. This region of the 
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Wntl locus should not, therefore, be excluded a priori from an investigation into the 
regulation of Wntl expression. 
Pax3 and Cardiac Development 
One of the most interesting phenotypes observed in the Pax3 mutant mouse is the 
presence of a defect in cardiac development, see (Epstein, 1996) and (Creazzo, 1998) 
for a general overview. The cardiac defect in the Splotch mouse was first observed in 
1954 (Auerbach, 1954) and is characterised by failure in the outflow vessels of the 
heart to properly septate and position over the chambers of the heart. This typically 
leads to anatomical conditions of the Persisting Truncus Arteriosus (PTA) family or, 
in less severe examples, Double Outlet Right Ventricle (DORV) (Creazzo, 1998). 
These defects are identical to those observed in avian models of neural crest ablation, 
and specifically in those where the ablation is limited to regions of cranial neural crest 
between mid -otic placode and somite 3 (Van den Hoff, 2000). Similarly, fate mapping 
neural crest cells in the mouse embryo reveals an important role for neural crest 
derivatives in the development of the outflow tracts of the heart (Jiang, 2000) .The 
Splotch alleles have been shown to be mutations of the Pax3 locus (Epstein et al., 
1991) and the nature of the mid- gestational lethality in 51)2H homozygous mice was 
convincingly shown to correlate exactly with the incidence of congenic heart 
malformation (Conway et al., 1997b) and not with the neural tube related phenotypes 
demonstrated by these mutants. The immunolocalisation of the slug protein (a marker 
of neural crest, downstream of Pax3 (Monsoro -Burq, 2004)) in the outflow tracts of 
the avian heart further supports the hypothesis that neural crest are important in the 
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proper development of these tissues since slug represents a downstream marker of 
Pax3 function in avians (Carmona, 2000). 
Much work has been done to characterise the nature of this defect. Transgenic rescue 
of the cardiac malformations in Pax3 mutants using Pax3 driven by a promoter 
specific to the neural tube and not the somites (another major region of Pax3 
expression) (Li et al., 1999) has shown that the cardiac defects observed in these 
animals is due to the expression of Pax3 in ectodermally derived tissues (i.e., the 
neural tube and neural crest). More recent work has precisely labelled the source of 
cardiac neural crest in the mouse to originate from the neural tube opposite somite 
two, and for migration to occur from the seven somite stage (- E9.5). The route of 
migration of these cells is through pharyngeal arches 3, 4 and 6 and into the 
developing heart (Chan et al., 2004). In the Sp2H mutant, the number of these cells 
migrating to the heart and ultimately present in the developing outflow tract (and 
other neural crest populated structures such as the dorsal root ganglia) is defective 
(Conway et al., 1997b). Contrasting studies have been performed to assess whether 
the lack of cardiac neural crest cells reaching the outflow tract of the heart is due to 
defects in the migratory competence of these cells (Conway et al., 1997a; Epstein et 
al., 2000) or their proliferative ability (Conway et al., 2000). Reciprocal grafts of 
cardiac neural crest cells between wild type and Sp2H -I- tissues (Chan et al., 2004) 
have clearly demonstrated that a mutation in Pax3 affects both the migrating cells 
themselves and their ability to navigate in their environment. This finding is in 
keeping with earlier work (Mansouri et al., 2001) which found that, whilst Pax3 
function seemed to be cell autonomous in the neural tube and somites, its role in 
neural crest was not. Candidate molecules mediating this defect in cell - cell 
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communication in Pax3 mutants include integrins (Bajanca and Thorsteinsdottir, 
2002), NCAM (Glogarova and Buckiova, 2004), and versican (Henderson et al., 
1997). Given the number of genes the overexpression of Pax3 in a cell line can alter 
(almost 300 (Mayanil et al., 2001)), and the range of phenotypes exhibited by Sp211 -/- 
mice, a complexity of cell autonomy phenotype of this nature is not necessarily 
surprising. 
Could one of the non -cell autonomous features of this defect in Sp2H mice be due to a 
defect in Wntl signalling due to the absence of Pax3? The establishment of Wntl as a 
direct target of Pax3 in vivo would clearly be a significant step towards the resolution 
of this issue. Interestingly, in vitro, the expression of Pax3 in Saoss cells has been 
shown to activate the c- Jun -N- terminal kinase mediated non- canonical Wnt signalling 
cascade (Wiggan and Hamel, 2002), implying that the activation of Wnt signalling in 
response to Pax3 need not be mediated by the canonical (3- catenin pathway alone. 
A further line of evidence suggesting a role for Wnt signalling in the development of 
the outflow tract of the heart has also recently been reported (Clevers, 2002). In these 
studies in the mouse, a mutant component of the Wnt signalling pathway, Dishevelled 
2 (Dvl2), was shown to have an identical phenotype to the 5132H homozygote cardiac 
outflow tract (Hamblet, 2002) with an similar penetrance of - 50 - 60% to that 
previously reported for outflow tract defects in 5132H mice (Conway et al., 1997b). 
These mice also exhibited neural tube and somite defects, again reminiscent of the 
Pax3 mutation. Further analysis of this pathway revealed that the transcription factor 
Pitx2 (Kioussi, 2002) is a target of the Wnt/Dv/2 pathway in cardiac malformations, 
and that this transcription factor mediates its response through the regulation of the 
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G1 growth control genes (Hee Baek, 2003). Two interesting results are reported in the 
findings of this group. Firstly, Pax3 expression appears to be unperturbed in Pitx2 
knockouts, suggesting the cardiac phenotype is not due to an indirect effect of Pax3 
misregulation in these experiments and that Pax3 expression is genetically upstream 
of these defects. Secondly, Wntl and Pitx2 expression co- localise in migrating neural 
crest cells in the 3rd and 4th pharyngeal arches (through which the cardiac neural crest 
migrate (Chan et al., 2004)) (Kioussi, 2002). This expression domain mirrors the 
route of the cardiac neural crest in the wild type (Chan et al., 2004). 
The regulation of Wntl by Pax3 in this process could therefore link the cardiac 
phenotypes of the Pax3 and Dv12 I Pitx2 mutants to a common pathway, and indicate 
a specific Wnt molecule involved in the developmental processes examined in these 
papers. 
Finally, whilst the Wntl knockout mice themselves do not show any reported signs of 
cardiac malformations and are largely carried to term, which would argue against the 
presence of a severe cardiac defect (McMahon and Bradley, 1990; Thomas, 1990), the 
possible redundancy between Wntl and Wnt3a in the development of neural crest may 
explain this lack of cardiac phenotype in the Wntl knockout animals. Where both 
Wntl and Wnt3a are knocked out (Ikeya et al., 1997), no examination of cardiac 
outflow tract was reported and these embryos did not survive to term. It is also 
pertinent to point out that in this study the expression domain of Pax3 in the hindbrain 
of Wntl homozygote mutants appears normal, again arguing its position as genetically 
upstream. In the compound Wntl /Wnt3a mutant it was reduced, however. Whether 
this reduction in the double mutant reflects the presence of Pax3 in a downstream 
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genetic context to Wntl or Wnt3a, or whether this is due to the observed reduction in 
cell proliferation in these mutants was not determined. One group have also reported 
cardiac defects in mouse embryos injected with Wntl antisense RNA constructs 
(Augustine et al., 1993). 
Subsequently, the following hypothesis was investigated in this thesis: 
Hypothesis One 
Pax3 up regulates Wntl transcription directly, probably through the 3' distal 
enhancer region, in vivo during the development of the neural crest. 
Since the beginning of this project, one major paper concerning the development of 
the cardiac outflow tract in the mouse has been published (Kwang et al., 2002). In this 
paper a central role for the gene Msx2 in the development of an outflow tract defect in 
mice is evidenced. The authors demonstrate that Pax3 acts as a negative regulator of 
Msx2 expression in the wild type. In the Sp2H homozygote an increased level and 
ectopic expression domain of Msx2 is reported; the breeding of the Sp2H allele onto an 
Msx2 -I- background to generate a compound mutant rescues the heart defect of the 
Sp2H mutant animal. Interestingly, other neural crest derived structures (dorsal root 
ganglia, thyroid and thymus) defective in Sp2H homozygotes were not rescued. 
Similarly, non -neural crest defects observed in Pax3 mutants (neural tube closure, 
exencephaly) remained in the compound embryos. The authors conclude that Msx2 is 
the principal downstream effector of Pax3 in the development of the murine outflow 
tract. 
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To establish whether Wntl plays a role in the development of the outflow tract it was 
reasoned that, if Pax3 can be shown to regulate Wilt], the ectopic expression of Msx2 
in the Sp2H mutant would be hypothesised to have a negative effect on the expression 
of Wntl. In support of this hypothesis, analysis of Wntl expression (as determined by 
expression of a Wntl -LacZ reporter gene) on a Sp2H homozygous background 
illustrates a loss of expression in a population of cells migrating from the neural tube, 
presumably the neural crest (although it should be noted that no sections are presented 
in this work at an appropriate level to represent cardiac neural crest) (Serbedzija and 
McMahon, 1997). Similarly in Sp2H -/- embryos, in situ hybridization for Msx2 
transcript illustrates an expansion of Msx2 expression in the region of the embryo 
from which the cardiac neural crest would normally originate (Kwang et al., 2002). If 
a negative interaction between Msx2 and Wntl could be established, this would 
provide specific evidence for a role for Wntl in cardiac neural crest development. 
Msx2 and Msxl/Msx2 compound mutants do not display any cardiac defects (Kwang 
et al., 2002; Satokata, 2000). No experiments examining the expression of Wntl in 
these mutants was reported. 
The following hypothesis was therefore also investigated. 
Hypothesis Two 
Wntl transcription is directly down regulated by Msx2, most probably by the distal 3' 
enhancer element, in vivo with implications for the normal development of the 
cardiac neural crest. 
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Hypothesis One and Hypothesis Two are addressed in Chapters 3 and 6 of this thesis. 
Pax3 and Somite and Limb Muscle Development 
Another major area of Pax3 expression in the developing embryo is in the tissues that 
contribute to and populate the developing limb musculature. The area of tissue 
adjacent to the newly formed neural tube, the presomitic paraxial mesoderm (PSM) is 
induced to bud off into somites during vertebrate development, and this is one of the 
most easily observed developmental processes. The PSM buds off sequentially to 
form individual somites in a rostrocaudal wave of development, (see (Buckingham, 
2001; Buckingham et al., 2003; Christ and Brand -Saberi, 2002) for a general 
overview of these processes), with more rostral somites developing first. Somites are 
staged numerically as they form. For example, a stage IV somite would have three 
somites caudal before un- segmented mesoderm, a stage XX would have nineteen and 
so forth. This enables both the staging of somites between different ages and allows 
comparative analysis of somite development between species. 
Sp2H homozygous mutants have severe defects in their hypaxial musculature (Franz, 
1993) and the Pax3 gene has been shown to be expressed in both PSM, developing 
somites and in the developing limb mesenchyme (Buckingham et al., 2003; Franz, 
1993). Clearly many important targets for Pax3 regulation may exist in these 
mesodermal tissues. 
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An overview of somitogenesis is illustrated in Figure 1.6. The PSM buds off to 
generate the epithelial somite which expands and then, in response to signals from the 
notochord (Goulding et al., 1994), differentiates into the sclerotome ventrally 
(characterised by the expression of Pax1 and Pax9 and fated to become skeletal and 
cartilaginous tissues) and dermomyotome dorsally. The dermomyotome is patterned 
in response to factors released from the neural tube and ectoderm (Amthor, 1999). As 
the name would suggest, the dermomyotome constitutes the future cells of the dermis 
and musculature, and can be separated into the epaxial (medial) and hypaxial (lateral) 
components. As these structures progress further throughout their development, the 
myotome differentiates from the dermomyotome to lie between this tissue and the 
sclerotome, and ultimately generates epaxial musculature (Denetclaw, 1997). At the 
level of the limb buds, the ventrolateral edge of the dermomyotome generates 
migrating muscle precursors (which express Pax3) which then progress into the limb 
bud before differentiating into muscle fibres (Tremblay, 1998). It has been suggested 
that the paraxial mesoderm is an entirely naive tissue, and the dorsoventral and 
mediolateral patterning events which ultimately generate the sclerotome, myotome 
and dermomyotome are thought to be generated by multiple, often redundant signals 
arising from the neural tube, notochord, overlying ectoderm (Dietrich, 1997) and 
adjacent lateral plate mesoderm (Pourquie, 1995). 
Factors regulating Pax3 in the mesoderm 
Pax3 expression is initially found throughout the PSM (Goulding et al., 1994). Once 
the epithelial somite is formed, this expression is restricted dorsally by signals 
emanating from the notochord (Goulding et al., 1994), probably Shh in a manner 
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Figure 1.6: 
A) Schematic representation of somitogenesis. Somites 
are formed and develop in a rostrocaudal gradient on 
both sides of the neural tube (Image taken from 
Buckingham, 2001) 
B) Pax3 whole mount immunohistochemistry on chick 
embryo. Illustrating migration of muscle precursor cells 
into the forelimb from the ventrolateral edge of the 
dermomyotome (white arrow), and the high levels of 
Pax3 expression observed at the ventrolateral and 
dorsomedial edges of the somite at interlimb levels. 
Dorsal is up on both panels (Image taken from Venters 
et al, 2004) 
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analogous to that in the neural tube (Fan, 1997). The initial induction of Pax3 is likely 
to be mediated by BMP signals, specifically BMP4 from surface ectoderm and this 
has been shown to be important in the maintenance of Pax3 in proliferating 
populations of muscle precursor cells (Amthor, 1999). Sustained Pax3 expression 
requires constant exposure to dorsalising signals throughout somitogenesis. Later 
expression and maintenance of Pax3 in the somites is also likely to be Wnt dependent, 
since the expression patterns reported for BMP4 in the chick embryo would not 
enable prolonged expression of Pax3 (Dietrich, 1997). Wnt signals have been shown 
in vitro to induce Pax3 expression in culture (Fan, 1997), and the Wnt's 1, 3, 3a, 4 
and 6 are expressed in the appropriate patterns to induce Pax3 expression in the 
somite from dorsal neural tube (Wntl, Wnt3, Wnt3a, Wnt4) and surface ectoderm 
(Wnt4, Wnt6) (Parr, 1993). Ectopic Wntl expression has been shown to up- regulate 
Pax3 and other dorsal somite markers (Capdevilla, 1998; Maroto et al., 1997). 
Furthermore, the downstream components of canonical Wnt signalling (Frzl, Lef and 
(3- catenin) are also present in the presomitic mesoderm and are up- regulated in the 
dorsal somite where Pax3 is expressed (Schimdt, 2000). 
Contrasting evidence has shown that neither expression of ectopically active (3- 
catenin nor LiCI treatment (which activates the (3- catenin pathway) can actually 
induce the expression of myogenic genes within the somite, however (Chen, 2004). 
Similarly, the expression of Lefl and f3-catenin in the somites is restricted to the 
myotomal compartment as development proceeds, and this expression is dependent 
upon a Shh signal from the notochord (Schimdt, 2000). Given that Pax3 is not 
expressed in the myotome, only in the dermomyotome, and that Shh signals are 
repressive to Pax3 expression in these tissues (Goulding et al., 1994), the maintenance 
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of this expression by Wnt signals from surrounding tissues seems unlikely to be 
operating via the canonical signalling pathway alone. A non -canonical Wnt 
responsive pathway, utilising adenylate cyclase, PKA, and CREB has been shown to 
both co- localise to Pax3 expressing dermomyotome and induce Pax3 expression in 
vitro (Chen, 2004). The specific Wnt signal involved in vivo in this system has yet to 
be identified, although both Wntl and Wnt7a were implicated in this study. The lack 
of somite or dermomyotomal defects reported in the Wntl /Wnt3a compound mutant 
mice, in spite of their survival to E18.5, suggests that these Wnt's may not be 
significant in vivo inducers of Pax3 in the mesoderm (Ikeya et al., 1997). (Oddly, 
Wnt3a mutants, however, do demonstrate a defect in somitogenesis, however 
(Takada, 1994)). The closer proximity of Wnt7a in the dorsal ectoderm to the Pax3 
positive dermomyotome would present this factor as a much more attractive Pax3 
inductive signal (Parr, 1993). It is likely that multiple, possibly redundant, signals 
converge on this process of somatic differentiation, however. 
As development proceeds, the expression pattern of Pax3 changes, as illustrated in 
figure 1.6B. The later expression of Pax3 in the dermomyotome exhibits a strong 
expression in the dorsomedial and ventrolateral domains, with weaker expression in 
the intermediate regions (Venters et al., 2004). The cells expressing Pax3 at the 
ventrolateral lip of the dermomyotome migrate into the developing limb bud (Figure 
1.6B, white arrow), and are essential for the later expression of myogenic 
differentiation markers (i.e. MyoD) (Venters et al., 2004; Williams, 1994). 
Furthermore, the expression of Pax3 in the developing limb bud has been shown to 
originate from this migratory population, and is not due to de novo Pax3 expression in 
limb mesenchyme by Quail - Chick Chimeras (Williams, 1994). 
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Pax3 function in mesoderm 
The roles of Pax3 in the developing somite and limb bud have been studied by several 
groups. Measurement of cell proliferation through the incorporation of BrdU into 
Pax3 positive cells, as observed by (Amthor, 1998) led to the implication of Pax3 as a 
regulator of cell cycle control and the proliferation of the dermomyotome population. 
Implicit with this is the converse regulation of MyoD, a basic helix -loop -helix 
transcription factor known to signal terminal differentiation of the myogenic lineage 
in the myotomal compartment (Amthor, 1998). Observations of somite development 
in the SpZH and Sp`' compound mutant (a SpZH / Sp" genotype was used to enable the 
embryos to develop further than the cardiac defect in SpZH homozygotes would 
normally allow) are in agreement with this role (Tremblay, 1998). Mutant 
dermomyotome fails to elongate and organize properly at both the medial and lateral 
edges implying a defective proliferation or organisation of the cells in this region. 
This is consistent with the strong bands of Pax3 expression recorded at these positions 
in the wild type (Venters et al., 2004). Similarly, the sclerotomal compartments 
(denoted by paraxis expression) and the myotomal compartments (denoted by MyoD 
and Myf5 expression) are truncated in the SpZH homozygous mutant (Henderson et al., 
1999), indicating a general function in overall somite proliferation for Pax3. 
Another aspect of the Splotch phenotype is attributed to the inability of Pax3 mutant 
cells from the dermomyotome to undertake the long -range migration required to 
populate the limbs at bud level. This can clearly be observed in contrasting Pax3 - 
LacZ reporter gene activity at this position between wild type and SpZH homozygotes 
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(Buckingham et al., 2003). A study of muscle precursor migration in the Sp2H 
homozygote reveals that the lack of muscle differentiation genes expressed in the 
developing limb bud is due to a migratory defect, as assessed by DiI labelling, and not 
incompetence for dermomyotome precursors to adopt myogenic cell fates since Sp2H - 
I- somites transplanted into wild type limb buds are competent to express myogenin 
(Daston, 1996). 
This migratory defect of dermomyotome derived hypaxial precursors in a Pax3 null 
background has been attributed to the loss of expression of the c -met transcript in 
these cells. The c -met gene encodes a tyrosine kinase receptor which is necessary for 
the migration of these precursors in the mouse (Bladt, 1995). No expression of this 
gene can be detected in the Sp2H homozygote embryo (Daston, 1996) (or detected at 
massively reduced levels, see (Mennerich, 1998)), and Pax3 has been shown to both 
bind and transactivate the human c -met promoter in culture via a defined consensus 
site (Epstein et al., 1996). In support of this interaction, the c -met ligand, scatter factor 
or hepatocyte growth factor (HGF), is expressed in the limb bud under control of 
signals from both the apical ectodermal ridge and zone of polarising activity and 
controls the motility and positioning of myogenic precursor cells (and Pax3 
expressing cells in particular) in this tissue (Scaal, 1999). One group have additionally 
demonstrated expression patterns of specific integrin dimers corresponding to the 
expression domain of Pax3 in migrating muscle precursors (Bajanca and 
Thorsteinsdottir, 2002). This may provide these cells with the extracellular proteins, 
necessary to complete their migration into the developing limb bud. The further 
observation by this group that the pattern of integrin expression changes on the 
surface of these cells after the induction of Myf5, another marker of terminal 
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myogenic differentiation, may also indicate a mechanism for changes in cell - cell 
contacts to reflect the morphological changes adopted by developing muscle fibres 
(see (Buckingham, 2001) for a review of this later process). 
Pax3 is also involved in other regulatory cascades in the developing musculature. The 
Six family of homeodomain proteins are involved in myogenesis, and mutations in the 
Sixl gene generates a muscle hypoplasia phenotype which particularly affects the 
hypaxial muscles (Laclef et al., 2003). Dominant negative Pax3 expression results in 
the inhibition of Sixl and its regulatory co- factor Eya2 (Ridgeway and Skerjanc, 
2001), implying that Pax3 lies functionally upstream of these factors. In contrast to 
these findings a recent study generating a Sixl /Six4 compound mutant mouse with an 
aggravated muscular phenotype has reported Pax3 and c -Met expression to be 
downstream of Six gene regulation (Grifone, 2005). Direct regulatory interactions 
between Pax3 and Six homeoproteins are not established in these studies and this 
contradictory evidence has yet to be resolved. 
Lbxl is another important target of Pax3 regulation and mice harbouring mutations in 
this gene also demonstrate defects in their musculature, particularly in the more distal 
hypaxial components (Brohmann, 2000; Gross, 2000). These mice demonstrate 
normal Pax3 and c -met expression in the dermomyotome (Brohmann, 2000). Sp2H 
homozygous mice demonstrate no expression of Lbxl transcripts and a Pax3 signal is 
at least partially required for the expression of this gene in the ventrolateral tips of the 
dermomyotome (Mennerich, 1998). These studies implicate Pax3 as a regulator of 
Lbxl in the developing somite. 
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The expression of Pax3 in migrating muscle cells is essential for the later expression 
of myogenic determination genes, and the cells which delaminate from the 
dermomyotome, under the control of factors such as Pax3 and Lbxl, are thought to be 
committed to a myogenic fate despite not expressing myogenic markers such as 
MyoD or Mrf5 (Bober et al., 1994). Pax3 is essential for the expression of MyoD, 
since Sp2H mutants cannot express this gene in hypaxial muscles, and double Myf5 I 
Pax3 mutants exhibit a total absence of body musculature (Tajbakhsh et al., 1997). 
Furthermore, ectopic expression of Pax3 alone in undifferentiated mesoderm is 
sufficient to cause the expression of MyF5, MyoD and myogenin markers (Maroto et 
al., 1997). This contrasts with the observations in the somite and migrating muscle 
precursors that the expression domains of Pax3 and MyoD do not overlap. The 
observation that in the wild type, Pax3 expression may determine myogenically fated 
but undifferentiated cells is of interest. The expression of Msxl in the ventrolateral tip 
of the dermomyotome and Pax3 positive migrating muscle precursor cells may 
explain this phenomenon ( Bendall et al., 1999). Msxl expression in these cells was 
shown to maintain this population in an undifferentiated state by antagonising the 
transcriptional activation of MyoD by Pax3. Even more remarkably, the ectopic 
expression of Msxl in terminally differentiated myotubes can completely repress the 
expression of MyoD, Mrf4 and myogenin and enable clonal populations to be re- 
differentiated into non -myogenic cell types (Odelberg, 2000). One caveat to the above 
is the observed ability of somites obtained from a Pax3 null (Sp2H) background 
transplanted into a wild type chick limb bud to acquire a myogenic fate, as determined 
by myogenin expression (Daston, 1996). One possible explanation for this is that a 
second signalling pathway is able to switch on myogenin expression in this context, 
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such as one controlled by Mrf4, which may act at least partially independently from 
the Pax3 /Myf5 specification of muscle cell types (Kassar -Duchossoy, 2004). 
Pax3 and Pax7 
In the developing mouse, another Pax gene, Pax7, is expressed in a highly dynamic 
and specific manner in the neural tube and developing musculature (Jostes et al., 
1990). Pax7 is of particular interest in muscle development due to its importance in 
the regulation of adult muscle regeneration, which is thought to be partially due to a 
reprisal of embryonic developmental pathways (Zhao and Hoffman, 2004). In 
regenerating muscle, a group of muscle derived stem cells can be isolated, and are 
induced to activate Myf5 and MyoD expression in response to appropriate signals (i.e. 
damage) through the activation of Pax7 expression generating so- called satellite cells 
(Seale et al., 2004). The role of Pax7 in these adult populations has interesting 
parallels with Pax3 in the developing musculature. Pax7 knock -out animals display a 
total absence of satellite cells, but do contain a stem cell population within muscle 
tissues (Seale et al., 2000). In these mutants this population is competent to 
differentiate into a significantly greater range of cell types than those isolated from 
wild type mice, indicating that Pax7, like Pax3 in the migrating muscle precursors of 
the embryonic limb, acts to commit these cells to a myogenic lineage. Interestingly, 
one group have also noted that differing allelic forms of the Pax 7 homeodomain 
correspond to differing efficiencies of muscle regeneration, implicating this portion of 
the protein in the regulation of the myogenic pathway (Kay et al., 1995) 
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An interesting aspect of this phenomenon with respect to embryonic development is 
that, in spite of Pax7 being involved in the regulation of myogenic targets in 
regenerating adult muscle, Pax7 is incompetent to replace the myogenic function of 
Pax3 in utero in transgenic mice (Relaix et al., 2004). Since Pax3 and Pax7 form a 
Pax gene subfamily, and have almost identical protein sequences across their DNA 
binding domains, see Figure 1.7, this difference in ability may reflect the 
transactivatory potential of their C- termini, rather than a difference in transcriptional 
targets. In keeping with this hypothesis the activation of the c -met receptor, essential 
in migrating muscle precursor cells and a target of Pax3 induction in the wild type 
(Bladt, 1995; Epstein et al., 1996), is described as "inefficient" rather than absent in 
these mice (Relaix et al., 2004). Pax7 knockout mice also do not demonstrate 
significant defects in musculature at birth, although a growth retarded post natal 
phenotype is demonstrated, leading to almost all (97 %) of these homozygotes dying 
within 3 weeks after birth (Mansouri et al., 1996), possibly due to defective muscle 
regeneration and growth. 
Pax3 has been implicated in the regulation of Pax7 through the observation of 
expression patterns in Sp211 homozygotes (Borycki et al., 1999). This study shows a 
clear expansion in the expression pattern of Pax7 in the neural tube of Pax3 mutants. 
Normally, Pax7 is expressed in dorsal neural tube, but omitted from the roof plate 
(Jostes et al., 1990). In Sp2H mice, the expression level is higher than in the wild type 
and includes the roof plate. Similarly, in the somites, the expression of Pax7 seems to 
extend from dorsal regions to the ventrolateral lip of the dermomyotome. This would 
imply a negative regulation of Pax7 by Pax3. In contrast to this, (Relaix et al., 2004) 
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Multiple alignment of the mouse Pax3 and Pax7 protein 
sequences (N to C- terminal). Note high level of conservation 
between regions corresponding to the Paired (red line, Pax3 
residues 34:162) and homeodomains (purple line, Pax3 
residues 228:278). Sequences diverge towards the C- 
terminus of the proteins (transactivatory domains); Pax7 
exhibits an extended C- terminal domain containing residue 
sequences not found in the Pax3 protein. 
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tube or somites in the Pax3 mutant mouse. These investigators attribute this 
difference to either genetic background or a possible truncated form of Pax3 
expressed from the Sp211 allele interfering with Pax7 expression. This latter 
explanation seems unlikely since it would imply a wild type interaction between the 
genes, and no truncated Pax3 protein product has yet been reported as expressed from 
the Sp211 allele. Finally, induction of P19 EC cells to a myogenic cell fate using 
DMSO, known to induce Pax3 expression in this line, also induces Pax7 (Ziman et 
al., 2001). Whether this effect is dependent on prior Pax3 expression has not been 
established. Two very recent studies have indicated that-a population of Pax3 / Pax7 
positive cells provide an important of pool of skeletal muscle progenitor cells in both 
the embryo and the adult, and represent the common origin for satellite cells in mature 
muscle (Gros, 2005; Relaix, 2005). Such a cell population presents an attractive target 
for potential therapeutic intervention in muscular diseases and, given the requirement 
of Pax3 and Pax7 co- expression for the proliferation and expansion of this population 
(Relaix, 2005), any regulatory interaction between these genes may be of interest in 
this context. 
Since no direct regulatory relationship between Pax3 and Pax7 has yet been explored 
in the literature, this thesis will also examine the possibility that Pax7 represents a 
direct target of Pax3 transcriptional regulation. 
Hypothesis Three 
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Pax7 is directly downregulated by Pax3, in vitro and in vivo, via defined regulatory 
elements and with implications for the development of both neural and mesodermal 
tissues. 
Hypothesis Three is addressed in Chapters 4 and 6 of this thesis. 
In contrast with Wn t 1, where well- defined cis -regulatory elements have been 
described in the mouse, at the start of this study no investigation into equivalent 
elements controlling transcription at the Pax7 locus has been described *. To date four 
studies have been performed analysing either the transcriptional start site of the 
human Pax7 gene (therefore providing an obvious location for a putative minimal 
promoter) (Schafer et al., 1994; Vorobyov et al., 1997) or the region of genomic 
sequence 5' proximal to this start site for cis -regulatory activity (Murmann et al., 
2000; Syagailo et al., 2002). These investigators identified transcripts of varying 
length at the 5' end, ranging from 664óp (Syagailo et al., 2002) to 60bp (Murmann et 
al., 2000). This thesis will initially establish a 5' UTR for the mouse Pax7 transcript, 
and use this to examine the proximal region of genomic sequence for basal promoter 
activity. A bioinformatic approach has also been used to try and identify putative 
functional elements for the mouse Pax7 gene. The regulatory sequences identified 
were then assayed for Pax3 responsiveness and binding both in vitro and in vivo. 
* Since the start of this investigation, one paper describing these elements in the 
mouse has been reported. These data will be considered later in detail, and related to 
the findings reported here. See Lang, D., Brown, C. B., Milewski, R., Jiang, Y. Q., 
Lu, M. M. and Epstein, J. A. (2003). Distinct enhancers regulate neural expression 
of Pax7. Genomics 82, 553 -60. 
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Conclusion 
The above introduction presents an overview of two major developmental pathways 
within which Pax3 is known to play an important biological role, namely the 
development of neural crest and somites. The identification of two putative targets for 
direct Pax3 regulation, and the resulting hypotheses directing much of the 
experimental work in the following chapters, are also included. This is not intended as 
an exhaustive review of all Pax3 functions or previously reported target genes. 
Another major omission is an increasingly large body of work describing the function 
of Pax3 (and Fax7) in the development of alveolar rhabdomyosarcomas due to a 
common chromosomal translocation event fusing the DNA binding domains of these 
factors to the transactivatory domain of the FKHR gene (see (Barr, 2001) for review). 
Since this reflects a pathological state only, and some groups describe a difference in 
the sets of target genes regulated by Pax3 and Pax3 -FKHR (Barber et al., 2002; 
Begum, 2005), this fusion protein has not been considered further in this thesis, 
except where directly relevant. 
In addition to the hypotheses described above, the aims of this investigation were to 
develop a potential methodology for determining new, direct, targets of Pax3 
regulation in vivo. The target genes described above were verified and then used as 
positive controls to verify the application of this methodology in vivo. The 
determination of direct Pax3 targets de novo enables an enhanced understanding of 
this transcription factor's biological role. It also helps to clarify some of the existing 
unresolved issues surrounding Pax3 function that have been generated by the 
conflicting evidence presented in the past. 
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Chapter 2: Materials and Methods 
Introduction 
This chapter will describe the rationale and methodologies behind the techniques used 
in the following results chapters. The following is intended as a reference to enable 
both an appreciation of the precise methods used and a starting point for any 
investigator wishing to reproduce or extend the findings outlined in this thesis. 
General molecular biology protocols were taken from (Sambrook and Russell, 2005) 
and adapted where necessary. Where more specialised protocols have been utilised 
(i.e. QRTPCR) a discussion of the experimental rationale and data treatment has also 
been included. All protocols referred to in this thesis are described below, unless 
stated otherwise in the text. Manufacturers instructions have been referred to where 
appropriate and should be consulted for detailed instructions where necessary. 
COSHH forms and risk assessments for these methods can be obtained by contacting 
the University of Edinburgh. Sigma was the supplier of basic reagents and chemicals, 




Escherichia coli (E. coli) were used for all steps involving bacteria. Sterile conditions 
were used throughout, excess cultures were disposed of in 5% Virkon, and glassware 
washed in 5% Virkon after use. All liquid cultures were grown in 2XTY, shaken at 
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220 rpm for 16 hours at 37 °C, and inoculated directly from LBA plates (with the 
exception of Maxi -preps where a 5m1 starter culture was inoculated and incubated for 
8 hours before being added to the 250m12XTY). 
2XTY 1.6% Tryptone 
1% Yeast Extract 
86.2mM NaC1 
The following volumes were used for different size cultures throughout the project, 
depending on the quantity of plasmid DNA required: 
Culture Size Volume 2XTY 
Mini -prep 1.5ml 
Midi -prep 50m1 
Maxi -prep 250m1 (5m1 starter culture) 
E. Coli were plated out on LB Agar (LBA) plates. LB was made using LB tablets 
(Sigma) and Agar added to 1 %. This was then autoclaved to sterilise and 10cm plates 
poured (using appropriate antibiotic) before cooling. 
Antibiotics 
The antibiotics used in this thesis were Ampicilin and Kanamycin as appropriate. 
Ampicillin was used at a final concentration of 1000 µg / ml. Kanamycin was used at 
a final concentration of 500 µg / ml. 
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Mammalian Cell Culture 
Cell lines 
Two cell lines were used in this thesis, and were ordered from ECACC. These were 
C2C12 (91031101) and NIH -3T3 (93061524). They were both maintained as 
described below. 
Maintenance 
All mammalian cell lines were maintained in sterile conditions, according to Class II 
procedures. Waste cultures and glassware were washed in Cells 
were grown at 37 °C and 5% CO2, in a humidified incubator. All cell lines were 
grown to -70% confluence (monitored by microscopy and estimated) before being 
routinely passaged: 
1) Wash cells in 1X PBS (Phosphate Buffered Saline, Invitrogen) 
2) Add 5m1 1X Trypsin -EDTA (Invitrogen) 
3) Incubate at 37 °C for 5 minutes 
4) Remove cells from incubator and ensure they have detached from flask 
5) Add 5m1 full growth medium 
6) Take 1ml cell suspension and add to 30m1 fresh growth medium in a new T75 
Tissue Culture flask (Grenier) 
7) Replace in incubator 
Growth Medium (Invitrogen) 440m1 DMEM -N 12 
1X glycine 
1X Penicillin / Streptomycin 
10% Foetal Calf Serum (FCS) 
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Mouse Colony 
CBA x C57BL /6F1 mice were maintained as according to Home Office regulations, 
on site, in a dedicated facility. Several breeding pairs were held over the course of the 
project, constituting one male heterozygote and one female wild type. The Splotch 
mutation is characterised by a white belly spot in the heterozygote. Only offspring 
carrying a white belly spot were kept, after we had confirmed by PCR genotyping 
strict concurrence of belly spot phenotype with a splotch heterozygous genotype. 
Mouse Embryos 
Mouse embryos were obtained by mating male and female mice, and observing 
vaginal plugs. Observation of a plug was taken as Embryonic Day 0.5 (E0.5), and 
litters were dated accordingly. Litters were collected on the day specified in the 
experimental protocol by anesthetising the mother, performing cervical dislocation 
and dissecting the embryos. Further embryo dissection was performed as described, 
using a dissecting microscope. 
Genotyping of Mice 
Genomic DNA was extracted from tails (adult) or amniotic sac (embryos) for PCR 





Plasmid DNA was extracted from bacteria using Qiagen mini, midi, or maxi -prep kits 
at the volumes described. DNA was then restricted to confirm the nature of the 
plasmid and quantify yield before any further experiments were undertaken. 
PAC (P1 Artificial Chromosome) 
Bacteria carrying PAC constructs were grown in 2XTY using 50% kanamycin, and 
incubated at 37 °C for 16 hours. PAC DNA was extracted as follows: 
1) Spin cultures down at 6,000 rpm, 15 minutes, 4 °C 
2) Re- suspend in 7.5ml solution PAC 1 
3) Add 7.5ml solution PAC2 
4) Invert gently 4 -6 times 
5) Incubate at RT for 5 minutes 
6) Add 7.5ml solution PAC3, agitating gently 
7) Invert 4 -6 times 
8) Incubate on ice for 5 minutes 
9) Spin at 10,000 rpm for 10 minutes at 4 °C 
10) Place tubes on ice, transfer the supernatant to a fresh tube by filtering through gauze 
11) Add 20m1 isopropanol 
12) Incubate on ice for 5 minutes 
13) Spin at 10,000 rpm, 15 minutes at 4 °C 
14) Wash twice in 70% ethanol, spinning for 5 minutes to recover 
15) Air dry pellet 
16) Re- suspend in 500111 ddHZO 
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Solutions: 
PACI 15mM Tris-HC1 (pH 8.0) 
10mM EDTA 
100µg /ml RNaseA 
PAC2 0.2M NaOH 
1% (w /v) SDS 
PAC3 3M K.OAc (pH 5.5) 
Genomic DNA 
Genomic DNA was extracted from mouse tail tips (adults) or amniotic sac (embryos) 
for genotyping as follows: 
1. Add proteinase K (100mg /ml) to TTLB 
2. Add 5000 of this to each sample 
3. Incubate at 55 °C for 16 hours 
4. Vortex and spin for 15 minutes at 13,000 rpm 
5. Pour off supernatant into tubes containing 500111 isopropanol 
6. Mix gently and spin at 13,000 rpm for 5 minutes 
7. Discard supernatant 
8. Dry at 37 °C for 30 minutes 
9. Add 2501.11 ddH2O, shake for 30 minutes at 55 °C 
10. Add 25Oµ1 PLIA, vortex and incubate at RT for 5 minutes 
11. Spin 13,000 rpm for 5 minutes 
12. Remove upper layer into new tubes 
13. Precipitate DNA as described 
14. Re- suspend pellet in 100µl ddH2O 
TTLB 1% SDS (w /v) 
10mM Tris -Base, pH7.4 
1mM EDTA 
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PCR genotyping was then performed using primers P3GENOL/R, 1.5mM MgC12, on 
program 60 ̂ 30 (see PCR section for a description of this nomenclature). Products of 
127bp (wild type allele) and 95bp (Spill allele) were resolved using a 2.5% agarose 
gel and ethidium bromide staining. Heterozygotes were identified by a doublet. 
RNA Extraction 
RNA was extracted from both cell cultures (70 -80% confluence) or embryos (E9.5 - 
E12.5, various) using several different techniques. These are outlined below. 
Trizol 
Trizol (GibcoBRL) was used to extract total RNA from both cells and embryos 
according to manufacturer's instructions. This is a Phenol -Chloroform based protocol. 
RNeasy Mini 
RNeasy Mini kits (Qiagen) were used to extract total RNA from cell cultures 
according to manufacturer's instructions. This is a column based protocol for small 
quantities of starting tissue. 
RNeasy Midi 
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RNeasy Midi kits (Qiagen) were used to extract total RNA from embryos, according 
to their weight and manufacturer's instructions. This is a column based protocol for 
larger quantities of starting tissue (i.e. whole embryo RNA) 
mRNA 
A Micro -FastTrack 2.0 Kit (Invitrogen) was used to isolate mRNA specifically from 
both cell cultures and embryos, according to manufacturer's instructions. This is a 
column based protocol, using oligo (dT) cellulose to specifically isolate mRNA from 
tissues. 
NP -40 isolation of cytoplasmic RNA 
To isolate cytoplasmic RNA, excluding hnRNA, NP -40 Lysis Buffer protocol was 
used on cell cultures as follows (based on one 70 -80% confluent T75 flask of cells): 
1) Trypsinise cells (as above) 
2) Spin at 1,000 rpm for 5 minutes at RT 
3) Wash in 1X PBS 
4) Spin at 1,000 rpm for 5 minutes at RT 
5) Re- suspend pellet in 40011.1 NP -40 Lysis Buffer 
6) Transfer to an Eppendorf and spin at 13,000 rpm for 2 minutes at 4 °C 
7) Transfer supernatant to a new Eppendorf, discarding the pellet of cell nuclei 
8) Add 40011l phenol, 501_1l 10% (w /v) SDS 
9) Vortex 
10) Incubate at RT for 5 minutes 
11) Spin at 13,000 rpm for 5 minutes 
12) Transfer aqueous phase to a new tube 
13) Precipitate RNA 
14) Re- suspend in 501A1 ddH2O 
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NP40 Lysis Buffer 150mM NaC1 
10mM Tris-HC1 (pH7.4) 
0.5% NP40 (w /v) 
1mM MgC12 
DNA / RNA precipitation 
DNA and RNA were precipitated using ammonium acetate. The following general 
protocol was used for a given volume n of nucleic acid: 
1. Add 0.4 x n 5M NH4.OAc, pH5.5 
2. Add 2.5 x n 100% ethanol 
3. Vortex 
4. Spin at 13,000 rpm for 30 minutes at 4 °C 
5. Discard Supernatant 
6. Wash in 75% ethanol 
7. Spin at 13,000 rpm for 10 minutes at 4 °C 
8. Air dry pellet 
9. Re- suspend in appropriate volume of ddH2O 
DNA Quantification 
Plasmid DNA was quantified using agarose gel electrophoresis and comparing to a 
known quantity of ladder DNA. Ethidium bromide and an UV transilluminator, in 
conjunction with imaging software, were used. DNA would be linearised by 
restriction digest and the band intensity, quantified by the software, compared to that 
of a band on a DNA ladder of known concentration. Every six months the accuracy of 
the equipment would be tested using serial dilutions of ladder and linearised plasmid 
of a concentration specified by a supplier to ensure operating range and accuracy. 
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RNA Quantification 
RNA was quantified using an UV spectrometer by measuring the absorbance at ? = 
260 nm. 
DNA Sequencing 
DNA was sequenced using the MWG Sequencing Facility (http://www.mwg- 
biotech.com). Briefly, plasmids were precipitated as described (1µg per sequencing 
reaction) and posted off for sequencing. Primers used in the sequencing reactions 
were either supplied by MWG- Biotech or defined as required to extend sequencing 
runs, and synthesised by MWG- Biotech for sequencing on -site. 
Agarose Electrophoresis 
DNA and RNA were routinely separated using agarose electrophoresis. Low melting 
point agarose was dissolved by boiling in 1X TBE. Ethidium Bromide (at 101.1g /m1) 
was added to 11.11/m1 TBE -Agarose. Gels were left to set ( -30 minutes) at RT before 
being covered in 1X TBE, samples loaded, and electrophoresed at 45mA /cm for 
varying amounts of time. 
Polyacrylamide Electrophoresis (Denaturing) 
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DNA and RNA were routinely separated using denaturing polyacrylamide 
electrophoresis. 6% polyacrylamide gels containing 8M Urea were made to as 
follows: 
Acrylamide Gel Mix 1X TBE 
15% Acrylamide / Bis -acrylamide 
(40% mix) 
8M Urea 
20cm glass plates designed to fit in a BioRad Protean II electrophoresis system were 
cleaned, and the outer plate inner surface coated in RepelcoteVS (BDH). The plates 
were then assembled using 1mm spacers and a comb of appropriate size. A 10% (w /v) 
ammonium persulphate solution was then made, and 1m1 added to the acrylamide gel 
mix to remove oxygen from solution (this is inhibitory to the polymerisation 
reaction). 100 . l of TEMED (N,N,N',N'- Tetramethyl -1,2- diaminomethane) was then 
added to initiate the radical based polymerisation. The gel mix was then poured 
between the plates, with care to avoid bubbles, and allowed to set. Gels were run in 
1X TBE at 450 V for 2.5 hours, fixed in a solution of 5% acetic acid and 15% 
methanol for 15 minutes, and dried under vacuum overnight prior to exposure to X- 
ray film. 
Cloning 
Throughout the thesis several cloning strategies have been employed to manipulate 
DNA for various experimental purposes. The following is a general description of the 
techniques involved in every case. Specific cloning strategies can be found in the 
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results chapters pertaining to specific constructs. A full list of all DNA constructs 
made in this thesis and their cloning strategies can be found in Appendix 1. 
Restriction Digests 
Restriction enzymes were typically obtained from New England Biolabs (NEB), 
Promega or Fermentas, dependent on availability. Digests were conducted at 37 °C 
(unless the enzyme was active at a different temperature) for one to two hours. A 
general protocol for a single digest was as follows: 
Digest of 20 µl 2 pl 10X Reaction Buffer 
2 pi 10X BSA 
1 pl Enzyme (10 units) 
n pl DNA (required µg quntitiy) 
(20 - (5 + n)) µl ddH2O 
Reaction buffer at 10X was supplied by the manufacturer, 100X BSA was supplied by 
the manufacturer and made to 10X fresh for each digest with ddH2O. Whilst digest 
volumes and quantities of DNA were altered as required, all digests were scaled 
according to the above and the final concentration of total enzyme never exceeded 
10% of the reaction volume. 
Phosphatasing to remove end phosphate groups 
Shrimp Alkaline Phosphatase (SAP, Roche) was used to phosphatase nucleic acids as 
according to the manufacturer's instructions. Phosphatasing was used either to 
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prevent open vectors from self -ligating if that were a possibility, or to remove end 
phosphates from a DNA ladder to enable kinase radiolabelling in Primer Extension or 
RPA protocols. 
Kinasing 
T4 Polynucleotide Kinase (NEB) was used to add phosphate groups to nucleic acids 
according to manufacturer's instructions. For radiolabelling, 32Py -ATP (Amersham) 
was added to the reaction mixture (quantities described for each protocol, below). 
Ligations 
Ligations were performed using T4 Ligase (Promega). T4 Ligase buffer was 
separated into 10 µl aliquots and a fresh aliquot used for each ligation reaction. 
Ligations were generally set up as follows: 
Ligation Reaction 2O1.t1 2 µl 10X T4 Reaction Buffer 
1 µl T4 Ligase (10 units) 
x µl Insert (required µg) 
y !al Vector (required µg) 
(20 - (3 + x + y)) µl ddH2O 
Quantities and ratios of vector and insert were determined empirically and were often 
a range within a given set of ligation experiments. Ligations were conducted at 16 °C 
for 16 hours before being transformed into competent E. coli as described and plated 
out on LBA with the appropriate antibiotic selection. 
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TOPO -cloning 
A major method of creating plasmid clones of PCR products used in this thesis 
utilised a topoisomerase method rather than conventional ligase based cloning. These 
protocols used a range of vectors from Invitrogen where a topoisomerase enzyme is 
cross linked to an open vector designed to facilitate the rapid and efficient 
recombination of different PCR products before further cloning steps. Often these 
vectors were intermediates to enable more efficient downstream cloning steps or to 
enable rapid sequencing screening before further manipulation. The vectors used were 
as follows: 
PCR Product Type TOPO vector used 
Taq amplified, 3' A overhang pCR -II- TOPO -TA 
Pfu amplified, no overhang pCR -II- TOPO -Blunt 
Large product (> 2 kb) pCR -II -XL -TOPO 
For detailed protocols, see manufacturer's instructions. 
Heat -Shock Transformation 
Plasmids and ligations were transformed into super competent (109 colonies µg 1 
plasmid DNA). Top -10 E. coli (Invitrogen) using the heat shock protocol (at 42 °C) 
specified in the manufacturer's instructions. Bacteria were then plated out on LBA 
with the appropriate antibiotic and incubated overnight at 37 °C. 
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PCR (Polymerase Chain Reaction) 
PCR was used widely throughout this thesis. The following describes the general 
conditions used for every reaction, methods of optimisation typically used where this 
was required, followed by the notation used to define experimental conditions in each 
specific reaction. Primers were designed using MacVector 7.2 software. The names of 
primers used in each reaction are given in the results chapters; a table of all primers 
used and their sequences can be found in Appendix 2. 
PCR Reaction Conditions 
All PCR reactions used the following basic set of conditions, reagents were generally 
supplied by Promega and primers synthesised to order by MWG- Biotech. 
PCR Reaction Mix 2.5 pi 10X Reaction Buffer 
x 11l25mM MgC12 
1.25 1115' Primer (10µM) 
1,25 1113' Primer (10µM) 
1 111 dNTP mix (Promega) 
y 111 DNA Template (required pg) 
0.5 111 Taq Polymerase (5 units) 
(25 - (x + y)) 111 ddH2O 
PCR Program Step 1 : 1 Minute at 95 °C 
Step 2 : 1 Minute at 95 °C 
Step 3 : 30 Seconds at Tm 
Step 4 : 1 Minute at 72 °C 
Step 5 : Go To Step 2 n Times 
Step 6 : 10 Minutes at 72 °C 
Step 7 : 4 °C Forever 
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The variations to this protocol specific to each reaction were T,,, (annealing 
temperature for Primer and template) and the number of cycles (n). These are 
annotated throughout as Tm A n (i.e. 55 ̂ 35 would denote a T,,, of 55 °C and 35 cycles 
of amplification). All reactions were optimised to have identical reaction conditions 
otherwise. 
PCR Optimisation 
PCR reactions were optimised using the above basic reaction program and by varying 
the concentration of MgC12 between 0.5mM and 2.5mM and Tm spread over the mean 
average predicted by the software used to design the primers. The Tm, cycle number, 
and [MgC12] used in each reaction are specified where relevant, although it is the 
experience of this investigator that PCR reaction conditions are generally 
indiosyncratic to the specific equipment, reagents and source material used. 
Independent optimisation of conditions should be anticipated in every case. 
TEPCR 
Template Enriched PCR (TEPCR) was used to clone from DNA where conventional, 
restriction digest mediated cloning was difficult. This protocol uses high 
concentrations of template and primers, combined with low PCR cycle number, to 
maximise product concentration in the final reaction mix. It was reasoned a lower 
cycle number would minimise the number of mutations generated by the polymerase 
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during the amplification cycle and therefore the number of colonies screened before 
an appropriate clone was found. Typically 10 - 15 cycles were used in each case. 
RTPCR 
Reverse Transcriptase PCR (RTPCR) was performed in a number of experiments. 
This technique uses the RT enzyme to generate a cDNA copy of mRNA which can 
then be amplified using gene specific primers. In each experiment, RNA was isolated 
using one of the methods described, quantified, and subjected to an RT step using 
SuperScript III Reverse Transcriptase (Invitrogen), as per the manufacturer's 
instructions. PCR steps were then conducted on the cDNA template as previously 
described, product confirmed by agarose electrophoresis, and where necessary, 
cloning and sequencing. No RT controls were included where appropriate, and when 
possible primers were designed to span introns to control for contamination from 
genomic DNA. 
QRTPCR 
To enable the repeatable and rapid quantification of levels of transcript between wild 
type and mutant embryos, Quantified Reverse Transcriptase PCR (QRTPCR) was 
used (for a review see (Bustin, 2000)). In this method the incorporation of a 
fluorescent dye into PCR product is measured over the course of a PCR reaction. 
Since the dye fluoresces only when it intercalates into dsDNA (in a mechanism 
analogous to ethidium bromide), the level of fluorescence observed in a sample is 
73 
linearly proportional to the quantity of DNA of a given range of product sizes 
( >250bp). Since these samples were cDNA's synthesised from DNase treated total 
RNA preparations, and since all no RT controls performed during the PCR steps of 
this protocol were negative, the only dsDNA available for the incorporation of 
fluorescent dye must be PCR product derived from the amplification of cDNA. The 
following derivation has been adapted and simplified from (Livak and Schmittgen, 
2001). 
In the linear phases of a PCR reaction, the quantity of product after n cycles, X , is 
related to the quantity of starting material Xo by the relationship: 
X = X,x(1 +EX) 
Where EX represents the efficiency of amplification of product X in the reaction (i.e. if 
the efficiency was 100% EX = 1, (1 + Ex)" = 2" or a doubling every cycle). 
If the level of fluorescence after n cycles, F , is directly proportional to X (i.e. F a 
X ) then it follows: 
F / c.(1 + EX) = Xa 
Therefore, for any samples where EX is equivalent, a measurement of F at cycle 
number n is equivalent to a measure of the quantity of starting material in that sample. 
Conversely, a difference of F,, after the same number of cycles in two different 
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samples (where Ex is equivalent) is a measure of the difference in amount of starting 
material between those samples. 
To ensure that EX is invariant between reactions, a plot of the difference of the number 
of cycles required to reach a given level of fluorescence against the difference in 
concentration of starting product must be linear. If 
F1/c.(1+Ei)"=Xl and F2/c.(1+E2)"=X2 
Then 
Xi -X2 = F1 / c.(1 + E1)" - F2 / c.(1 + E2)" 
If 
E1 = E2 
Then 
k.AX= AF 
Where k = amplification constant c.(1 + E2) ". 
Experimentally this can be tested by a dilution series of cDNA (X) against 
fluorescence (F) after n cycles. If this plot is linear then the efficiency of PCR 
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amplification is identical across that range of cDNA concentrations, and then the 
measurement of fluorescence can be interpreted as an indicator of quantity of starting 
material. 
The purpose of the QRTPCR experiments conducted in this thesis was to determine 
the difference in quantity of mRNA of each product between wild type and mutant 
embryo samples. This was performed in the following manner. 
Firstly, two Spill +1- were mated to generate embryos which were genotyped using 
PCR as described, and Sp2H +1+ and 5132H -I- E9.5 sibling pairs used in the 
experiments. Total RNA was extracted and quantified as described, and equal 
quantities of RNA were used in three separate RT experiments for each embryo (with 
one -RT for each embryo). These replicates control for variation in cDNA synthesis 
from each sample. 
For each of the genes analysed (i.e. for each PCR), a series of dilutions for the wild 
type samples were performed, from 1.0 µl of cDNA to 0.01 pl of cDNA. This 
generates a plot of concentration of cDNA vs. Fluorescence observed after n cycles 
(cycle threshold). In every case this was linear, showing that amplification 
efficiencies were identical over this concentration range. 
This also generates an standard curve of arbitrary units where the wild type samples 
are set at 1 (undiluted). Each of the three +RT reactions from the wild type and 
mutant embryos are then interpolated off of this graph, at this cycle threshold, to show 
the relative amounts of starting material present in the cDNA. 
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Each sibling pair generates 18 readings. Three sets of 6 readings for each of these 
genes analysed, namely GAPDH, Wntl and Pax7. For each gene, there are 3 wild 
type and 3 mutant readings. Variation between these replicates is a measure of the 
variability of the production of cDNA from the RNA samples, samples where the 
variation was high were excluded from the final data pool. 
Four sibling pairs were analysed in this way and contributed to the final data pool. 
Mean averages of the level of expression of each transcript in the Sp2H mutants were 
expressed as % of wild type expression. 
i.e. wild type = -1.0 or each gene (since we are quantifying relative expression from 
the standard curve generated by serial dilution of wild type cDNA), and mutant = < 
1.0 if the transcript is less represented than the wild type or > 1.0 if more abundant in 
the mutant. 
This method does not simply normalise by the value obtained for GAPDH but tests to 
ensure GAPDH transcript levels remain unchanged. If this is the case, any changes in 
transcript levels observed have been assumed to be real. 
Total RNA was extracted from littermate wild type and Sp2H -I- embryos as described, 
and quantified. Identical µg quantities of RNA were then subjected to an RT step 
(above) and the cDNAs then used with QuantiTect SYBR Green reagent (Qiagen) in 
PCR reactions on an Opticon single wavelength PCR machine and data analysed 
using the Opticon Monitor software. Dilution series were performed for all genes 
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analysed to ensure linearity of response across a concentration gradient, and to enable 
relative quantisation of each transcript. All reactions were run on the program 55 ̂ 40, 
and [MgC12] 1.5mM. Amplicons were all < 250bp to ensure linearity of SYBR Green 
incorporation (i.e. c is identical between all reactions, Qiagen), and melting point 
curves were examined to ensure the specificity of each reaction. Levels of Sp2H -/- 
transcript expression were expressed as % of wild type, and GAPDH was used a 
normalising control. 
Site Directed Mutagenesis 
Mutation of the core Pax3 binding consensus was performed using the QuikChange 
Site Directed Mutagenesis Kit (Stratagene) according to manufacturer's instructions. 
Briefly, this protocol uses primers carrying the desired mutations to anneal to the 
unmutated sequence on the plasmid of interest. A Pfu polymerase then extends the 
primers around the plasmids on both strands, generating nicked, non methylated 
complementary strands. The parental DNA (methylated) is then digested away with 
the DpnI enzyme leaving only the new, mutated strands. These are then annealed and 
transformed into E. coli as described above. 
Primers used were W1_ sub FWD/REV in conjunction with the pW1P(1.2)Luc 
plasmid and P7_sub_FWD/REV in conjunction with the p1.5I1RLuc plasmid. 
Colonies were grown up and plasmid DNA extracted for sequencing, as described, to 
confirm the substitution of the Pax3 core consensus site. 
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Primer extension 
Primer extension was used to size the 5' Untranslated Region (UTR) of the Pax7 
mRNA, a diagrammatic representation of this method can be seen in Chapter 4 
(Figure 4.3A). Briefly this method employs a radiolabelled primer which anneals to a 
known sequence within the transcript of interest (i.e. Pax7 coding exons) and is then 
used by the RT enzyme to prime a cDNA extension to the 5' end of the mRNA. Since 
the primer is first kinase labelled with 32P at the 5' end, this can be visualised on a 
denaturing poyacrlyamide gel against an ssDNA ladder (also radiolabeled). This 
enables the 5'UTR of the transcript to be sized. 
Total and messenger RNA was extracted from C2C12 (Pax7 positive) cells and 
embryos as described above. This was quantified and 8µg RNA used in each 
extension step. Primers were ordered from MWG- Biotech (detailed in Chapter 4 and 
Appendix 2) and 100 pmol kinase labelled with 32P y -ATP at 3000 Ci /mMole using 
the T4 polynucleotide kinase protocol. Labelled primer was then separated from 
unincorporated 32P y -ATP by application of the reaction mix to a G -25 size exclusion 
column (Amersham). Purified, labelled primer were then frozen and equal quantities 
used in each extension experiment. 
8 µg of RNA was then placed in the following reaction mix: 
Extension Mix (uses SuperScripi 
RT (Invitrogen) reagents) 
8 µl MgC12 (25mM) 
4 pl 10X Reaction Buffer 
4 µl dNTP mix (Promega) 
1 µl RNase OUT (Ambion) 
n µl RNA (8 µg) 
79 
(35 - (17+ n)) µl ddH2O 
This was then heated to 70 °C for 10 minutes to denature RNA secondary structure 
and then snap cooled on ice for 5 minutes. 4 Labelled Primer was then added and 
the mixture incubated at RT for 5 minutes to allow primer - RNA complexes to form. 
1 µl SuperScript III RT (Invitrogen, final reaction volume 40 µl) was then added and 
the mixture incubated at 55 °C for 45 minutes. Reactions were then stopped by 
heating to 100 °C for 5 minutes. Samples were then boiled in Formamide Loading 
Buffer II (Ambion) and analysed by running on a 1 mm thick 6% polyacrylamide 8M 
Urea denaturing gel (see above). A DNA ladder of pBR322 (MspI, NEB) was 
phosphatased using SAP (Roche) and then kinase labelled using 32P y -ATP as 
described. This was used to size the primer extension fragments. 
The gels were ran for 2.5 hours at 450 V and then fixed in a solution of 5% acetic acid 
and 15% methanol in ddH2O for 20 minutes. The gels were then dried overnight 
under vacuum, and exposed to X -ray film (Kodak) for 12, 24, 48 and 72 hours at -80 
°C in an imaging cassette. 
5'RACE 
To further examine the Pax? transcript, 5' RACE (Rapid Amplification of cDNA 
Ends) was used to amplify, clone and sequence the 5'UTR. This methodology uses a 
set of gene specific primers and a set of primers complementary to sequences 
annealed to the 5' end of the transcript to perform nested PCR and amplify the 5'UTR 
of the gene. Oligonucleotides of known sequence are generally annealed to the very 
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5' end of the mRNA or cDNA. The precise method by which this occurs differs from 
protocol to protocol, and is described below. Once these linker sequences have been 
annealed, PCR or RTPCR (depending on whether the linkers anneal to the mRNA or 
cDNA population) can then be used to specifically amplify the gene of interest. 
The SMART RACE cDNA amplification kit was used in the first instance (Clontech). 
In this protocol total RNA is extracted from the source of interest (in this instance 
C2C12 or wild type E11.5 embryos) and an RT step performed with an enzyme blend 
designed to leave an oligo -C overhang at the very 3' end of the cDNA. This is then 
used to anneal a primer containing an oligo -G 5' end with a 3' known sequence. The 
RT enzyme then switches templates and extends along this new primer, generating a 
cDNA with a known 5' sequence. This population of cDNA's can then be used in a 
conventional nested PCR reaction using gene specific primers to isolate and sequence 
the 5'UTR required. 
Due to the seemingly foreshortened nature of many of the 5 'RACE clones isolated 
with the above method when compared to the primer extension data (see Chapter 4), a 
second method of performing 5'RACE was then utilised to try and exclusively select 
for full length transcripts. A FirstChoice RACE -Ready cDNA kit (Ambion) was used. 
This method selects for full length 5'UTR's by exploiting the 5' terminal 7- 
methylguanine cap present only on full length mRNA's. Firstly, a phosphatase 
activity is used to remove phosphates from any RNA species without a 5' cap (i.e. 
those partially degraded). Next the 5' cap guianine is removed from full length 
mRNA molecules. This generates a population of RNA's in which only those which 
were full length will have a 5' phosphate moiety capable of accepting the ligation of 
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an RNA primer of known sequence to the 5' end of the transcript. Thus a population 
of mRNA's with a 5' end of known sequence are generated. This is then used in an 
RTPCR reaction with primers designed against this sequence and within the gene of 
interest to amplify and clone the 5'UTR. 
Cytoplasmic RNA was isolated from C2C12 cells of wild type embryos, and 
quantified, as described. Gene specific primers were designed using MacVector, and 
the 5'RACE followed according to the manufacturer's instructions. PCR products 
were TOPO cloned and sequenced using MWG- Biotech. Sequences were aligned to 
the genomic using a CustalW local alignment. 
Ribonuclease Protection Assay (RPA) 
RPA analysis was employed to further analyse the Pax7 5'UTR. RPA utilises a radio 
labelled antisense RNA probe against the sequence of interest (see figure 4.5A) to 
anneal to the mRNA. This forms an RNA -RNA duplex where the sequences are 
complementary. RNase is then used to digest away un- annealed RNA and probe 
sequences, leaving a probe - target complex intact. These are then purified and run 
out on a denaturing polyacrylamide gel. Since the probe sequence is known (and 
overlaps with the coding sequence of Pax7 at one end), this can be used to size the 
5'UTR accurately. Since the probe was designed to cover the UTR's predicted by 
both primer extension and 5'RACE it was hoped that this method might help resolve 
differences between the 5'UTR's predicted by PEXT and 5'RACE for Pax7. 
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A probe was cloned into a vector containing an SP6 promoter in the appropriate 
orientation (see Chapter 4). This was linearised at a final concentration of 0.5µg /µ1 
and in vitro transcription performed with the MAXlscript in vitro transcription kit 
(Ambion) according to manufacturer's instructions and using 32P a -UTP at 
800Ci /mmol as the radiolabel. Probes were then subjected to DNaseI digestion and a 
G -25 size exclusion column used to purify as described previously. Probes were then 
run out on a 6% acrylamide gel and exposed to X -ray film for 1 hour to position 
within the gel. Full length probes were then extracted overnight into buffer. 
RNA was then extracted from C2C12 cells (cytoplasmic RNA) or E11.5 wild type 
embryos (total RNA) and quantified. 5µg of RNA was used in each RPA reaction and 
this was made up to 501..tg RNA using yeast tRNA (a negative control reaction using 
Pax7 negative NIH -3T3 was also performed). Hybridisation was conducted using the 
HybSpeed RPA kit (Ambion) according to manufacturer's instructions. Samples were 
then treated with RNase and protected fragments separated on a denaturing 
polyacrylamide gel, as described. Fragments were sized using pBR322(MspI) kinase 
- labelled ladder as before, fixed, dried and either exposed to X -ray film for two 
weeks or to a phosphorimager. 
PAC Library Screen 
A mouse PAC genomic library was utilised to clone the mouse Pax7 genomic locus. 
PAC clones can carry up to 150kb of insert and, given the size of the Pax7 genomic 
region (figure 4.1A), these were deemed an appropriate source from which to clone 
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this region of DNA. The PAC library, gridded on to nylon filters, was obtained from 
the HGMP. A probe was synthesised from plasmid pP7HYB (520bp EcoRI fragment, 
human sequence, see Chapter 4) using 32P a -CTP and the HighPrime kit (Roche). 
Unincorporated radioactivity was removed by applying the reaction mix to a G -25 
size exclusion column (Amersham). Filters were probed using the following protocol: 
1) Soak filters in 2X SSC for 1 hour at RT 
2) Remove from 2X SSC 
3) Stack filters one on top of another, DNA facing upwards, with a nylon membrane 
placed between the sheets 
4) Roll filters up and place into a Hybridisation Tube 
5) Add 20m1 Church Hybridisation Mix 
6) Incubate at 65 °C for 2 hours (pre- hybridisation step) 
7) Pre -warm 15m1 Church Hybridisation Mix to 65 °C 
8) Pour Church pre- hybridisation solution off filters and discard 
9) Add labelled probe to 15m1 pre -warmed Church Hybridisation Mix 
10) Place in tube with filters, rotate for 16 hours at 65 °C, ensuring even coverage of 
filters with probe solution 
11) Remove probe solution and discard 
12) Wash filters three times in Church Wash solution, pre -warmed to 65 °C 
13) Monitor filters for background 
14) Starting with 2X SSC, wash filters with increasing stringency of SSC until filter 
background is acceptable and specific hot spots can be detected 
15) Wrap films in cling film 
16) Expose to X -ray film in imaging cassette at -80 °C for 24 hours to one week, 
depending on signal strength 
17) Identify positive clones and order from HGMP collection 
The solutions used were as follows: 
20X SSC 3M NaCI 
300mM Na- citrate 
1M NaPO4 pH 7.2 1M Na2HPO4.7H20 
0.4% H3PO4 
Church Hybridisation Mix 250 mM NaPO4 pH 
7% SDS (w /v) 
1mM EDTA 
1% BSA (w /v) 
7.2 
Church Wash 1% SDS 
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1mM EDTA 
40 mM NaPO4 pH 7.2 
Southern Blot 
To map and confirm the PAC clones identified by the PAC library screen, southern 
blotting was performed using a 770bp PCR probe amplified from mouse genomic 
DNA, see Chapter 4. Probes were labelled as described for the PAC library screen. 
PAC clones were grown up and PAC DNA extracted as described. The DNA obtained 
from each clone was then digested with 7 different enzymes for 16 hours at 37 °C. 
The digests were then run out on a large (200m1) 1.2% agarose gel for 16 hours at 30 
V. The gels were then stained and photographed to ensure digestion and separation. 
Southern blotting was then conducted as follows: 
1) Wash gel in ddH2O for 30 minutes, shaking gently on a rotating platform 
2) Wash gel in ddH2O with 12.5m1 concentrated HC1 for 30 minutes 
3) Wash gel in 2 x excess of Denaturing Solution for 30 minutes each 
4) Wash gel in 2 x excess of Neutralising Solution for 30 minutes each 
5) Place gel on blotting set -up containing 20X SSC 
6) Cover with cling film and cut a hole around the gel, removing this 
7) Cover gel surface with 2X SSC 
8) Cut nitrocellulose filter to the size of the gel and place on top, taking care to remove 
any air bubbles 
9) Wet filter with 2X SSC 
10) Place two pieces of Whatmann paper, soaked in 2X SSC, cut to the appropriate size 
on top of the filter 
11) Stack absorbent paper towels on top of the Whatmann papers 
12) Apply heavy weight to the top of the blotting set up 
13) Leave for 16 hours 
14) Replace Whatmann paper and towels, re -apply weight 
15) Leave for a further 8 hours 
16) Remove filter, wrap in cling film 
17) UV cross link 
18) Air dry, then bake at 120 °C for 15 minutes 
19) Place filter in hybridisation tube with nylon membranes 
20) Add 20m1 Church Hybridisation Mix, pre- warmed to 65 °C, containing 20 p.1 
denatured salmon sperm DNA 
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21) Pre -hyb for 30 minutes 
22) Remove pre -hyb solution 
23) To 10m1 pre- warmed Church Wash add 10 µl denatured Salmon Sperm DNA and 
radiolabeled probe 
24) Rotate in a hybridisation oven for 16 hours at 65 "C 
25) Remove probe wash 
26) Wash filter 4 x 30 minutes in 20 ml Church Wash 
27) Wrap moist filter in cling film 
28) Expose to X -ray film in an imaging cassette for 24, 48 and 72 hours, as required 
The solutions used were as follows: 
20X SSC As above 
1M NaPO4 pH 7.2 As above 
Church Hybridisation Mix As above 
Church Wash As above 
Denaturing Solution 0.5M NaOH 
1.5M NaC1 
Neutralising Solution pH 7.5 0.5M Tris Base 
1.5M NaC1 
pH with HC1 or NaOH 
Transfections 
Luciferase Assay Transfections (protocol for adherent NIH -3T3 and 
C2C12 cells) 
Cultures of NIH -3T3 and C2C12 cells were maintained in class II conditions as 
described. One day prior to transfection, cells were trypsinised and re- suspended in 
antibiotic free DMEM N -12. Cells were counted using a haemocytometer and 2 x 106 
cells were added to each well of a sterile 24 well plate containing 500111 antibiotic free 
DMEM N -12. These cultures were left incubated for 16 hours to reach 80 -90% 
confluence prior to transfection. 2 hours prior to transfection the growth medium was 
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aspirated, the cells washed with PBS twice and covered in 500111 Opti -MEM 
transfection medium (Invitrogen) per well. Cultures were then replaced in the 
incubator for two hours prior to transfection. 
Plasmid DNA was grown and purified as described before being linearised and 
quantified. Equal µg quantities of DNA were added to the cells in each transfection. 
Also, equal µg quantities of CMV and SV40 strong and weak promoters were added 
to the cells where appropriate. This was to prevent variations in luciferase output and 
Renilla / luciferase ratios due to promoter - promoter interactions and competition for 


















Well A 0.5 0.1 0.0 0.4 
Well B 0.5 0.1 0.05 0.35 
Well C 0.5 0.1 0.1 0.3 
Here, all three wells have a total of 1µg plasmid DNA added, varying the amount of 
Pax3 expression plasmid, enabling the effect of several concentrations of Pax3 
expression to be investigated on the luciferase reporter plasmid, the total amount of 
CMV promoter is constant. (NB. Since the sizes of pCMV- Script and pCMV -Pax3 
vary this is not strictly speaking true. pCMV -Pax3 is 25% larger and so, weight for 
weight, will carry 25% fewer `molecules' of CMV promoter into the transfection. 
Since an excess of the smaller plasmid is used in each experiment, the actual 
difference in number of CMV promoters is minimal, i.e. 0.4 in Well A compared with 
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(0.3 + (0.75 x 0.1)) = 0.375 = 6% difference in Well C). Since the observed luciferase 
induction was always much greater than these small differences in CMV promoter 
composition, and DNA -Lipofectamine ratios thought to have a much greater effect on 
transfection ratios, (Invitrogen, product insert), this was considered acceptable). For 
24 well plates the optimal total amount of DNA was found to be 1.5µg per well for 





µg pCMV -PAX3 
plasmid DNA 
µg pCMV- Script 
plasmid DNA 
0.5 0.1 x 0.4 + y 
Where x + y = 0.5µg DNA 
Lipofectamine -2000 reagent was then used to transfect the plasmid DNA into each 
well as follows: 
1) Add all DNA to 5011 Opti -MEM 
2) Mix and incubate at RT 
3) Add Lipofectamine -2000 to a second S01.11 Opti -MEM. Add nµl Lipofectamine - 
2000 where n = (jig DNA x 2). For example, 11.tg total DNA = 2u1 Lipoectamine- 
2000 
4) Mix and incubate at RT for 5 minutes 
5) Mix DNA - Opti -MEM and Lipofectamine -2000 - Opti -MEM together 
6) Incubate at RT for 30 minutes 
7) Add to well containing 5000 Opti -MEM 
8) Mix gently and incubate at 37 °C, 5% CO2 for 24 hours 
After 24 hours, cells were washed in PBS and harvested using the Passive Lysis 
Buffer component of the Dual Luciferase Reporter Assay System (Promega). 
Luciferase and Renilla Luciferase expression was then assayed according to 
manufacturers instructions and using a TD -20/20 Luminometer (Turner Biosystems). 
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Relative Light Units (RLU) were measured for each luciferase, and recorded for every 
sample. RLU was measured cumulatively over 10 seconds and performed twice for 
each sample to ensure accuracy of measurement. Individual transfections were 
conducted in triplicate in each run to ensure each set of conditions gave a reliable 
result within a run of transfections. These runs were repeated between 3 and 12 times, 
depending on the specific experiment, and this is then recorded as the n value for each 
experiment. 
Appendix 4 contains a detailed description of the Luciferase rationale and data 
treatment used in this thesis. 
Transfections for Western Blotting 
To confirm the expression of Pax3 and Msx2 full length protein product from the 
plasmids pCMV -Pax3 and pCMV -Msx2 Western blotting was also used. These 
plasmids were transfected into both NIH -3T3 and C2C 12 and the proteins harvested 
for Western blotting. Transfections containing varying quantities of expression vector 
and pCMV- Script, or pCMV- Script alone (negative control), were conducted as 
described above but in 6 well plates. All quantities of cells and reagents were 
multiplied by 5 to account for the larger size of the wells and transfections conducted 
using Lipofectamine as normal. 
After incubating for 24 hours, cells were washed twice in PBS, trypsinised and re- 
suspended in DMEM N -12 medium. These were then spun down (1000 rpm, 5 
minutes), washed in cold PBS, re -spun and the re- suspended in 100111 cold Western 
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Lysis Buffer. These were transferred to ice for 15 minutes, passed through a small 
gauge syringe 10 times, spun down at 13,000 rpm and the protein concentration of the 
supernatant assayed as described. Protein samples were stored at -80 °C, and Western 
blotting performed as described below. 
Proteins 
Choice of peptides used to raise a -Pax3 antibody 
The amino acid sequence of the Pax3 protein was derived from the cDNA sequence, 
and used to design immunogenic peptides to raise against the Pax3 protein. Peptide 
sequences and modification specifications were emailed to Genosphere 
Biotechnologies Ltd. who synthesised, modified and finally conjugated the peptides 
to Keyhole Limpet Heamocyanin. This was then injected into Rabbits over several 
weeks, and the serum checked for immunogenicity using an ELISA with the original 
peptides as primary substrate. Once good titres had been obtained the un- purified sera 
was shipped back from the company for analysis and purification in our lab. 
Protein Quantification 
Protein concentration was determined using the BCA Reagent Kit (Pierce), against a 
known range of BSA concentrations, according to the manufacturer's instructions. 
Assays were conducted in a 96 well plate and absorbance at X562 was measured on a 
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plate reading spectrophotometer. A standard curve was drawn, linear regression 
performed and the resulting equation used to calculate the concentration of total 
protein of samples. 
Western Blotting 
Western blotting was used to confirm the specificity of the a -Pax3 antibody, 
expression of Pax3, Msx2 and Pax7 in cell culture and embryonic tissue. The 
following general protocol was used in all cases; the specific antibody concentrations 
used were determined empirically for each serum. 
SDS-PAGE 
10% Tris -Glycine polyacrylamide Novex pre -cast gels (Invitrogen) were used to 
separate proteins in one dimension. 10µg protein was loaded on each gel after being 
reduced by boiling in the following mixture: 
Protein Loading Mixture n pd protein sample (14tg) 
1 pl ß- Mercaptoethanol 
5 µl SDS 4X Sample Loading Buffer 
(n + 6) - 20 pi Western Lysis Buffer 
Samples were boiled for at least 10 minutes at 100 °C and then loaded into a lane 
filled with 1X SDS Running Buffer. The gels were set up in the Xcell SureLock Mini - 
Cell (Invitrogen) and run for 1 hour and 40 minutes at 150V. Magic Mark 
(Invitrogen) was used as a ladder to enable sizing of bands. 
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Protein Transfer 
Immediately after electrophoresis proteins were transferred onto nitrocellulose 
membrane. The gel was removed from the SDS -PAGE apparatus, rinsed in ddH2O 
and Transfer Buffer before being placed in a sandwich between two sheets of 
Whatmann paper and two thick nylon sponges on the outer surface. Next to the gel 
inside the sandwich a piece of nitrocellulose membrane (Biorad) was placed on the 
side which would face the positive electrode in the transfer tank. This was then placed 
into a transfer tank and covered in Transfer Buffer. Transfer was conducted at 4 °C at 
50mA for 16 hours. The transfer apparatus was then dismantled and the nitrocellulose 
stained with Amido Black to demonstrate transfer and examine equal loading of 
protein samples. Excess Amido Black was then washed off in ddH2O and an image of 
the membrane recorded. Membranes were chopped into separate pieces at this stage if 
necessary. 
Immunodetection 
The following protocol was used during immunodetection. 
1) Block membrane in Blocking Buffer for 1 hour 
2) Add primary antibody at appropriate concentration, diluted in Blocking Buffer 
3) Incubate with shaking at 4 °C for 16 hours 
4) Wash three times in PBS -T 
5) Add secondary antibody at appropriate concentration, diluted in Blocking Buffer 
6) Incubate with shaking at RT for 2 hours 
7) Wash three times in PBS -T 
92 
8) Detect using the ECL+ detection system (Amersham) according to manufacturer's 
instructions and exposing to X -Ray film 
The solutions used were as follows: 
Western Lysis Buffer 150mM NaCI 
25mM Tris-HC1 (ph 7.5) 
1% Triton X -100 
0.1% SDS 
+ Complete Protease inhibitor 
tablets (Roche) 
4X Sample Loading Buffer 0.5M Tris -HC1 (pH 6.8) 
10% SDS (w /v) 
10% Glycerol 
0.1% Bromophenol Blue 
5X SDS Running Buffer 0.125M Tris -Base (pH 8.3) 
0.96M glycine 
0.5% SDS 
Western Transfer Buffer (make frc 100mM glycine 
120mM Tris -Base 
200m1 methanol 
Amido Black 0.1% Amido Black 
25% isopropanol 
10% acetic acid 
PBS -T 1X PBS 
0.1% Tween -20 
Blocking Buffer 5% powdered milk solution in 
PBS -T 
Immunohistochemistry 
Mouse embryos were obtained and dissected at specific ages as described. Embryos 
were then fixed in 10% paraformaldehyde for 16 hours at 4 °C and placed in 70% 
ethanol before being embedded in paraffin. Waxed embryos were then sectioned at 
101..tm thickness and placed on glass slides. 
The following protocol was used for immunohistochemistry. 
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1) Dewax sections in xylene (twice for10 - 20 minutes) 
2) Rehydrate sections in series of descending ethanols (100% - 50 %) 
3) Wash with PBS (3 times for 5 minutes) 
4) Block endogenous peroxidases with a solution of 3% H202 and 10% methanol in 
PBS for 15 minutes in the dark 
5) Wash with PBS -TX (3 times for 5 minutes) 
6) Wash with (3 times for 5 minutes) 
7) Wash in l OmM Sodium Citrate Buffer for 15 minutes 
8) Boil slides in microwave for a total of 20' (5' -20') as follows: 
9) 5 minutes at full power 
10) top up with dH2O 
11) repeat up to 3 more times 
12) Rest slides for 20 minutes to cool down 
13) Incubate with Blocking Solution for 2 hours at RT 
14) Wash with PBS -TX for 5 minutes 
15) Incubate with primary antibody diluted in Blocking Solution for 16 hours at 4 °C 
16) Wash with PBS -TX 5 times for 5 minutes 
17) Incubate with biotinilated secondary antibody (1:200) Blocking Solution for 1 hour 
at RT 
18) Wash with PBS -TX 5 times for 5 minutes 
19) Incubate with the Streptavidine -HRP complex (1:400, ABC Kit) Blocking Solution 
for 1 hour at RT 
20) Wash with PBS -TX twice for 5 minutes 
21) Wash with PBS 3 times for 10 minutes 
22) Develop with a solution of 0.03% DAB and 0.003% H202 in PBS 
23) Wash slides 3 -5 times in PBS 
24) Counter stain with Crystal Violet if necessary 
25) Dehydrate sections in a series of ascending ethanols and xylene 
26) Mount the tissue with DPX 
Sections were examined under an inverted light phase contrast microscope and 
images taken using a digital camera. 
The solutions used were as follows: 
PBS -TX 0.2% solution of Triton X -100 in PBS 
Sodium Citrate Buffer (pH 6.0) 100mM sodium citrate 
Blocking Solution 0.2% gelatine 
10% goat serum 
in PBS -TX 
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Antibody Purification 
After the immunogenicity of the a -Pax3 serum was confirmed, column purification 
was performed using Protein -G sepharose (Amersham). The sepharose was degassed 
under vacuum for 30 minutes at RT before being packed onto a 1 cm diameter glass 
EconoColumn (Biorad). Flow rate was adjusted to lml per minute, and the column 
washed with 10 bed volumes of ice cold TBS. All purification was conducted in the 
cold room unless otherwise stated. 
The volume of serum purified was calculated as follows: 
Binding capacity of column (5m1) = 100mg IgG 
Assume 90% binding efficiency = 90mg, and that rabbit IgG concentration is 5mg per 
ml, therefore 90/5 = 18ml serum applied to column. 
Any debris from the serum was spun out at 15,000g for 5 minutes at 4 °C, and then 
applied to the column at a flow rate of 1 ml per minute. The serum was passed 
through the column twice. The column was then washed with 180m1 ice cold TBS 
until no protein could be detected from the eluate using the BCA Kit (Pierce). 
100µ1 Neutralisation Buffer was added to 20 x 1.5ml Eppendorfs as all the TBS was 
allowed to drain from the column. The column was transferred to RT and 15ml RT 
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pH 2.7 Elution Buffer was applied. 10 x 1ml fractions were collected. 15 ml of RT pH 
1.9 Elution Buffer was the applied and 1ml fractions were collected. Samples were 
mixed immediately to ensure neutralization and placed on ice. The BCA Kit (Pierce) 
was then used to quantify the protein concentration and the X562 was measured. X562 
vs. fraction number was then plotted and two peaks were identified and separated into 
two fractions for later testing with Western blot and immunohistochemistry. For long 
term storage, the fractions had BSA added to 5 %, aliquoted and stored at -80 °C. 
TBS 50mM Tris-HC1 (pH 7.4) 
150mM NaC1 
Neutralization Buffer 1M Tris -HCl (pH 8.0) 
1.5M NaC1 
1mM EDTA 
Elution Buffer pH 2.7 50mM glycine (pH 2.7) 
Elution Buffer pH 1.9 50mM glycine (pH 1.9) 
Chromatin Immunoprecipitation (ChIP) 
Chapter 6 is dedicated to ChIP experiments, and so a detailed description of the 
rationale behind this method is not given here. 
PCR primers were designed to amplify a region of either the promoter or downstream 
cis -regulatory elements of both the Pax7 and Wntl gene loci. PCRs were optimised 
for use on genomic DNA. The position of these primers and the reasoning behind 
their design is included in Chapter 6. ChIP primer sequences are recorded in 
Appendix 2. 
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Mouse embryos were obtained as described and sacrificed at E10.5. Embryos were 
dissected out and the telencephalon removed. These regions were deemed as being 
likely to contain tissues where the hypothesised interactions suggested from Chapters 
3 and 4 (i.e. neural tube and somite / mesenchyme) might be found. 
An in vivo ChIP methodology was designed specifically for use in this thesis as an 
amalgamation of in vitro methods used by other groups, and published on the interne. 
Several approaches were tested, and the following is a description of the method 
which proved successful. One of the major considerations in using an embryological 
source is the rapid and uniform fixation of the source material. Over exposure to 
formaldehyde would result in excessive crosslinking making subsequent enrichment 
steps impossible. To enable embryonic tissues to be manipulated in a manner closer to 
that of the tissue culture cells usually used in this type of analysis, a gentle 
disassociation protocol was utilised after dissection to generate a suspension of single 
cells. This also enabled cell counting and a uniform quantity of starting material to be 
used in each repeat experiment. 
Dissected embryos were then immediately disassociated using the Papain 
Dissociation System (Worthington Biochemical Corporation) to obtain a suspension 
of cells in PBS. Cells were counted and equal numbers of cells used in every ChIP 
experiment (1 x 107). Cell suspensions were then fixed by adding formaldehyde to 
1%, and incubating with gentle agitation at 37 °C for 10 minutes. The fixing process 
was then quenched by the addition of glycine to 125mM. The cells were then pelleted, 
washed in PBS, and then re- suspended in 200111 Lysis Buffer and incubated on ice for 
10 minutes. 
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Sonication conditions were previously optimised on disassociated mouse embryos to 
generate fragments of 500bp to 1kb, see Figure 6.3B. This should be optimised for 
every individual sonciator and probe before attempting these experiments since large 
variation between individual equipment and probes is generally observed. 
Suspensions were then sonicated to generate fragments of an appropriate length. 
Samples were then centrifuged at 13,000 rpm for 5 minutes at 4 °C to remove debris. 
Supernatants were then transferred to new tubes. 300111 fresh Lysis Buffer and 501.11 
protein G sepharose (Amersham) with Salmon sperm DNA (2.5 µg /µl) was added to 
pre -clear the lysates. The samples were then gently rotated at 4 °C for 2 hours. The 
beads were spun down, 6,000 rpm for 1 minute, and the supernatants transferred to 
fresh tubes. 20 .ig of purified a -Pax3 antibody was then added and the samples 
rotated at 4 °C for 16 hours. 
50µ1 Protein G Sepharose was then added to each sample, and rotated for a further 4 
hours at 4 °C. Immunoprecipitated complexes were then spun down at 6,000 rpm for 
1 minute and the supernatant discarded. Complexes were then washed in 500 µl of the 
following, spinning down to recover the beads each time (all steps performed at 4 °C): 
1) Lysis Buffer, 10 minutes 
2) Lysis Buffer, 5 minutes 
3) Low Salt Buffer, 5 minutes (low stringency) 
4) High Salt Buffer, 5 minutes (high stringency) 
5) LiC1 Buffer, 5 minutes (removal of non -specific chromatin - agarose interactions) 
6) TE Buffer (pH 8.1), 30 minutes 
7) TE Buffer (pH 8.1), 5 minutes 
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Finally the complexes were re- suspended in fresh Elution Buffer , and vortexed at RT 
for 15 minutes. The sepharose was then spun out and the supernatant transferred to a 
fresh tube. Formaldehyde cross linking was then reversed by adding 5111 8M NaC1, 
1µl RNaseH (Qiagen), 5111 Protinase K (Promega) and incubating at 65 °C for 16 
hours. 
DNA was then purified using phenol chloroform and precipitated using ammonium 
acetate as described. The seeDNA nucleic acid reagent (Amersham) was added during 
precipitation to visualise the pellet. Pellets were re- suspended in 50µ1 ddH2O and 5µl 
ran out on an agarose gel against serial dilutions of `input' sonicated chromatin (the 
source of positive control, see Chapter 6) to ensure that similar quantities of template 
DNA were added to each PCR reaction. 5111 of ChIP and input chromatin were then 
used in each PCR reaction. PCR conditions were as shown in Chapter 6 and PCR 
products visualised on a 2% agarose gel. 
The solutions used were as follows: 
Lysis Buffer 150 mM NaCI 
25 mM Tris -HC1 ph 7.5 
1% Triton X -100 
0.1% SDS 
0.5 % Deoxycholate 
Low Salt Buffer 0.1% SDS, 
1% Triton X -100 
1mM EDTA 
20mM Tris -HCI, pH 8.0 
150mM NaC1 
High Salt Buffer 50 mM Tris -HCI, pH 8.0 
500 mM NaC1 
0.1 % SDS 
1% Triton X -100 
1 mM EDTA 
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LiCI Buffer 50 mM Tris, pH 8.0 
1 mM EDTA 
250 mM LiC1 
1% NP -40 
0.5% Deoxiholate 
TE Buffer 10 mM Tris -HC1, pH 
1 mM EDTA 
8.0 
Elution Buffer 1% SDS 
0.1M NaHCO3 
Every solution had protease inhibitors added fresh before use in each experiment, and 
were kept at 4 °C. Complete Protease Inhibitor Cocktail tablets (Roche) were used. 
Bioinformatics 
DNA sequences were obtained, where available, from www.ensernbl.org and 
annotated manually. Global alignments were performed using PipMaker (Schwartz, 
2000), Jemboss, and ClustalW software, all available from www.hgmp.ac.uk. 
Transcription factor binding sites were predicted using the Matlnspector program, 
available from Genomatix; data outputs were then dumped into Excel and analysed 
manually with this software. Cloning and DNA analysis was performed using the 
MacVector 7.2 software from Accelrys. 
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Chapter Three: Wntl regulation 
Introduction 
In this chapter, the interaction between Pax3 and the regulatory elements of the Wntl 
gene are investigated. As described in Chapter 1, Wntl provides an attractive potential 
target for regulation by Pax3 due to both its expression pattern, timing and its 
apparent position as genetically downstream of the Pax3 signal (see (Conway et al., 
2000; Deardorff, 2001; Meulemans and Bronner- Fraser, 2004; Monsoro -Burq, 2004) 
for representative evidence). This chapter will show that, whilst Pax3 cannot be 
demonstrated to have any significant regulatory effect on the 3' distal enhancer 
region, (Echelard et al., 1994), the identification of a putative Pax3 consensus site 5' 
proximal to the transcriptional start site of the Wntl gene enables a regulatory 
interaction between this region and the Pax3 transcription factor to be established in 
vitro. Hypothesis One will be addressed first. 
Hypothesis One 
Pax3 regulates Wntl directly, most probably through the 3' distal enhancer region, in 
vivo during the development of the neural crest. 
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Wntl expression is decreased in Sp2H homozygotes 
Before establishing Wntl as a direct target of regulation by Pax3, it was important to 
unequivocally demonstrate the misregulation of this gene in vivo. Whilst other groups 
have shown Pax3 to be unperturbed in Wntl mutants (Ikeya et al., 1997) and later 
studies have shown evidence from in situ hybridisations which suggest Wntl is 
significantly downregulated in the Sp2H homozygous mutant (Conway et al., 2000), 
no quantitative proof of this misregulation in the Splotch mouse has been reported. 
Demonstrating a change in Wntl expression on a Pax3 null background was 
perceived as an essential step before an investigation into the potential regulatory 
relationship could be taken further. 
To achieve this, Quantified Reverse Transcriptase PCR (QRTPCR) was performed on 
RNA extracted from wild type and mutant sibling pair embryos at E9.5 as described 
(see Chapter 2 for a detailed description of the QRTPCRT technique). Primers pairs 
used were GAPLITEF /R and W 1 LITEF /R, (all primers are listed in Appendix Two). 
The assay was performed on four pairs of embryos, genotyped by PCR (primers 
P3GENOF /R), which were then homogenised and RNA extracted using a RNeasy 
Midi kit (Qiagen). RNA was then quantified using a UV spectrophotometer, and a 
fixed quantity added to a reverse transcriptase reaction. QRTPCR, using the SYBR 
Green dye (Qiagen) and a Opticon Monitor system (MJ Research), was then 
performed using the 55 1'35 program as described. Expression levels for mutant 
embryos were then reported as a % of wild type. A wild type standard curve was used 
to interpolate and the results averaged across the four sib -pairs. Blank and no RT 
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controls were negative, and blank fluorescence automatically subtracted from the data 
set by the Opticon software. These data can be seen in Figure 3.1. 
This figure clearly shows a significant reduction of Wntl expression of around 40% (p 
= 0.003). In contrast no detectable difference in GAPDH expression was observed in 
the same embryo pairs. This figure is in keeping with previously published estimates 
of 50% (Conway et al., 2000) and was interpreted as meaning that the levels of Wntl 
expression in the Sp2H mutant are significantly reduced in comparison to the wild 
type. This result does not indicate why this difference is observed. Wntl may be 
entirely independent of Pax3 regulation, but expressed within a cell population that is 
reduced in Sp2H homozygous mutants. To establish a regulatory role for Pax3, a more 
detailed analysis of the regulatory elements known to control Wntl expression was 
performed. 
Pax3 does not interact with the Wntl 3' enhancer 
The expression of Wntl has been faithfully recaptured by the expression of a LacZ 
reporter cassette driven by a 5.5kb enhancer fragment 3' distal to the transcriptional 
start site (Echelard et al., 1994). This region has been investigated in detail, and a 
number of potential transcription factor binding sites have been mapped to this region 
(Iler et al., 1995; Rowitch et al., 1998). To enhance this investigation a bioinformatic 
analysis of this 5.5kb sequence was performed using Matlnspector software 
(Matlnspector). This searches genomic sequence for significant matches to known 
transcription factor binding sites based on known targets and sequence affinities. 
Whilst over 600 sites were predicted, with a core similarity of 75% or over, only three 
T 
T 
Figure 3.1 : 
QRTPCR of Wntl and GAPDH transcript levels 
in Pax3 -1- embryos. Levels expressed as % of 
wild type expression. GAPDH 94.01% of wild 
type (no difference), Wntl 59.4% of wild type 
expression (40.6% reduction). n = 4 wild type / 
homozygous mutant sibling pairs. Error bars are 










potential Pax binding sites were identified. These were all predicted as Pax5 binding 
sites. Since Pax3 and Pax5 are not from the same Pax gene subfamily, and Pax5 is 
thought to be primarily involved in B- lymphocyte development (Urbanek, 1994), 
these seemed unlikely to be potential Pax3 binding sites. 
A lack of predicted binding sites does not preclude a regulatory interaction between 
this fragment and the Pax3 protein via a novel site. To investigate this possibility the 
5.5kb enhancer fragment spanning this region was cloned from the pWEXP3 plasmid 
(A. McMahon, kind gift) as BglII fragment into the pGL3promoter Luciferase 
reporter construct (Promega) BamHI site and clones screened to ensure genomic 
orientation relative to the Luciferase ORF. The pGL3promoter construct carries a 
Firefly Luciferase reporter gene under the control of a weak SV40 promoter, and is 
designed to enable the dissection of enhancer elements. This construct was then co- 
transfected into NIH -3T3 cells (Pax3 and Wntl negative by RTPCR, data not shown) 
with a Pax3 expression construct, pCMV -Pax3. The expression construct was 
generated by cloning full length Pax3 cDNA from wild type E10.5 RNA by RTPCR 
using the primers 3/5 P3IRES to amplify full length Pax3 cDNA. This was then 
TOPO cloned into pCR -II -TOPO -Blunt and sequenced using the Pax3 sequencing 
primers shown in Appendix Two. Full length Pax3 with no mutations was then sub - 
cloned into pCMV- Script (Stratagene) as a Sacll - BamHI fragment. This generated a 
plasmid with the full length Pax3 cDNA under the control of the CMV promoter. 
These constructs are shown in Figure 3.2A. 
pCMV -Pax3 was then co- transfected into NIH -3T3 cells with pW1ELuc, and the fold 
induction over pGL3promoter baseline calculated for 6 triplicate runs, see Figure 
Figure 3.2: 
A) Illustrating Wntl enhancer Luciferase reporter 
construct and pCMV -Pax3 expression construct, B = Bglll 
- BamHI cloning sites. 
B) Luciferase data illustrating normalised luminescence 
for pW1 ELuc with and without Pax3 expression (100ng 
pCMV -Pax3 or 100ng empty vector). Data is expressed 
as fold induction over pGL3promoter (pW1 ELuc without 
Wntl enhancer fragment). n = 6, error bars are SEM, 
induction is non -significant (p = 0.24, two sample t test) 
pW1 ELuc 
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3.2B. A detailed description of the Luciferase protocol and the data treatment used in 
this thesis can be found in Appendix 4 and is not given here. Whilst a very slight 
induction was observed with the addition of pCMV -Pax3 versus empty vector, 
pCMV- Script, this was not significant. The reverse enhancer orientation was also 
examined in this assay, but again no change in Luciferase activity could be detected 
on co- transfection with pCMV -Pax3 (data not shown). 
To ensure the pCMV -Pax3 expression vector was producing full length Pax3 protein 
in these cells, Western blots on protein extracts from samples transfected with pCMV- 
Pax3 and those transfected with pCMV- Script were performed. The primary antibody 
was derived as described in Chapter 5. Un- purified serum was used in these 
experiments since non -specific bands enable an easy control of loading equivalence 
between lanes. A representative blot can be seen in Figure 3.3. This clearly shows the 
expression of full length Pax3 protein in these samples (red arrow). It was concluded 
that the lack of Luciferase induction in these samples could not be attributed to a 
problem with Pax3 expression from the pCMV -Pax3 construct. 
In this in vitro assay, Pax3 could not be shown to interact with the 3' distal enhancer 
element of Wntl. 
The Wntl 5' promoter is Pax3 responsive 
Since the 3' distal enhancer of Wntl did not show any reaction to Pax3 co- expression, 
the 5' promoter region of the locus was then examined. The examination of this 
region, in spite of the control of Wntl expression being generally attributed to the 
Figure 3.3 : 
Western blot confirming expression of Pax3 in Luciferase 
assay system (NB. samples taken from actual luciferase 
experiment and unpurified a -Pax3) Pax3 -53KDa 









enhancer element investigated above, was seen as important for several reasons. 
Firstly, (Serbedzija and McMahon, 1997) reported that the expression of a Wntl -LacZ 
transgene was altered on a Pax3 null background. This transgenic was constructed 
using the WZT9B construct, and contains both the 5.5kb 3' enhancer region and a 
portion of the Wntl genomic 5' proximal promoter (Echelard et al., 1994). Further, 
studies in Xenopus (Gao et al., 1994) have implicated this region as important in 
inducing reporter gene expression concomitant with neural cell specification. Also, 
the differentiation of P19 embryonal carcinoma cells along a neuroectodermal lineage 
using retinoic acid treatment has been illustrated to induce both Pax3 (Pruitt, 1992) 
and the expression of Wntl via an element in the 5' promoter region (St -Arnaud and 
Moir, 1993). Finally, the Wntl promoter is essential in Six3 mediated repression of 
Wntl expression in the developing telencephalon (Lagutin et al., 2003), establishing a 
regulatory precedent for this region in anterior neural tissues. 
The Wntl 5' proximal promoter was then subjected to bioinformatic binding site 
analysis (Matlnspector). This identified 178 potential transcription factor binding sites 
in the proximal 1.5kb upstream of the Wntl gene. Several Pax gene consensus sites 
were found, including Paxl , Pax4 and Pax9. Most importantly, one Pax3 consensus 
was discovered in extreme proximity to the Wntl transcriptional start site (46óp 
upstream). This is shown in Figure 3.4A. ClustalW local alignments were then 
performed on this region between human and mouse genomes, and illustrated a high 
degree of conservation (Figure 3.4B) suggesting functional significance. Finally, 
analysis of the human, mouse, Fugu and Xenopus Wntl promoters (from (ensembl)) 
revealed putative Pax3 binding sites in similar positions in all 4 species (Figure 3.4C). 
This site is also found 
A 
Figure 3.4 : 
A) Identification of Pax3 binding consensus in the Wntl 
5' promoter. 
B) Local alignment of human and mouse promoters 
showing high overall level of conservation. Red bar 
highlights Pax3 consensus site. 
C) Alignments showing conservation of consensus in 
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on the murine Wntl promoter fragments used in the constructs examined in 
(Serbedzija and McMahon, 1997) and (St -Arnaud and Moir, 1993). 
To investigate the possible functional significance of this conserved element, 
Luciferase constructs were made to test this in Pax3 co- transfection assays. The Wntl 
proximal promoter was obtained from pMT86 (R. Nusse, kind gift) as a 4.9kb BamHI 
/ NcoI fragment and cloned into the BglII / NcoI sites of the pGL3basic (Promega) 
Luciferase reporter vector. The NcoI site in the Wntl sequence contains the ATG start 
codon of the Wntl gene. Cloning into the NcoI site of pGL3basic (also the ATG of 
the Luciferase ORF) positions the Wntl promoter in an identical position to the 
Luciferase ORF as it is to the translational start of Wntl in vivo. pGL3basic contains a 
Firefly Luciferase ORF in a promoterless construct to enable the investigation of 
putative promoter elements. This construct was named pW 1 PLuc and is illustrated in 
Figure 3.5A. This was co- transfected into NIH -3T3 cells with either the pCMV -Pax3 
expression construct or empty vector. Four triplicate runs were completed for these 
assays, and the normalised luminescence baselined to pGL3basic background to 
generate fold induction. A clear induction of Luciferase activity concomitant with 
Pax3 expression can be seen in Figure 3.5A. 
To compare this induction with the results obtained with the pW1ELuc construct, the 
data was rebased to uninduced samples (i.e. co- transfections with empty vector) and 
illustrated in Figure 3.5B. It was concluded from this analysis that Pax3 is able to 
cause induction of a reporter gene via the proximal promoter of Wntl , and not via the 
distal enhancer element, in vitro. 
Figure 3.5: 
A) Induction of luciferase activity from pW1 PLuc on co- 
transfection with pCMV -Pax3. Data is normalised luminescence 
expressed as fold induction over pG3basic (pW1 PLuc without 
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Figure 3.5: 
B) Comparison of Pax3 induction of pW1 PLuc and pW1 ELuc. 
Data is normalised luminescence, fold induction over baseline 
(respective luciferase vectors without Wntl regulatory sequence), 
indexed to un- induced to allow direct comparison. n = 4 and 6, 
respectively, error bars = SEM. 
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To further investigate the relationship between the Wnt1 promoter and the Pax3 
protein a series of deletion constructs were made using restriction sites native to the 
element. pWIPLuc was digested with Asp718 to remove 3.7kb of sequence distal to 
the Luciferase ATG. The backbone was then re- ligated to generate pW1P(1.2)Luc. 
Similarly, twin Apal sites were used to remove the proximal 3.1kb of the Wntl 
promoter to generate pW 1 P(- 1.8)Luc. In this latter construct the Pax3 consensus site 
is also removed. These constructs are illustrated in Figure 3.6A. Each of these 
constructs were then co- transfected into NIH -3T3 cells with either pCMV -Pax3 or 
empty vector, as previously described, to assay any transcriptional response to the 
Pax3 protein. These results can be seen in Figure 3.6B. Clearly, whilst both pWIPLuc 
and pW1P(1.2)Luc retain their response to Pax3 expression, the pW1P(- 1.8)Luc 
construct does not. Since this latter plasmid has lost the Pax3 consensus site identified 
in Figure 3.4, this data further argues for a functional role for this site in binding 
Pax3, at least in vitro. Finally, the pWIPLuc and pW1P(1.2)Luc were exhaustively 
tested in pCMV -Pax3 co- transfection assays using a range of expression vector 
quantities (this was also shown to generate a proportional range of Pax3 expression 
levels within the cells transfected, see Figure 4.15A). This was to ensure both 
specificity of Pax3 response by illustrating a concentration dependence and to test the 
result reported by (Chalepakis et al., 1994) which demonstrates a biphasic 
transcriptional response of increasing Pax3 concentrations when binding to reporter 
gene constructs carrying the NCAM promoter. This can be seen in Figure 3.6C. 
Whilst these data clearly demonstrate a concentration specific response to Pax3 gene 
expression over the concentration range examined, no biphasic response (i.e. loss of 
transcriptional inductive ability at higher Pax3 concentrations) was observed. Whilst 
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Figure 3.6: 
A) Schematic of pW1 PLuc and deletion constructs pW1 P(1.2)Luc 
and pW1 P(- 1.8)Luc, Asp = Asp718, Apa = Apal sites 
B) Luciferase data comparing the induction of the Wntl promoter 
deletion constructs with 100ng pCMV -Pax3 vs. empty vector. Data 
is normalised luminescence expressed as fold induction over 
baseline (pG3basic) and indexed (empty vector = 1) to enable 
comparison between constructs. n > 3 for each data point. 
C) Variation in Luciferase induction from pW1 PLuc and 
pW1 P(1.2)Luc over a range of Pax3 concentrations (expressed as 
ng pCMV -Pax3 plasmid used in each transfection). Data is 
normalised luminescence expressed as fold induction over baseline 
(pGL3basic) and indexed to enable comparison bewteen 
experiments n = 5 - 11 (depending on data point), error bars 
represent SEM. 
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generate this biphasic response, the apparent plateau of transcriptional induction from 
250ng of pCMV -Pax3 per well would suggest this is not the case. Perhaps the mode 
of Pax3 transcriptional induction on the Wntl and NCAM promoters differs, 
explaining this discrepancy. 
The data presented above strongly argue that Pax3 can bind to and transactivate the 
Wntl promoter in vitro, and that this interaction occurs via the Pax3 consensus site 
identified. To show that the Pax3 consensus site is necessary and sufficient for this 
observed Pax3 induction, site directed mutagenesis was performed to ablate the core 
binding residues, and replace them with a low affinity sequence. Primers were 
designed to mutate the TCGC core Pax3 binding consensus (as defined by 
MatInspector and (Chalepakis and Gruss, 1995; Phelan and Loeken, 1998; Underhill, 
1997), etc) to the sequence ATAA. The actual primers held a mutation in an 
additional base 5' to the TCGC sequence, altering the native sequence CTCGC to 
GATAA. The reason for this additional change is that the mouse promoter sequence 
contains a tandem repeat of the core consensus; TCGCTCGC. It was feared that the 
preceding TCGC might be able to substitute for the mutated core consensus, so the 
final base of this was also mutated. An alignment of these sequences can be seen in 
Figure 3.7A. Site directed mutagenesis was performed on pW1P(1.2)Luc using a 
QuikChange Site Directed Mutagenesis kit (Stratagene), and the primers 
W1_sub_FWD and W1_ sub REV (see Appendix 2). Clones were screened by 
sequencing (from the GL3 primer within the Luciferase ORF (Promega)) and aligned 
to the wild type sequence to confirm the specificity of the mutagenesis. The resulting 
plasmid was named pW 1 PALuc. 
T 
Figure 3.7 : 
A) Sequence alignment of wild type and mutated Pax3 core 
consensus sequence 
on the plasmids pW1 P(1.2)Luc and pW1P<delta>, respectively 
B) Luciferase data contrasting luciferase induction on co- transfection 
with pCMV -Pax3 between pW1 P(1.2)Luc and pW1P<delta>. Mutant 
Wnt1 promoter shows a compete loss of Pax3 induction; co- 
transfection experiments with wild type promoter were conducted in 
tandem to ensure any loss of luciferase induction in the mutant could 
not be attributed to other factors. n = 3, error bars are SEM. 
A Mutated Promoter Sequence 
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Co- transfection experiments, using pCMV -Pax3 at levels previously shown to elicit a 
strong induction of Luciferase activity from the un- mutated plasmid (100ng) were 
then performed using pW1PALuc as the reporter construct. A total loss of Pax3 
induction was observed on co- transfection with the pCMV -Pax3 plasmid. To ensure 
this loss of induction was due to the consensus site mutation and not a general failure 
of the Luciferase assay system, experiments using the un- mutated pW1PLuc reporter 
construct were run in tandem. No loss of Pax3 induction was observed. These data 
can be seen in Figure 3.7B. 
It was concluded from these experiments that the transcriptional induction driven 
from the Wntl promoter by Pax3 was due to the interaction of the protein with this 
consensus binding site. 
Electrophoretic mobility shift analysis (EMSA) was not performed on this sequence. 
This was because the mutation incorporated into the pW1PALuc plasmid was based 
on one made by (Kwang et al., 2002). In this study, the core consensus site for Pax3 
binding to the Msx2 promoter, TCAC (TCGC here) was mutated to GATA (GATAA 
here). This mutation was used to show the specificity of Pax3 binding in a series of 
EMSA experiments where this mutation causes a complete loss of Pax3 binding. 
Given the similarities of the core consensus sites in question, and the nature of an 
EMSA experiment (i.e. purified protein binding to radiolabelled oligonucleotide), an 
EMSA performed using the Wntl promoter Pax3 consensus described above would 
be an almost exact copy of the experiment reported by this group. It was decided that 
an EMSA could not generate a sufficiently informative result in this context and was 
therefore omitted. 
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Discussion (Hypothesis One) 
The above studies address several of the issues raised by Hypothesis One. Pax3 does 
appear to be able to up- regulate the expression of a reporter gene, at least in vitro, 
using the Wntl regulatory elements and via a defined consensus site. This interaction 
does not occur via the 3' distal enhancer element but by the 5' proximal promoter, as 
shown here. These experiments do not confirm the occupation or biological relevance 
of this site in vivo. The experimental data reported in Chapters 5 and 6 will complete 
the investigation of this hypothesis by addressing this final issue. 
Regulation of Wntl by Msx2 
To investigate the potential role for Wntl in the regulation of the cardiac neural crest, 
as implicated by both the Sp2H mutant phenotype (Conway et al., 2000) and Dv12 and 
Pitx2 knockout phenotypes (Hamblet, 2002) and (Kioussi, 2002), the possibility of a 
further regulatory interaction between Msx2 and Wntl was examined, given the data 
presented in (Kwang et al., 2002). 
Hypothesis Two 
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Wntl transcription is directly downregulated by Msx2, most probably by the distal 3' 
enhancer element, in vivo with implications for the normal development of the 
cardiac neural crest. 
To investigate this possibility in vitro, a series of luciferase co- transfection 
experiments were conducted in a manner analogous to that described above. Firstly, 
an Msx2 expression vector was required. A search of the HGMP clone database was 
conducted and a potential full length Msx2 cDNA was identified. This was ordered 
and sequenced to confirm this was indeed a full length and mutation free Msx2. The 
vector within which the cDNA was supplied was a CMV expression vector (pCMV- 
Sport6 (Invitrogen)) analogous to the one used to generate the pCMV -Pax3 construct. 
Sequencing also confirmed that the Msx2 cDNA was in the correct orientation and 
position to enable its expression to be driven by the CMV promoter on transfection 
into a mammalian cell line. This construct is illustrated in Figure 3.8. 
NIH -3T3 cells were transfected with pCMV -Msx2, and a Western blot using an anti - 
Msxl/2 monoclonal obtained from the Developmental Studies Hybridoma Bank 
(DSHB) was then conducted on the protein extracts to confirm expression. This can 
be seen in Figure 3.8; the predicted molecular weight of Msx2 is -28kDa (ensembl). 
This confirms the expression of Msx2 in cells transfected with the pCMV -Msx2 
plasmid. 
The Matlnspector analyses of putative transcription factor binding sites in the Wntl 
promoter and enhancer elements were then re- examined to identify any Msx2 
consensus in these regions. This analysis revealed no Msx2 sites in the Wntl promoter 
Figure 3.8 : 
Schematic of pCMV -Msx2 and Western blot 
confirming expression in transfected NIH -3T3 cells 
using anti- Msx1 /2 from DSHB resource. 
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region, but an Msx2 consensus site in the distal 3' enhancer. Furthermore, this site 
was found to lie within the conserved 1 l0bp element shown by (Rowitch et al., 1998) 
to control Wntl expression in the early neural plate and developing brain. This site is 
illustrated in Figure 3.9B. 
To investigate this further, co- transfections of the pCMV -Msx2 vector and the 
pW 1 PLuc and pW 1 P(1.2)Luc reporter plasmids were performed. No consistent 
response to Msx2 co- expression could be observed over a range of pCMV -Msx2 
concentrations with either plasmid, see Figure 3.9A. The pCMV -Msx2 construct was 
then tested with the pW1ELuc plasmid, see Figure 3.9B. This experiment illustrated a 
potentially interesting and highly significant repression of around 50% at 250ng 
pCMV -Msx2, n = 3. 
To analyse this interaction further, a series of deletion constructs were made of the 
Wntl enhancer. In these constructs the 5.5kb Wntl enhancer fragments present in 
pW1ELuc was restricted further by BamHI and Spel digests to extract internal 
fragments. The backbone was then re- ligated to generate the serial deletion plasmids 
pW 1 E(bam)Luc and pW 1 E(spe)Luc. These are illustrated in Figure 3.10A. Neither of 
these constructs carry a deletion for the Msx2 consensus site predicted by 
MatInspector analysis. Deleting a small region containing this site in the plasmid by 
restriction digest proved impossible. Two MbiI sites were observed flanking a small 
region containing the Msx2 consensus and the highly conserved 110bp element within 
the larger enhancer region. Since the presence of other MbiI sites elsewhere within 
the backbone prevented a conventional deletion, the inverse experiment was 
performed. In this case, the 816bp MbiI fragment was then extracted from a digest of 
Figure 3.9 
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A) Wntl promoter constructs used to test the response of the 
Wntl promoter to co- expression with Msx2 (from pCMV - 
Msx2). Luciferase response to co- expression with Msx2. 
Data expressed as fold induction over baseline (pGL3basic). 
n = 3, error bars represent SEM 
B) Wntl enhancer construct used to test the response of the 
Wntl enhancer to co- expression with Msx2. Luciferase 
response expressed as fold induction over baseline 
(pGL3promoter). n = 3, error bars represent SEM. 
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the pW1ELuc plasmid and then shuttled into an empty pGL3Promoter vector 
restricted with Smal. This not only extracts the Msx2 containing fragment from the 
Wntl enhancer, but also places it within a different context within the Luciferase 
reporter vector. Since this region has been shown to behave as a canonical enhancer 
element by other groups (Echelard et al., 1994; Rowitch et al., 1998) and is therefore 
thought to be position and orientation independent, this was hoped to have no adverse 
effect on the ability of this element to respond to Msx2. This construct is also 
illustrated in Figure 3.10A 
Co- transfection with pCMV -Msx2 expression plasmid revealed that neither the 
pW 1 E(bam)Luc nor the pW 1 E(spe)Luc reporter plasmids demonstrated any 
significant loss of Msx2 inhibition. Both of these plasmids retain the Msx2 consensus 
site. When Msx2 was co- expressed with the pW1E(mbi)Luc plasmid with the Msx2 
containing fragment shuttled into a new vector, an almost identical level of repression 
was observed. These data can be seen in Figure 3.10B and 3.10C. (N.B. Previous 
controls (see the Luciferase Assay subsection in Chapter 2) were performed to ensure 
that the SV40 weak promoter carried on the pGL3promoter vector did not respond to 
Msx2 co- expression). 
From the above it was concluded that the Wntl enhancer, and not the Wntl promoter, 
was able to respond to Msx2 to repress transcription of a reporter gene. Furthermore, 
this repressive response could be mapped to an 816bp region containing an Msx2 
consensus binding site within an area of the Wntl enhancer demonstrated by previous 
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A) Schematic of Wntl enhancer deletion constructs used to 
dissect the response of the Wntl enhancer to co- expression with 
Msx2. B = BamHI, S = Spel, M = Mbil sites used in cloning 
B) Luciferase response of deletion constructs to co- expression with 
100ng pCMV- Msx2.Data expressed as fold induction over baseline 
(pGL3promoter), n = 3,error bars represent SEM 
C) Luciferase response of pW1 E(Mbi)Luc construct to co expression 
with 100ng pCMV- Msx2.Data expressed as fold induction over 
baseline (pGL3promoter), n = 3,error bars represent SEM 
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significance. Unfortunately, attempts to mutate this site with site directed mutagenesis 
were not be performed due to time constraints within this project. 
Pax3 and Msx2: a regulatory relationship at the Wntl locus? 
Any possible role of Wntl regulation in the development of the cardiac neural crest is 
likely to be extremely complex. The above study, however, has demonstrated that, in 
vitro, there is the possibility that Pax3 may act to induce the expression of Wntl via 
its promoter and that Msx2 may conversely inhibit Wntl expression via its 3' 
enhancer. The basis for much of this hypothesis in terms of the cardiac neural crest is 
derived from a study by (Kwang et al., 2002) where they demonstrate that Msx2 is a 
downstream target for negative regulation by Pax3, and its expression domain is 
expanded in the Sp2N mutant background (See Chapter 1 for a full discussion of these 
findings). It would be interesting to examine the possibility that the inhibition of Wntl 
expression by Msx2 can further be overridden by the induction of Pax3 binding to the 
Wntl promoter. This would give Pax3 two mechanisms through which to ensure the 
correct level of Wntl expression in the wild type; both inhibition of Msx2 expression, 
as established by (Kwang et al., 2002), and also through the alleviating the repression 
of Wntl by Msx2 via an interaction on the regulatory elements of this gene. 
To begin to examine this possibility in vitro, a construct was made carrying both the 
Pax3 responsive Wntl promoter and the Msx2 responsive Wntl enhancer. This 
construct was named pW1EPLuc and was made by shuttling the Wntl promoter 
fragment from pW1P(1.2)Luc as an Asp718 - NcoI fragment into the same sites on 
the pW1E(bam)Luc reporter construct. This construct is illustrated in Figure 3.11A. 
Figure 3.11: 
A) Schematic of construct pW1EPLuc, A = Asp718 N = Ncol sites 
used in cloning 
B) Luciferase response of pW1EPLuc on co- transcfection with 250ng 
pCMV- Script (blue), 250ng pCMV -Msx2 (orange) and 250ng of both 
pCMV -Msx2 and pCMV -Pax3. n = 9, 3 and 3, repectively. * p = 
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130 
pW 1 EPLuc was co- transfected with pCMV -Msx2 to show that Msx2 was still able to 
significantly inhibit the transcription of the Luciferase reporter in this context. Next 
pCMV -Pax3 was also co- transfected with pCMV -Msx2 and it was demonstrated that 
the induction by Pax3 via the Wntl promoter was clearly able to override any 
inhibitory effect mediated by Msx2 in this experimental system, see Figure 3.11B. 
This enables the very tentative conclusion that Pax3 may be able to alleviate any 
repression of Wntl expression generated by Msx2. Obviously, there are numerous 
substantial flaws with this final piece of analysis, and these results should be 
interpreted with great caution. Firstly, the relative levels of expression of Msx2 and 
Pax3 from their respective expression constructs could not be meaningfully assessed; 
even Western blotting could not control for differing affinities of the two antibodies. 
It is impossible in this system to control for the levels of protein produced. An 
alleviation of repression by Pax3 could simply be a reflection of the pCMV -Pax3 
plasmid producing significantly more protein than pCMV -Msx2. Secondly, the 
observable level of repression from Msx2 co- expression with the pW1EPLuc reporter 
is inherently much lower than with the pW1ELuc family of reporters. This is because 
the endogenous activity of the Wntl promoter in the NIH -3T3 line is very low 
compared to that driven from the SV40 weak promoter found on all pGL3promoter 
derived vectors used to generate the pW1ELuc vectors (no cell line naturally 
expressing Wntl has been reported). Any reduction of expression in this context is 
necessarily going to be difficult to observe. Finally, this experiment contains four 
variables (two regulatory elements and two transcription factors) and is therefore 
almost impossible to meaningfully control. This data should be treated with extreme 
131 
caution and is presented here merely as a final observation of a potential relationship, 
rather than as proof of any interaction. 
Discussion (Hypothesis Two) 
The above studies address the issues raised by hypothesis two in a number of ways. It 
was demonstrated that Msx2 can repress reporter gene expression in vitro and that this 
occurs via the 3' enhancer element as predicted. The responsive region was mapped 
to an 816bp MbiI fragment containing an Msx2 consensus, but mutagenesis of this 
fragment was not conducted. It is concluded that this repression is likely to be 
mediated by this binding site, in light of the other evidence presented. Finally, 
evidence is provided that the inductive ability of Pax3 mediated by the Wntl promoter 
may be able to override the inhibitory effects of Msx2 on the Wntl enhancer, although 
this is a tentative conclusion. None of the above experiments demonstrate occupancy 
of these sites in vivo. This aspect of hypothesis one and hypothesis two is addressed in 
Chapter 6. 
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Chapter Four: Pax7 regulation 
Introduction 
In this chapter regulatory elements for the Pax7 gene are described, and potential 
direct regulatory interaction between these and the Pax3 protein tested and mapped in 
vitro. Pax7 represents an interesting potential target of Pax3 regulation not only due 
to its developmentally dynamic expression pattern (Jostes et al., 1990) or role in the 
development of regenerating muscle from an adult stem cell population (Seale et al., 
2000), but also due to the existing controversy over the relationship between these 
two genes in the mouse (Borycki et al., 1999; Relaix et al., 2004). A range of both wet 
and dry approaches were used to characterise the mouse Pax7 genomic locus, identify 
a number of interesting features and map a candidate region for both a 5' proximal 
promoter and a regulatory feature within intron 1. These were then verified 
experimentally in a Pax7 expressing cell line (C2C12) and a Pax3 response 
determined. 
Pax7 regulatory regions: Bioinformatics 
Since no information on the mouse Pax7 genomic locus had been reported, and no 
regulatory regions had been experimentally verified, a bioinformatic analysis of the 
Pax7 gene was performed. Using the mouse genome sequence database 100kb on 
either side of the predicted mouse Pax7 gene was downloaded and used in subsequent 
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analyses (ensembl). Firstly, the exons and introns were mapped using the published 
mouse cDNA sequence (Ziman et al., 2001). The mouse Pax7 locus is shown in 
Figure 4.1A, and shows a similar genomic organisation to that reported for human 
PAX7 (Vorobyov et al., 1997). 
In the search for gene regulatory elements, the obvious starting point is the 5' end of 
the gene which is likely to contain a minimal promoter driving transcription. To this 
end, -10kb around exon 1 (N.B. since the 5'UTR for the mouse Pax7 gene had not 
been determined experimentally, `exon 1' refers to the coding sequence from the 
ATG start site through to the first intron boundary) was subjected to a NIX analysis 
(HGMP). This uses a range of sequence analysis software to identify putative features 
of genomic sequence, taking into account species of origin and size of fragment. This 
analysis identified a CpG island, a putative promoter region and a potential RNA 
polymerase II start site, all 5' proximal to exon 1 (within 1 kb upstream). These are 
illustrated in Figure 4.1B. 
To take this analysis a step further, the mouse Pax7 locus was then analysed in 
tandem with the human Pax7 genomic region. Comparative sequence analysis can be 
used to identify likely regions of regulatory significance in non -coding DNA on the 
basis of sequence conservation. The assumption is that sequence changes in important 
genomic elements (i.e. coding or regulatory sequences) will be strongly selected 
against in evolution. Similarly, sequences encoding no genetic information can be 
mutated without any adverse effect on the fitness of the organism and are therefore 
not selected against. If a region of non -coding DNA is conserved at the sequence level 
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N.B. Exon 1 in all figures starts at ATG of coding sequence. 
A) Annotated Pax7 locus, spanning 200kb. Red boxes are exons 
predicted from cDNA sequences, shaded blue boxes represent 
areas of significant PIPMaker identified homology of >60% between 
human and mouse genomic sequences (see Figure 4.1E, and 
appendix 3 for a complete output). 
B) Inset of 5' end of Pax7 locus shown in A. Shows relative 
positions of exons 1 - 4, CpG islands predicted by NIX and 
PIPMaker analyses, RNA Polll and promoter sites identified by NIX, 
and regions of homology identified by Jemboss Dotmatcher 
software (see Figure 4.1D) 
C) %C +G plot for 3kb around Pax7 exon 1 (upper) and 
corresponding genomic locus (lower) showing NIX identified 
features. %C +G calculated as moving average from window of 100 
bp. Note increase in CG content proximal to the 5' end of exon 1 
(red line). 
D) Dotmatcher dotplot of human (y axis) vs mouse genomic (x axis) 
Pax7 locus upstream of ATG. Sequences of high position and 
sequence identity represented by a diagonal line of dots between 
the two axis. Results summarised graphically in Figure 4.1 B. 
(Window size = 10, Threshold = 23, Blossum matrix) 
E) PIPMaker output for the first 40kb of the Pax7 locus. Showing 
CpG islands, repetitive sequences, exons and percentage identity to 
human sequence (dots in vertical dimension running beneath 
genomic locus in horizontal plane represent % identity at that point) 
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homology can be interpreted as a potentially important site of regulation (see (Cooper 
and Sidow, 2003; Wasserman and Sandelin, 2004) for review). 
Firstly a simple alignment program, representing regions of homology between two 
sequences as a dot plot was performed. Regions of significant homology are 
summarised in Figure 4.1B and the Dotmatcher output (HGMP) shown in Figure 
4.1D for the 5kb immediately upstream of exon 1. The presence of a CpG island in 
this region also potentially infers a regulatory significance (Cross and Bird, 1995). 
The MacVector program was then used to independently analyse the CG content 
regions upstream of exon 1, and also identified a CpG island in the upstream lkb 
(Figure 4.1C). Finally, the PIPMaker suite was used to compare the entire genomic 
Pax7 locus between human and mouse (Schwartz, 2000). The sample output can be 
seen in Figure 4.1E, and complete output in Appendix 3. This program found clear 
regions of homology in the sequences upstream of exon 1, and also identified a CpG 
island across the 2.5kb surrounding exon 1 (Figure 4.1B). The PIPMaker output can 
be seen in summary in Figure 4.1A as blue boxes demarcating regions of high human 
- mouse homology ( >60 %) next to the corresponding genomic region. Since a 
number of different bioinformatics programs had identified significant homologies 
between human and mouse sequences, and several other features of potential 
regulatory importance, it was concluded that the 1 -1.5kb upstream of exon 1 provided 
an attractive candidate location for a Pax7 promoter. 
Pax7 regulatory regions: 5'UTR mapping 
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Bioinformatics can only identify regions of potential regulatory interest. To clone and 
test the Pax7 promoter, it was necessary to first characterise the 5' untranslated region 
(5'UTR) of the Pax7 transcript. This is because the regions of homology identified 
upstream of the coding exon 1 may represent novel upstream non -coding exons, 
rather than a promoter element, therefore positioning the transcriptional start site for 
the gene elsewhere. A schematic of the Pax7 transcript, with a hypothetical lkb 
5'UTR drawn for illustrative purposes, can be seen in figure 4.2A. Several groups 
have studied the Pax7 5'UTR in humans, using two different techniques, and these 
results are summarised in figure 4.2B. In all cases, the 5'UTR reported represented an 
extension of the first coding exon, and not a novel upstream non -coding exon. 
To investigate the 5'UTR of the mouse Pax7 gene a number of different approaches 
were employed. Firstly, primer extension (PEXT) was used to size the 5'UTR of the 
mouse Pax7 transcript. A schematic of this protocol can be seen in Figure 4.3A. 
Briefly, an antisense primer (kinase labelled at the 5' end with 32P) anneals to the 
Pax7 mRNA coding sequence, and the reverse transcriptase (RT) enzyme is then used 
to extend a cDNA from this point to the end of the 5' end of the 5'UTR. This is a 
quick method of approximately sizing the 5'UTR of Pax7 from a number of different 
sources. These results are shown in Figure 4.3B. Several gels are shown illustrating 
results from using different Pax7 mRNA sources and extending with different 
primers. Two 5'UTR sizes were repeatably (7 PEXT experiments, 4 different RNA 
sources / preparations) obtained from this method, corresponding to a 5'UTR of 300 - 
500bp and another of around 100bp (after correction for the positioning of the 
antisense primers within thé coding region of Pax7). These are referred to as High Mr 





N.B. Pax7 5'UTR shown is for illustrative purposes only 
A) Mouse Pax7 transcript illustrating positions of all 9 exons, 
5'UTR, start (ATG) and stop (TGA) codons and 5'Cap (5' terminal 
7- methylguanine) at the very distal end of the mRNA 
B) Table of published data to date highlighting source material, 
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Figure 4.3: 
N.B. Pax7 5'UTR shown is for illustrative purposes only 
A)illustration of 5' end of Pax7 mRNA, showing positions of 
primers EX2, B2 and B4 used in primer extension experiments 
shown in 4.3B and others. Primers are complementary to coding 
sequence and anneal 78bp (EX2), 171 by (B2) and 183bp (B4) 
downstream of the ATG at their 5' ends. Primers are radiolabelled 
at the 5' end, annealed to Pax7 mRNA and RT activity used to 
extend along the 5'UTR to the 5'CAP. ssDNA products are then 
ran out on acrylamide and sized according to kinase labeled 
ladder. Size of fragment - distance from 5' end of primer to ATG = 
size of 5'UTR 
B) Representative images of primer extension gels, showing 
banding pattern obtained (pBR322(Mspl) ladder used in every 
case) 
Bi and Bii: 
Primer EX2 used. Lane 1 = C2C12 total RNA, 2 = C2C12 mRNA, 
3 = C2C12 total RNA, 4 = E11.5 total RNA, 5 = E11.5 total RNA 
from a Pax3 -I- embryo. Illustrating PEXT products at 350 - 600 bp 
(high Mr) and 160 - 180 (low Mr) 
Biii) 
All lanes are E11.5 mRNA, Primers EX2, B2 and B4 used as 
marked. Illustrating PEXT products for EX2 at high and low M1 as 
for Bi and ii (red lines), and corresponding bands for primers B2 
and B4 (blue lines), taking into account differing positions of 
primer annealing sequences within the Pax7 transcript (green 
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previously published for human Pax7, see Figure 4.2B, but the High Mr bands are 
novel. 
Since the 5 'UTR sizes obtained in the PEXT experiments represented fragment sizes 
which would be easily amplifiable by PCR, a 5'RACE (Rapid Amplification of 
cDNA Ends) methodology was then used to try and clone and sequence these 
fragments from wild type embryo RNA. Two different kits were used, see Chapter 
Two, to minimise experimental artefacts due to specific methodologies. Nested PCR 
was used from the Pax7 coding region, see Figure 4.4A, and the product TOPO- 
cloned for sequencing. Over 40 clones were sequenced and 18 of these were found to 
be carrying an insert. The results can be seen in the alignment in Figure 4.4B. A range 
of 5'UTR sequences were cloned, ranging from 93bp (which would correspond to the 
Low Mr bands observed in the PEXT experiments) to I lbp. All of these sequences 
align exactly to the genomic sequence upstream of the Pax7 coding region. 
Interestingly, no clone which would correspond to the High Mr bands observed in the 
PEXT gels could be identified by 5'RACE. Bands of -500óp were sometimes seen 
when running out amplification products, but these proved to be unclonable in spite of 
several attempts. 
Finally, in an attempt to characterise the High Mr bands from the PEXT experiments 
and confirm the results from the 5'RACE, a Ribonuclease Protection Assay (RPA) 
was performed. A riboprobe was made by amplifying 770óp of the Pax7 upstream 
sequence by PCR, see Figure 4.5A, using primers P7RT1L /R. This was then sub - 





















































































































































































































































































































































































































































































































































































































and confirmed by sequencing. Figure 4.5A illustrates the position of this riboprobe 
and the predicted sizes of protected fragments which would be obtained from the 
High Mr , Low Mr , and 5'RACE 5'UTR's (assuming the High Mr bands are not 
obtained from novel exons upstream of this probe binding site). The RPA gel is 
shown in Figure 4.5B for a C2C12 total RNA sample and an E11.5 total RNA sample. 
Protected fragments present in both RPA's are at 74, 105 and 135óp, in agreement 
with the PEXT and 5'RACE data. No larger protected fragment which would 
correspond to the High Mr bands observed in the PEXT gels could be detected. 
To summarise the above data, a plot of 5'UTR length and frequency of observation 
has been drawn in Figure 4.6. This shows that all 3 methods employed agree on a 
5'UTR length of around 100bp. Both 5'RACE and RPA experiments indicate this 
5'UTR represents an upstream extension of the coding region and not a novel 5' exon 
for Pax7. This is in agreement with some data published for the human Pax7 locus 
(Murmann et al., 2000; Schafer et al., 1994). This UTR also contains a stop TGA 
codon on the + strand 40bp upstream of the Pax7 ATG. The existence of several 
shorter 5'UTR's determined by 5'RACE, and several repeatable larger PEXT 
fragments is puzzling, however. It is worthy to note that this region of genomic DNA 
is extremely CG and repeat rich. These sequences are reportedly often difficult for RT 
enzymes and polymerases to metabolise properly in vitro, and may explain the 
foreshortened 5'RACE products observed. The reliance of this method on PCR and 
cloning, which may preferentially select for shorter products, could explain why these 
fragments are observed in RACE clones but not by either PEXT or RPA. The 
repeated observation of a larger set of PEXT products is more difficult to explain. 
Whist several groups have reported longer 5'UTR's for the human Pax7 gene 
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1 = Positive control, 
undigested probe 
2 = Negative control, (NIH- 
3T3 RNA) 
3 = pBR322(Mspl) ladder 
4 = pBR322(Mspl) ladder 
5 = RPA, C2C12 RNA 





N.B. Pax7 5'UTR shown is for illustrative purposes only 
A) Illustration of Pax7 mRNA, showing 5'UTR's predicted so far by 
5'RACE and primer extension (PEXT). The riboprobe cloned and used 
in the RPA shown in B is positioned in blue (685bp). The predicted 
fragments are shown below (to scale). A 5'UTR in agreement with 
RACE and the smaller primer extension products would generate 
protected fragments of around 100bp. 5'UTR's of the size predicted by 
the larger primer extension product would generate protected 
fragments of around 350 - 500 bp (only 500bp fragment shown here 
for simplicity) from the same riboprobe. Populations of transcripts 
containing both should generate fragments of both sizes. 
B) RPA gel, visualized on a phosphorimager. Band and ladder sizes as 
marked, lane key as shown. Note no evidence of any bands 
corresponding to the larger primer extension products shown in Figure 
4.3 
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Figure 4.6: 
Summary graph of all experiments performed to determine the 
length of the mouse Pax7 5'UTR. The graph is a plot of length of 
5'UTR (x axis) against frequency of experimental observation (y 
axis). Primer extension is represented by the blue trace (n = 40), 
RPA is pink (n = 6) and 5'RACE is yellow (n = 18). All methods 
cluster a predicted 5'UTR at around 100 bp (in the region reported 
by Schafer et al 1994 and Lang et al 2003) but primer extension 
repeatedly determines a longer extension products from -300 to 
500 bp (in the region reported by Vorobyov et al 1997, Murmann et 
al 2000 and Syagailo et al 2002) which has not been detected by 
either 5'RACE or RPA 
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(Syagailo et al., 2002; Vorobyov et al., 1997), these are all at least 150bp bigger than 
the bands observed in these PEXT experiments, and since these were also 5' 
extensions of the Pax7 coding sequence and not novel upstream exons, these should 
also have been detected by RPA. It is possible that these PEXT bands represent 
5'UTR's of genes other than Pax7. Since three different primers all show extension 
products in this region, the most likely candidate for this would be Pax3, given the 
level of homology of between Pax3 and Pax7. C2C12 cells do not express Pax3 (data 
not shown and (Borycki et al., 1999)) and give PEXT products of this size. It would 
therefore seem unlikely that this PEXT product represents an accidental extension of 
the Pax3 5'UTR. Furthermore, all primers were subjected to BLAST analysis to 
ensure specificity during the design process. The data presented here does not 
adequately explain this observation, and further investigation is needed. Given the 
convergence of all three methodologies on a transcriptional start site of around 100bp 
upstream of the Pax3 coding sequence, it was decided for the purposes of this thesis 
to take this as the major transcriptional start site for mouse Pax7. 
Pax7 5' Promoter: Cloning 
Since the 5' extent of the Pax7 transcript was taken to include around 100bp of 
sequence upstream of the coding region, it was reasoned that the genomic sequence 
upstream of this, containing a CpG island and a high level of homology to the 
equivalent region in the human genome, might contain a minimal promoter for the 
mouse Pax7 gene. In the human, a similar homologous region has been shown to 
confer Pax7 promoter activity in cell culture (Murmann et al., 2000; Syagailo et al., 
2002). 
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To investigate this experimentally, this region of the Pax7 locus was cloned. Initially, 
a mouse genomic PAC library was screened using a 520bp probe (made by 
amplifying human genomic DNA (primers P7HYB 1 L /R) and TOPO- cloning into 
pCR -II- TOPO -TA to generate pP7HYB). The predicted hybridisation region is 
illustrated in Figure 4.7. Several positive clones were identified and these were then 
confirmed by Southern blot. Figure 4.8A and B illustrate the position of the probe 
used (a 770bp PCR product amplified from mouse genomic DNA using primers 
P7RT1L /R) and fragment sizes predicted from the mouse genomic sequence. PAC 
clones were digested using the restriction enzymes indicated and Southern blotting 
performed, see Figure 4.8C. Clone 14 gave positive signals of the correct size in each 
case and was used to clone the Pax7 promoter region. 
Since this region proved resistant to cloning via conventional methods, TEPCR was 
used to TOPO clone a 3.5kb fragment into pCR -XL -TOPO using primers 
PAX7PROML /R to generate p3.5TOPO. The insert was then sequenced completely, 
and a 3kb (BamHI - FspI) putative promoter fragment was then shuttled into 
pGL3basic, (via an intermediate construct, see appendix one), generating p3.0Luc, see 
Figure 4.9A and B. To test the proximal 1kb region of human - mouse homology 
initially identified by bioinformatics, two deletion constructs were made using tandem 
Asp718 or BglII sites to delete the distal and proximal regions of this putative 
promoter region, respectively (Figure 4.9B). These were named pl.5Luc (distal 
deletion) and p- 1.8Luc (proximal deletion). 
1 2 3 4 
1 I I I 1 1 I I 1 I 1 1 1 1 
45K 46K 47K 48K 49K 50K 51K 52K 53K 54K 55K 
ME 
520 bp PAC probe 
Figure 4.7: 
Pax7 genomic locus showing predicted hybridization of 520bp 
fragment (cloned into pP7HYB, human sequence) used to probe a 
mouse genomic PAC library 
Figure 4.8: 
A) Illustration of Pax7 locus and predicted restriction sites used in 
Southern blotting to verify validity of PAC clones 
B) Table of enzymes and predicted restriction fragments 
C) Representative Southern blots of PAC clone 14 showing predicted 
fragments 
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To test the ability of these regions of proximal genomic sequence to drive Luciferase 
reporter gene expression, these plasmids were transfected into the C2C12 mouse 
myoblast cell line which is Pax7 positive. Figure 4.9C illustrates these results. A 
detailed description of the Luciferase protocol and the data treatment used in this 
thesis can be found in Appendix 4 and is not dealt with here. In the C2C12 cell line, 
the constructs p3.0Luc and p 1.5Luc were clearly able to drive reporter gene 
expression over baseline (pGL3basic, or empty vector). In the construct p- 1.8Luc, 
where the sequence proximal to the transcriptional start site has been deleted, no 
induction could be observed. This enabled the proximal 1.5kb of mouse genomic 
sequence to be established as a Pax7 minimal promoter in the C2C12 cell line. 
During the bioinformatic analysis of this region of the mouse genome, a potential 
regulatory element within the first intron of the Pax7 gene was also identified. This 
region was highlighted by the PIPMaker program as having >91% homology between 
human and mouse sequences. Given that the coding sequences for Pax7 generally 
only demonstrate 75 - 80% identity, this represented a potentially interesting feature. 
This is illustrated in Figure 4.10A. To investigate experimentally, the region was 
cloned using TEPCR from the I4 PAC clone, with primers P7INT1REGF/B 
(containing BamHI sites) and directly into the BamHI site (3' to the Luciferase ORF) 
of both pGL3promoter and p1.5Luc. Both orientations of the element were cloned and 
screened with restriction digests, before sequencing to confirm insertion. These 
constructs are represented in Figure 4.10B, and were named pI 1 RLuc and 
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Figure 4.9: 
A) Genomic locus of Pax7 showing region cloned by TEPCR into 
p3.5TOPO, and the BamHl and Fspl sites then used to clone a 3kb 
fragment into pGL3basic via shuttling through pintermediatel (pBSII 
backbone) 
B) p3.0Luc, p1.5Luc and p- 1.8Luc constructs showing regions deleted and 
restriction sites used. 
C) Luciferase data of Pax7 promoter luciferase plasmids on transfection 
into the Pax7 expressing C2C12 cell line. Data is normalised 
luminescence expressed as fold induction over baseline (pGL3basic). n = 
3, error bars are SEM 
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3.5kb TEPCR fragment 
Figure 4.10 
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A) Schematic of Pax7 genomic locus showing region of very high sequence 
conservation between human and mouse genomes (>91%). Since this 
homology is greater than that demonstrated for the exon sequences, 
primers were designed to amplify and clone this sequence into Luciferase 
reporter vectors (shown). B = BamHl sites engineered into PCR product 
and used for cloning into pGL3Promoter and p1.511 RLuc 
B) pl1 RLuc and p1.511 RLuc reporter vectors used to test the effects of the 
highly conserved sequence found within intron one. The 11R fragment was 
cloned behind the Luciferase ORF in plasmids containing the SV40 weak 
and Pax7 endogenous promoters, respectively. 
C) Luciferase data showing the silencing effects of the I1 R element on 
reporter gene activity driven by both the SV40 and Pax7 endogenous 
promoters (top panels). The silencing effect is also orientation independent 
(bottom panel). Data is normalised luminescence, expressed as fold 
induction over empty vector (pGL3promoter and pGL3basic). n = 3, error 
bars are SEM. 
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To test the effects of this element on transcription, these plasmids were transfected 
into the C2C12 cell line as before, and levels of reporter gene expression examined 
with and without the I1 R insert. These data are shown in Figure 4.10C. The I 1 R 
element demonstrated a robust silencing activity which was both promoter and 
orientation independent. This silencing activity was also observed in NIH -3T3 cells 
(data not shown). It was therefore hypothesised that this element may also function to 
regulate Pax7 expression in vivo through the binding of inhibitory elements. 
Regulation of Pax7 by Pax3 
The identification of some potential regulatory regions within the Pax7 locus now 
enables the final hypothesis described in Chapter One to be investigated. 
Hypothesis Three 
Pax7 is directly downregulated by Pax3, in vitro and in vivo, via defined regulatory 
elements and with implications for the development of both neural and mesodermal 
tissues. 
To test this hypothesis, the regulatory regions identified above were initially subjected 
to a bioinformatic analysis to identify potential transcription factor binding sites using 
the Matlnspector program (MatInspector). Both the minimal promoter and IIR 
element were analysed in this way. One Pax3 binding consensus was identified in the 
proximal promoter region. Local alignment using the ClustalW program illustrated 
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that this region of the Pax7 promoter is highly conserved between human and mouse, 
and this consensus is present in both species, see Figure 4.11A. Figure 4.11B 
positions this site in both p3.0Luc and p1.5Luc. 
To test the Pax3 responsiveness of this site in vitro, these constructs were co- 
transfected into C2C12 with and without the pCMV -Pax3 expression construct, as 
described previously (see Chapter Three). These data are shown in Figure 4.11C. 
Despite relatively high variation in normalised luminescence, no significant change in 
reporter gene expression could be obtained for either construct. This indicates that 
Pax3 cannot interact with this promoter consensus in vitro. To ensure this result was 
not an artefact of cell line activity, these experiments were also conducted in the NIH- 
3T3 cell line; and an identical result was obtained (data not shown). 
Since the hypothesis under investigation predicts that Pax3 down regulates Pax7 
activity, and a silencing element was identified at the Pax7 locus, it was decided to 
investigate any potential interaction between Pax3 and this element in spite of a 
failure of MacVector to identify any consensus binding sites. A similar approach was 
adopted and pI1RLuc (Figure 4.12A) was co- transfected with and without the pCMV- 
Pax3 expression vector, and the changes in normalised luminescence recorded. Again, 
no change in fold induction was observed, Figure 4.12B, indicating this element does 
not respond to Pax3 co- expression in vitro. 
Finally, the p 1.5I1 RLuc construct was tested. This construct contains both the Pax7 
proximal promoter and the II element around the Luciferase ORF, Figure 4.13A. 









































































































































































































































































































































































































































































































































































A) CustalW alignment of mouse and human Pax7 promoter regions 
showing high level of homology and position of Pax3 consensus 
sequence (highlighted). Consensus site has been gapped in mouse by 
alignment software but is clearly present in both species 
B) Illustration of p3.0Luc and p1.5Luc showing position of Pax3 
consensus site 
C) Luciferase response to co- transfection with the pCMV -Pax3 
expression plasmid. No significant change in reporter gene expression 
observed, n = 3 error bars are SEM. Data expressed as fold induction 
over baseline (pGL3basic). 
Pax3 
1K 























p1.5Luc p1.5Luc + 100ng 
pCMV-Pax3 
Figure 4.12: 
A) Plasmid pl1 RLuc 
B) No change in reporter gene activity on co transfection with pCMV 
Pax3, n = 3 error bars are SEM. 
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p1.511 RLuc p1.5I1RLuc+ 
100ng pCMV- 
Pax3 
+p1.5I1RLuc -0-p1.5Luc --&-pI1RLuc 
0 100 200 300 
ng pCMV-Pax3 
400 500 600 
Figure 4.13: 
A) Plasmid p1.511 RLuc 
B) Pax3 response to co- transfection of p1.511 RLuc with 10Ong pCMV- 
Pax3. A clear induction in Luciferase activity is observed, n = 3 error bars 
are SEM. 
C) To test the observations in Figures 3.11, 3.12 and B, a range of ng 
quantities of pCMV -Pax3 were co- transfected with each of pl.5Luc, 
pli RLuc and p1.511 RLuc. An induction of reporter gene activity is 
observed only on co- transfection of the pCMV -Pax3 expression construct 
with p1.511 RLuc (containing both the Pax7 promoter and Pax7 intron 1 
silencer element). Blue trace is p1.511 RLuc, pink is pl .5Luc, yellow is 
pl1 RLuc. Data is expressed as normalised luminescence fold induction 
over baseline and indexed to Ong pCMV -Pax3 to enable direct comparison 
between data sets. n = 3 - 5 (dependant on data point) error bars are 
SEM. 
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of the above, and this time a clear response to Pax3 co- expression was obtained, 
Figure 4.13B. To test this response further, and to ensure a concentration dependent 
response to Pax3, a range of quantities of pCMV -Pax3 were co- transfected for each 
of the plasmids p 1.5Luc, pI 1 RLuc, and p 1.5I1 RLuc. Only the latter construct 
responded to pCMV -Pax3 co- transfection over the range investigated, see Figure 
4.13C. 
Interestingly, this result implies that Pax3 can interact with the Pax7 regulatory 
elements defined here, at least in vitro, but that this interaction would appear to `de- 
repress' the silencing effect of the I1R element, rather than being a simple activating 
or inhibitory relationship. 
Since the reporter gene assays described above do not indicate whether Pax3 is 
interacting with the promoter or silencer element, it remained possible that the Pax3 
consensus identified by the Matlnspector analysis mediates this response. To 
investigate this possibility, the core consensus Pax3 binding site within the Pax7 
promoter was mutated using site directed mutagenesis. The p 1.5I1 RLuc plasmid was 
used with the QuikChange Site Directed Mutagenesis kit (Stratagene) and primers 
P7_ sub _FWD /REV. Clones were screened by direct sequencing to confirm 
substitution of the core consensus TCGC to ATAA, Figure 4.14A. Reporter gene co- 
transfections were repeated using this mutated construct (pP7P <delta >) and the 
original p1.5I1RLuc plasmid. No change to the Pax3 response was observed, see 
Figure 4.14B, indicating that Pax3 does not bind to this consensus sequence to 
mediate its effect in this system. 
T 
Figure 4.14: 
A) Site directed mutagenesis of the Pax3 consensus site in the Pax7 
promoter sequence alignment 
B) Luciferase response of p1.511 RLuc and pP7P <delta> illustrating no 
change in Pax3 response on co- transfection with 250ng pCMV -Pax3. 
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Finally, since this `de- repression' of Pax7 regulatory elements by Pax3 was not 
predicted in the literature, and is in fact in direct contradiction to data presented by 
(Borycki et al., 1999) for the expression of Pax3 in the C2C12 cell line, Western 
blotting analysis of Pax3 and Pax7 was performed to see if the implied changes in 
Pax7 regulation could be observed at the protein level in C2C12 cells. The Pax3 anti- 
serum (rabbit) described in Chapter 5 and the DSHB a -Pax7 (mouse) were used for 
all pCMV -Pax3 quantities used in the above reporter gene assays. A (3 -actin antibody 
(goat) was also used to control for loading differences on the Pax7 blot, after 
stripping. This result can be seen in Figure 4.15A. 
These data show that, as more pCMV -Pax3 is transfected into the C2C12 cells, more 
Pax3 protein is made. They also indicate that the level of Pax7 protein expressed by 
these cells is initially undetectable in this assay, but is induced by increasing 
quantities of Pax3. The (3 -actin control indicates that this change is not an artefact of 
loading. To contrast this result, a northern blot published by (Borycki et al., 1999) is 
included in Figure 4.15B, clearly showing a loss of Pax7 activity in C2C12 cells 
stabling expressing Pax3. 
Discussion (Hypothesis Three) 
The aims of this chapter were to first try and establish experimentally some regions of 
the mouse Pax7 genomic locus that might control expression of this gene in vivo and 
then to use these elements to test the third hypothesis outlined in Chapter One. Since 
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A) Western blotting for Pax3, Pax7 and (3 -Actin from C2C12 cells 
transfected with 0 - 500ng pCMV -Pax3, showing increase in Pax3 
protein and Pax7 protein (ß -Actin shown as lane loading control) 
B) Contrasting evidence from Borycki, A. et al 1999, of a Northern 
blot illustrating Pax7 RNA levels from two C2C12 cell lines stably 
transfected with a Pax3 expression construct 
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project, the minimal promoter was perceived as good starting point. To this end a 
comprehensive bioinformatic analysis was performed over the entire Pax7 region, and 
highly conserved CpG island was identified in the 1 - 2kb upstream of the Pax7 
coding exon. To ensure this region could act as a minimal promoter, the 5'UTR of the 
Pax7 gene was also characterised in the mouse to see if upstream, non -coding exons 
could be detected. Since the coding sequence of the Pax7 gene covers around 200kb 
of genomic DNA the potential existence of upstream exons, which would position any 
minimal promoter away from the area identified by bioinformatics, had to be 
considered. The results from PEXT, 5'RACE and RPA indicated a definite 
transcriptional start site around 100bp upstream of the start of the Pax7 coding 
sequence. This is in agreement with some reports published concerning the human 
Pax7 gene (Murmann et al., 2000; Schafer et al., 1994). PEXT repeatably 
demonstrated a second population of 5'UTR's of between 300 - 500bp. This product 
was not detected in 5'RACE or RPA experiments. It was concluded that, given the 
range of sources of RNA used in the PEXT experiments, this seemed unlikely to be 
an artefact of PEXT methodology. Previous reports have indicated Pax7 may have a 
longer (600 - 650bp) 5'UTR, which would be closer to the size reported here 
(Syagailo et al., 2002; Vorobyov et al., 1997). None of these researchers report a 
novel non -coding exon, however. Since the start of this project, one paper analysing 
the Pax7 promoter in the mouse has been published (Lang et al., 2003). This group 
conclude that the Pax7 5'UTR is 73óp, and encodes no novel exons. Whilst this is in 
agreement with my data, the evidence presented by this group does not rule out the 
possibility of larger 5'UTR's. Given the heterogeneity of actual start sites reported for 
this gene, and the extremely high CG content of the proximal sequence, it possible a 
discrete single start site for Pax7 does not exist. In other systems, such conditions 
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have been attributed as causative factors for a `stuttery' transcriptional start sites, 
(Ayoubi and Van den Ven, 1996), where transcription starts at numerous places 
within a defined region. This may explain the differences observed between both the 
data obtained from different techniques here, and that reported in the literature. 
Importantly, no novel upstream exons have been reported for Pax 7, allowing a 
putative promoter region to be positioned here. 
This region was cloned and used in reporter gene assays in Pax7 positive cell lines, 
and promoter activity mapped to the proximal 1.5kb. Initial bioinformatic analyses 
also indicated a highly conserved element within intron one. This was cloned and 
found to act as a canonical silencer element in vitro. This element was also identified 
by (Lang et al., 2003) and shown in transgenic assays to act as a Pons -specific 
enhancer, in contrast to the role indicated here. 
To address hypothesis three, the minimal promoter was assayed for an in vitro 
response to Pax3 in co- transfection assays, since a Pax3 consensus had been 
identified in this region. This did not demonstrate a response, nor did the I1R silencer. 
When both elements were carried on the same reporter vector, a Pax3 dependant `de- 
repression' of reporter gene activity was observed. Mutagenesis indicated this activity 
was not mediated by the Pax3 binding consensus identified in the promoter. 
Finally, the effect of Pax3 expression on endogenous C2C12 Pax7 expression was 
conducted by Western blotting. Interestingly, a clear induction of Pax7 was observed 
with increasing quantities of Pax3. This was in contrast to previously published 
reports 
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It was concluded from the above that Pax3 is able to effect the transcription of Pax7 
in vitro, but that this regulation may be from either the proximal promoter or the I1 R 
element identified above. Therefore hypothesis three can be partially confirmed; Pax3 
does seem to have an effect on the regulatory elements defined here in vitro, but the 
mechanism and in vivo significance of that effect is unclear. Chapter Six will attempt 
to investigate which of these elements, if any, are occupied by the Pax3 protein in 
vivo, and attempt to establish a role for Pax3 in the regulation of Pax7 in an 
embryonic context. 
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Chapter Five: Generation of a novel a -Pax3 antibody 
Introduction 
Chromatin Immunoprecipitation (ChIP) requires relatively large (µg) quantities of 
specific antibody, to reduce background and increase the sensitivity and specificity of 
detection. At the start of this project, only one anti -Pax3 antibody had been described 
(Stark, 1997). This was a rabbit polyclonal derived by another group, and therefore 
not reliably available in large quantities. The decision was made to raise and design a 
new anti -Pax3 antibody, using specific peptide sequences, to enable multiple ChIP 
experiments to be performed and optimised. This chapter describes the methods used 
to design and raise a rabbit polyclonal antibody to specific peptide sequences within 
the Pax3 protein. The anti -sera obtained were characterised using both Western 
blotting and immunohistochemistry to confirm detection of the Pax3 epitope at the 
correct molecular weight and expression pattern. One of the sera was then selected 
and purified to obtain mono -specificity on Western blot and clean expression patterns 
with immunohistochemistry. 
Peptide Design and Antibody Production 
The Pax3 sequence and predicted structure were considered in the design of the 
peptides used to generate anti -Pax3 sera. From X -ray analyses of both Paired domains 
(Xu, 1995) and structural dissections of Pax3 (Chalepakis et al., 1994) it has been 
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shown that the N- terminal regions contain the DNA binding domains, whilst the C- 
terminus of the protein is involved in recruiting transcriptional complexes. The C- 
terminus of the Pax3 protein sequence was examined to identify possible 
immunogenic peptide sequences. It was reasoned that the N- terminal DNA binding 
domains may contain less structural epitopes accessible to an antibody when bound to 
DNA due to conformational restrictions and the possible presence of associated co- 
factors or the RNA polymerase machinery. The C- terminal portion of the related Pax6 
protein has been hypothesised to be less structurally ordered on contact with DNA 
than the paired domain (Xu, 1999). Structural disorder has been cited as a possible 
factor increasing the immunogencity of an epitope experimentally due to its increased 
availability for antibody binding. Furthermore, since ChIP depends upon transcription 
factor - DNA contact peptides in the N- terminal portion of the protein would be 
undesirable since they may disrupt protein - DNA interactions. 
Figure 5.1 shows the full peptide sequence of Pax3, and highlights the peptide 
sequences initially considered for immunisation. Peptides A and B were chosen. 
Peptide A represents the natural C- terminus of Pax3, contains -60% polar residues 
(green) one charged residue (lysine at position 12 - red) and the negatively charged 
carboxyl group at position 16. Peptide A was chemically modified to include an 
cysteine residue at the very N- terminus; this was to enable chemical linkage to the 
carrier protein (Keyhole Limpet Haemocyanin) via the sulphydryl group. Peptide B is 
a shorter peptide, has an overall negative charge, and is also composed of --60% polar 
residues. This peptide was chemically modified to amidate the C- terminus; since this 
sequence is internal in the protein this would better represent the chemical 
environment of the N- terminal region of this sequence. Analysis of the C- terminus of 
Figure 5.1: 
A) Scale drawing of the Pax3 polypeptide. Major features illustrated; 
yellow boxes show the position of peptide sequences A, B, and C. 
B) Peptide sequences (green = polar, red = charged side chains). 
C) Antigenicity and flexibility plots for the C- terminus of Pax3; Peptide 
A and B sequences highlighted in red. 
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Peptide A :TGYQYGQYGQSKPWTF 
Peptide B :CPPTYSTAGYSMD 
Peptide C : EHMKNVDSLPTSQPYC 
Antigenic Index: Window = 7 
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EPTTTVSASCSQRLEHMKNVDSLPTSQPYCPPTYSTAGYSMDPVTGYQYGQYGQSKPWTF 
Protein flexibility: Window = 7 Peptide B Peptide A 
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EPTTTVSASCSQRLEHMKNVDSLPTSQPYCPPTYSTAGYSMDPVTGYQYGQYGQSKPWTF 
Peptide B Peptide A 
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the protein using MacVector antigenicity index and flexibility plot prediction 
software further illustrated that these peptide sequences represented regions of the 
protein which had both high flexibility and antigenicity (Figure 5.1C). Peptide C was 
initially identified as potentially antigenic sequence, but was ultimately not used as 
this epitope was considered too far into the protein, risking the epitope being occluded 
by tertiary structure in the intact protein. Also bioinformatic analysis suggested a low 
antigenicity index (Figure 5.1C). Anti -sera were raised in rabbits as described in 
Chapter 2; two rabbits were immunised for each peptide, generating four batches of 
anti -sera. 
Verification of a -Pax3 immunogenicity 
To evaluate the sera obtained from immunisation with peptides A and B, Western 
blotting was performed on NIH -3T3 cells transiently transfected with pCMV -Pax3 
plasmid, as described in Chapter Two. The pCMV -Pax3 plasmid contains a full 
length Pax3 cDNA driven by a strong (CMV) promoter, and was used in these 
experiments as a source of in vitro expressed Pax3 protein. NIH -3T3 were previously 
shown not to express Pax3, as detectable by RTPCR (data not shown). Mock 
transfected NIH -3T3 cells (transfected with the pCMV- Script plasmid) were therefore 
used as a source of negative control protein. All four sera were tested by comparing 
pre - immune with post immune sera (to ensure any bands observed were the result of 
immunisation against the Pax3 peptides), on protein extracts from transfected and 
mock -transfected NIH -3T3 cultures. Serum generated from peptide A (rabbit 1) gave 
the best potential -band at this stage and was therefore used in all later experiments. 
179 
Peptide A (rabbit 2) and one of the rabbits immunised with peptide B did also 
generate Pax3 bands, but these were weaker and therefore not used (data not shown). 
Figure 5.2A shows the initial Western blot for the peptide A serum, comparing pre 
and post -immune sera on protein samples containing Pax3 and matched negative 
controls. The Pax3 band, at 53 kDa is highlighted in the post -immune western. 
Western blotting conditions were further optimised, Figure 5.2B, to reduce 
background. The antibody was then used to detect Pax3 protein from NIH -3T3 (± 
pCMV -Pax3), C2C12 ( +pCMV -Pax3) and E11.5 wild type and Sp2H homozygous 
mutant (Pax3 null) mice (Figure 5.2C). As Figure 5.1A illustrates, the Sp2H mutations 
would truncate any protein product from the splotch allele before the peptide 
sequences used to raise the anti -sera. Therefore no Pax3 protein should be detectable 
by Western blot in extracts from Sp2H homozygous mutant embryos. 
To further confirm the specificity of the serum to Pax3, immunohistochemistry was 
then attempted using the un- purified serum. Unfortunately the background levels on 
all sections examined was too high to enable specific expression patterns to be 
reliably determined (data not shown). This is perhaps unsurprising given the number 
of non -specific bands observed on Western blots using this serum. 
Antibody Purification 
ChIP requires a source of anti -serum as specific as possible. To prepare the anti -Pax3 
serum for ChIP, and to enable its use in immunohistochemistry, a protein -G column 
purification, followed by a two step acid elution, protocol was used. After washing, 
Figure 5.2: 
A) Western blot using serum from 
rabbits immunised with peptide A. Comparison 
of pre- immune serum with post- immune serum 
on NIH -3T3 transfected with pCMV -Pax3 
expression plasmid or empty vector ( ±). Pax3 
pro -band highlighted. 
B) Western blot optimised using 
serum from rabbits immunised with peptide A. 
Pax3 clearly visible at -53kDa, and specific 
to cell transfected with pCMV -Pax3. 
C) Western blot showing presence 
of Pax3 in wild -type E11.5 embryos (lane 1), 
cells transfected with pCMV -Pax3 (lanes 3 and 
5). Homozygous Splotch embryo protein was 
loaded in lane 2. Lanes 4 and 6 represent 
protein extracts from cells lines transfected 








Pax3 pro -band ~at 53kDa 
Embryo NIH -3T3 C2C12 








elute was collected in 1 minute intervals (1m1) and the protein concentration 
determined by Bradford assay. A plot of protein concentration (expressed as OD at 
X,562) vs. elution volume can be seen in Figure 5.3. 
A clear elution peak can clearly be seen between elution volumes pH2.7(5) and 
pH2.7(9). These volumes were combined and referred to as a- Pax3(HT) (High Titre). 
The slow tail -off in protein concentration between volumes pH2.7(10) and pH2.7(14) 
was interpreted as a potential second peak, poorly resolved due to the relative crudity 
of the protein concentration assay. These elutes were also combined and referred to as 
a- Pax3(LT) (Low Titre). The mean (OD = 0.15 n = 6, SD = 0.004) blank 
(background) OD x,562 is shown on the plot for reference. No protein over 
background could be detected in any of the samples eluted with the pH1.9 buffer. 
These were discarded. 
a- Pax3(HT) and a- Pax3(LT) were therefore tested using the Western blot parameters 
outlined above (Figure 5.4A). This clearly shows that, whilst both fractions contain an 
anti -Pax3 immunogenicity, the a- Pax3(HT) still retains many of the non -specific 
bands previously described for the unpurified serum. This is possibly due to the use of 
a protein -G column, which binds IgG heavy chain irrespective of immunospecificity, 
rather than a peptide A specific column. The a- Pax3(LT), however, gave an 
extremely clear signal at the appropriate Mr for Pax3. During the process of deriving 
and purifying this antibody, a monoclonal anti -Pax3 resource became available from 
the DSHB (Developmental Studies Hybridoma Bank, Iowa). To compare 
specificities, Western blots were performed comparing the two antibodies (DSHB and 



























































































































































































































































A) Western blot on NIH -3T3 cells 
transfected with either pCMV -Pax3 ( +) or 
empty vector ( -). Comparing the LT and HT 
a -Pax3 fractions collected 
B) Western blot on NIH -3T3 cells 
transfected with either pCMV -Pax3 ( +) or 
empty vector ( -). Comparing a- Pax3(LT) 




















non -specific band of about 60kDa which was absent from the a- Pax3(LT) westerns. 
This correspond with Western blots obtained using a sample of the source polyclonal 
used to derive this monoclonal (A kind gift from M. Goulding, data not shown) when 
verifying the production of Pax3 from transfected NIH -3T3 cells. Since ChIP requires 
as mono -specific an antibody as possible, and the fact that the DSHB antibody was 
produced from the C- terminal 183 residues, rather than a specific peptide sequence 
(Venters et al., 2004), the a- Pax3(LT) was chosen for the ChIP experiments. a- 
Pax3(LT) is henceforth referred to as a -Pax3. 
a-Pax3 Immunohistochemistry 
Given the specificity of the a -Pax3 polyclonal on Western blot, 
immunohistochemistry on wax embedded, transverse sectioned, wild -type E12.5 
mouse embryos was performed. Figure 5.5A illustrates a transverse section showing 
clear specific staining in dorsal neural tube (NT), dorsal root ganglion (DRG) and 
facial mesenchyme. Figure 5.5B is a high -power image of the same section, showing 
nuclear staining in both NT and DRG cells, as expected for a transcription factor, and 
5.5C a high power image from another section, illustrating Pax3 positive cells 
delaminating from the dorsal edge of the NT, possibly neural crest. Also illustrated 
are comparative sections from published work (Dottori et al., 2001) and (Terzic and 
Saraga -Babic, 1999). Since the purpose of this exercise was to confirm the Pax3 
specificity of the a -Pax3 polyclonal produced, further expression analysis was not 





A) Transverse section through E12.5 WT embryo. Pax3 expression in 
dorsal neural tube (NT), facial mesenchyme (FM) and dorsal root 
ganglia (DRG). 
B) High power image of inset highlighted in A. Note Pax3 expression in 
migrating neural crest cells (NC). 
C) Comparison of similar published images illustrating Pax3 
expression. Human 9 week fetus Pax3 immuno (Terzic et al 1999), 
Mouse E12.5 transverse section Pax3 immuno (Pax3 = red and yellow 
signal) (Dottori et al 2001), another high power transverse section 
showing nuclear Pax3 staining. 
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across a developmental series would make this anti -serum a potentially attractive tool 
for future investigators, however. 
Discussion 
The a -Pax3 polyclonal described here was then aliquoted and stored appropriately for 
ChIP, described in Chapter 6. All experiments described in this thesis using an a- 
Pax3 antibody were performed using the above polyclonal. One interesting aspect of 
all Western blots shown here, whichever antibody was used, was the presence of a 
doublet (see Figure 5.4B). This was specific to Pax3 positive lanes only, and therefore 
could not be attributed to background. There are several possible explanations for 
this. Firstly, the doublet could represent one of the glutamine or exon isoforms of 
Pax3 (see Chapter 1 for an overview of relevant literature). Since many of the Pax3 
bands detected on these westerns were obtained from protein driven from a Pax3 
cDNA expression construct such isoforms must represent either novel splicing events 
within the mRNA produced from the plasmid or protein produced from the cells on 
genomic copies of Pax3 via an auto -regulation mechanism. Pax3 may have different 
phosphorylation states and this would clearly explain a band migrating a different rate 
on an SDS -PAGE gel. A more mundane explanation would be that the doublet simply 
represents a common degradation product which is detected in transfected cells due to 
the high quantities of Pax3 produced in these transfections. Further investigation is 
required to differentiate between these possibilities and determine the cause of this 
doublet. 
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Chapter Six: in vivo Chromatin immunoprecipitation 
Introduction 
In this chapter the occupancy of the transcription factor binding sites previously 
investigated on the cis -regulatory target sequences identified will be tested in vivo. 
This will bring together the in vitro studies that have attempted to establish a possible 
role for the regulation of Wntl and Pax7 by Pax3. To this end the anti -Pax3 antibody, 
designed and purified as described in Chapter 5, and the anti- Msxl /2 antibody 
obtained from the DSHB were used to develop specific Chromatin 
Immunoprecipitation (ChIP) assays on mouse embryonic tissue. This technique 
allows the localisation of transcription factor binding sites to specific regions of 
genomic DNA. The data described below confirms the in vitro observations for the 
Pax3 regulation of Wntl via the 5' proximal promoter region, raises some interesting 
possibilities for the interaction of Msx2 with these regulatory elements, and resolves 
the uncertainty over the location of Pax3 interaction within the Pax7 genomic locus. 
ChIP; an overview 
The ChIP technique isolates and enriches DNA sequences which are involved in 
protein -DNA interactions. The technique was originally designed for use with 
chromatin remodelling proteins (such as DNA methyltransferases and histone 
deacetylases) but has since been adapted for a number of other assays to assess any 
188 
kind of protein -DNA interaction (Ren, 2000b). An increasingly widely used 
application of this technology is the characterisation of transcription factors binding to 
target sequences within the genome. Generally this technique has been used to 
examine these interactions in cell culture, due to the relative ease of obtaining large 
amounts of source material, but the demand for in vivo ChIP to examine the validity 
of findings (such as those outlined in Chapters 3 and 4) in the tissues and organisms 
of interest is growing. 
A schematic of the ChIP process is shown in Figure 6.1. In the first stage, the 
transcription factor under investigation is assumed to bind to and activate / repress 
transcription of its target gene by binding to appropriate sequences within the genome 
(stage I - II). At this point the embryo or tissue is dissected and disassociated into 
single cells as rapidly as possible, and the cell suspensions treated with formaldehyde. 
The formaldehyde acts as a chemical cross linking agent between proteins (generally 
between the E -amino group of lysine residues and adjacent amide bonds) and between 
proteins and DNA (between lysine residues and the NH2 exocyclic moiety of adenine, 
guanine or cytosine (Siomin, 1973) -interestingly this requires the DNA to be at least 
partially denatured, or for the protein to be making close contact with the bases 
through the major or minor grooves of the DNA molecule. Both of these are thought 
to occur during the interaction of a transcription factor with its target sequence), see 
stage III. The transcription factor is then effectively `trapped' on its target genomic 
sequence. The cells are then placed in detergent -based lysis buffer and subjected to 
sonication to disrupt the cell and nuclear membranes and to break the chromatin into 
fragments of a desired size, stage IV. The tissue sample has now been broken into a 
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Figure 6.1: 
Schematic of in vivo ChIP protocol. 
Stage I: Transcription factor (circle) of interest is binds target element 
(box) on genomic DNA (line) in appropriate tissue / developmental 
stage 
Stage II: Transcription factor drives / alters expression of target gene 
Stage Ill: Cells / tissue extracted and treated with weak formaldehyde 
treatment to crosslink proteins and DNA in situ (curved lines) 
Stage IV: Crosslinking quenched, and cells lysed. Crosslinked protein - 
DNA complexes sonicated to break up genomic DNA into smaller 
fragments 
Stage V: Antibody specific to transcripiton factor of interest the added 
to pool of sonicated protein -DNA complexes 
Stage VI: Immunoprecititation performed to isolate Antibody - 
transcription factor - DNA complexes 
Stage VII: Protein - DNA complexes uncrosslinked, proteins and 
antibodies degraded with proteases, and DNA isolated by phenol - 
choloroform. Primers specific to the regulatory regions being tested for 
transcription factor occupancy then used to screen pool of DNA 
fragments and amplify sequences if present. 
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associated proteins bound co- valently. To enrich specifically for those complexes 
containing the transcription factor under investigation, an immunoprecipitation is 
performed using an antibody raised against the protein of interest (stage VI). Once all 
unwanted species have been washed away, the antibody - transcription factor - DNA 
complexes (stage VI) are then eluted from the IP and the formaldehyde cross links 
reversed using heat and halide (typically Cl). The proteins (antibody and transcription 
factor) and any co- purifying RNA are then enzymatically digested. This should leave 
a population of DNA fragments, of broadly uniform size due to the sonication process 
employed, which were bound to the transcription factor under investigation. These are 
then phenol chloroform purified and re- suspended in clean ddH2O. 
At this stage the occupancy of a specific site can be tested by designing flanking PCR 
primers and testing the pool of precipitated fragments for the presence of this site 
(stage VII). Enrichment can be meaningfully assessed by also attempting to amplify a 
genomic sequence to which the factor is known / thought not to bind to. It is 
important to ensure that the second sequence is not too close to the putative binding 
sequence so as not to co- purify on the same fragment. This makes the sonication step 
essential; care must be taken to ensure all chromatin is fragmented to a size 
sufficiently small that these two amplicons cannot occupy the same fragment, but 
large enough to ensure that both test primers can anneal to the same target fragment 
and enable PCR amplification to occur. A positive control PCR of `input' chromatin 
(i.e. sonicated chromatin from the source sample which is phenol chloroform purified 
without any intermediate immunoprecipitation) and a negative control `no antibody' 
PCR (i.e. a sonicated chromatin sample where water instead of antibody was added at 
the IP stage). 
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Alternatively the populations of enriched fragments can be cloned and sequenced, or 
applied to genome coverage microarrays. Both of these endpoints are generally used 
to identify novel target sequences and, whilst not being experimentally utilised in this 
study, will be discussed in more detail later. 
Thesis findings: an overview 
Figure 6.2 presents a diagrammatic review of the findings so far described in this 
thesis and the interactions that the following ChIP experiments were designed to 
investigate. Figure 6.2A summarises the in vitro interactions suggested between Pax3 
and the Wntl regulatory elements in an in vivo context. Illustrated is the mouse 
genomic Wntl region, highlighting the four exons, the distal 110bp enhancer (blue 
box) and the Pax3 consensus site contained within the 1.2kb proximal promoter 
region (green arrow). Deletion and site directed mutagenesis studies have strongly 
suggested that this Pax3 consensus may mediate an active binding site for the Pax3 
protein in vivo. ChIP was performed on these regions using the purified anti -Pax3 
polyclonal antibody described in Chapter 5 to confirm in vivo occupation of this site, 
and not the Wntl distal enhancer. 
Figure 6.2B summarises the putative relationship of the Msx2 protein with the Msx2 
consensus binding site in the Wntl distal enhancer, in the context of the mouse 
genomic Wntl locus. This interaction was supported by deletion and transposition 
studies using luciferase reporter vectors in vitro. No mutagenesis experiments were 
conducted on this site during this investigation. ChIP using the anti- Msxl /2 antibody 
Figure 6.2 
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Wntl mouse genomic locus 
1.2kb proximal promoter - --11. 1 2 3 4 
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Pax7 mouse genomic locus 
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-11---1 >91% homology 2 3 
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1.5kb proximal promoter 
Figure 6.2: 
A) Summary of model proposed from in vitro data described in Chapter 3 
and in investigation of hypothesis one. Pax3 binds to and transactivates 
the Wnt1 proximal promoter via a defined Pax3 consensus site, 
confirmed by mutagenesis and deletion studies 
B) Model proposed from in vitro data and investigation of hypothesis two 
described in Chapter 3. Msx2 binds to the Wnt1 distal enhancer (within 
the conserved 110bp element, see Echelard et al 1994) to repress 
transcription, confirmed by deletion and translocation studies 
C) Model proposed by in vitro data described in Chapter 4 and in 
investigation of hypothesis three. Pax3 binds to either the 1.5kb proximal 
promoter or the highly conserved I1 R element within intron one of the 
Pax7 locus, but not via the Pax3 consensus site present in the promoter 
region. Confirmed by mutagenesis and deletion studies 
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was used to try and show the in vivo occupation of Msx2 at this site, and not the Wntl 
proximal promoter, and is discussed below. 
Figure 6.2C summarises the in vitro data obtained during an investigation into the 
relationship between Pax3 and the Pax7 regulatory elements in vitro. The Pax7 
genomic locus is shown, illustrating the first three coding exons, the 1.5kb proximal 
promoter and the I1R silencer within intron 1. Luciferase experiments demonstrated 
that both the proximal promoter and the I1R element were necessary to observe a 
Pax3 driven transcriptional effect, although this was a de- repression (contrary to the 
relationship previously described by one group), and was not mediated by the Pax3 
consensus in the 5' proximal promoter (as determined by site directed mutagenesis). 
To try and see if either of these sites were occupied by Pax3 in vivo, and support the 
findings of Chapter 4 as potentially biologically significant (rather than an artefact of 
the Luciferase assay system), ChIP using the Pax3 antibody and primers specific to 
these regions was also performed. 
ChIP: technical considerations 
To examine the role of Pax3 or Msx2 in the transcriptional contexts described above 
and in previous chapters, it was necessary to utilise the correct embryonic tissues. The 
role of Pax3 in regulating Wntl transcription has been hypothesised to occur during 
the development of the murine neural tube, when both Pax3 and Wntl are being 
expressed, see Chapter 1. Similarly, any interaction between Msx2 and the Wntl locus 
is hypothesised to occur in the developing cardiac neural crest, also found within and 
around the dorsal neural tube. Finally the interaction between Pax3 and the Pax7 
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locus has been hypothesised to be in both the somitic mesoderm, limb bud and neural 
tube. Embryos were collected at E10.5, and the neural tube, forelimb bud and 
mesoderm dissected as shown in figure 6.3A. Care was taken to remove 
telencephalon and any tissues caudal to the forelimb bud. E10.5 is a little late to 
isolate tissues containing migrating neural crest cells. However, one of the major 
technical difficulties in performing in vivo ChIP is obtaining enough starting material 
to generate an amplifiable pool of DNA fragments at the end of the procedure. Trials 
with embryos from ages ranging from E8.5 to E12.5 were initially performed. The 
most reliable ChIP fractions (generating consistently strong positive control PCR 
products for all amplicons described below) were generated by embryos at E10.5. 
Since it was felt that a compromise had to be made experimentally between embryo 
age and reproducibility of data, E10.5 embryos, dissected as shown, were used in the 
following ChIP assays. 
The sonication of genomic DNA to the correct size is an essential stage in the design 
and implementation of ChIP experiments. Figure 6.3B shows the optimisation of 
sonication conditions. The left panel represents DNA extracted from E10.5 dissected, 
disassociated and fixed embryos which were then sonicated under a range of 
conditions. Conditions which favoured the generation of fragment sizes between 
500bp and 1kb were used in all following experiments and example sonications can 
be seen from four embryo preparations in the right panel. This average size of DNA 
fragment length is large enough to enable all of the ChIP PCR reactions to amplify 
(product range between 282 and 595bp) but small enough to ensure that the two 
amplicons cannot fall entirely on the same fragment (minimum distance between 
A 
Figure 6.3: 
A) Image of an E10.5 embryo showing 
locations of dissection when preparing 
sample for ChIP analysis (red lines). 
Mid / Forebrain and regions below the 
forelimb bud were discarded. 
B)Agarose gels to illustrate the 
optimisation of sonication conditions to 
generate genomic DNA fragments of 0.5 
- 1kb. Left panel shows initial 
optimisation of conditions for fixed, 
embryonic chromatin. Bar indicates 
increasing sonication power, U denotes 
un- sonicated chromatin. Right panel 
illustrates sample sonicated chromatin 
showing required fragmentation in four 
samples. Red line denotes 1kb level. 
U 
1 2 3 4 
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amplicons is 2.127kb on the Pax7 locus) thus preventing a false positive signal due to 
fragment co- purification. 
Pax3 interacts with the Wntl proximal promoter in vivo 
Chapter 3 provides strong evidence from both QRTPCR in vivo and Luciferase co- 
transfection assays in vitro that Wntl represents a direct target of Pax3 regulation. 
Furthermore this interaction appears to be mediated via a Pax3 consensus binding 
site, identified by bioinformatic analysis and confirmed with mutagenesis, in the Wntl 
proximal promoter region. To test occupancy of this site in vivo ChIP assays were 
performed as described. Primers were designed to amplify the Wntl genomic locus at 
either the 5' proximal promoter region (a 541óp product flanking the Pax3 consensus, 
primers W1_ PROM_ CHIP_ FWD /REV) or the 3' distal enhancer (a 282bp product 
containing the 110bp conserved element and the Msx2 consensus binding site, primers 
W1_ENHAN_CHIP_FWD /REV). These sites are separated by 8.789kb of genomic 
DNA and therefore are unlikely to be contained on the same sonicated fragment. An 
illustration of the Wntl genomic locus, showing exons, Pax3 consensus and primer 
binding sites (labelled W1P and W1E respectively) is illustrated in Figure 6.4A. 
The ChIP output for this experiment can be seen in Figure 6.4B. Input control was 
positive, indicating both fragments are present and competent to be amplified from 
the pre -IP pool of DNA and no antibody control negative, indicating that any bands 
observed are due to specific antibody binding during the IP. A clear positive signal is 
observed for three different wild type E10.5 dissected embryos, showing Pax3 is 
W1P 
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A Genomic Wnt1 locus showing 
ChIP primer binding sites, and 
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B) PCR products of anti -Pax3 ChIP 
using primers specific to the Wnt1 
locus. Wnt1 promoter positive in all 
three experiments, confirming 





bound to the Wntl promoter region and not the distal enhancer at this stage in 
development an in these tissues. 
This enables the conclusion that Pax3 mediates the transcriptional upregulation of 
Wntl in vivo via the 5' proximal promoter and the Pax3 consensus site described and 
in agreement with hypothesis one. 
Msx2 may associate with the Wntl locus in vivo 
Chapter 3 also provides evidence that the Msx2 transcription factor may mediate the 
repression of Wntl transcription through the binding of a consensus site in the 3' 
distal enhancer. These experiments were conducted in response to a study performed 
by (Kwang et al., 2002) where the misregulation of Msx2 in the Pax3 homozygous 
mutant was shown to be responsible for the cardiac phenotype observed in these 
animals. Given the importance of the Wnt - Dvl2 pathway in the development of the 
cardiac outflow tract in a second series of studies (Hamblet, 2002), it was postulated 
here that the Wnt signal involved could be Wntl, and that the expansion of Msx2 
expression in the Splotch mutant was able to repress Wnt1 expression in these 
migratory cardiac neural crest. To test this hypothesis, the cis -regulatory elements of 
Wntl were tested in co- transfection assays with an Msx2 expression construct. A 
repressive activity of Msx2 was observed in association with the Wntl 3' distal 
enhancer. This was mapped with deletion and transposition constructs to a region of 
the enhancer containing a highly conserved 110bp element and an Msx2 consensus 
site. 
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To test occupancy of this site in vivo, ChIP assays were performed on three wild type 
E10.5 embryos, dissected as described. Identical conditions and PCR primers to those 
used to test the occupancy of Pax3 in the Wntl promoter were employed here. These, 
and the position of the Msx2 consensus site, are illustrated in Figure 6.5A. The 
Msxl /2 antibody obtained from the DSHB was used in the IP stage of these assays. 
Figure 6.5B illustrates the ChIP output for these experiments. Unfortunately, whilst 
the positive and negative controls were correct, the ChIP assays themselves did not 
give a consistent or easily interpretable result. Two of the embryos assayed gave 
positive signals for both the promoter and the enhancer, whereas the third gave no 
signal at all. There are several ways in which to interpret this data. Firstly it is 
possible that the experiment simply did not work properly and has simply given 
random signals. More repeats are necessary to determine if this is the case. Given that 
the Pax3 ChIP worked consistently under identical conditions for this locus other 
possible causative factors are considered. Assuming that the third embryo examined 
simply did not work the presence of bands in both the promoter and enhancer lanes 
may suggest a number of other outcomes. It is possible that Msx2 is binding to one or 
other region of the Wntl locus, but the sonication did not separate the two fragments 
efficiently or these regions were in close physical proximity and were bound together 
during the formaldehyde treatment. Since this was not the case for the Pax3 ChIP 
illustrated in Figure 6.4 using identical source tissues and cross linking conditions, 
this would seem improbable. It is possible that Msx2 was bound to both the promoter 
and enhancer regions in these tissues, although the lack of in vitro response from the 
Wntl promoter fragments to the Msx2 protein would argue against this. One major 
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this cannot differentiate between the binding of either protein to the Wilt/ regulatory 
elements, and may account for the observed result. Further investigation is obviously 
required, perhaps using a mono -specific antibody or site directed mutagenesis of the 
Msx2 site within the Wntl enhancer. It is tentatively concluded that Msx2 is found in 
association with the Wnt1 locus in vivo, although the precise position of this 
interaction is unclear. This is therefore in partial agreement with second hypothesis 
presented in this thesis, although much further work is required. 
Pax3 binds to the Pax7 I1 R element in vivo 
Chapter 4 presents data which both establishes two regulatory elements potentially 
controlling Pax7 expression in the mouse genome, and presents data that Pax3 may 
interact with one or both of these elements to regulate the transcription of Pax7 in 
vivo. Luciferase assay experiments investigating the interaction of Pax3 with either 
the Pax7 proximal promoter (as established by activity in the C2C12 cell line and by 
(Lang et al., 2003)) or the I1R silencer revealed that both elements were required to 
generate a response in vitro. The mutagenesis of a Pax3 binding site consensus in the 
Pax7 proximal promoter region did not abrogate this effect (in contrast to the Pax3 
binding site in the Wntl promoter) indicating that the interaction was not mediated 
through that site. 
To examine if Pax3 does indeed interact with the Pax7 locus in vivo, and whether the 
interaction is through the promoter or IIR silencer element, ChIP was performed on 
the Pax7 locus on dissected E10.5 mouse embryos. Primers were designed to amplify 
a 595bp region of the Pax7 promoter (primers P7_PROM_CHIP_FWD /REV) or a 
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546bp region of the Pax7 intron 1 silencer (P7_INTRON_CHIP_FWD /REV). The 
Pax7 genomic locus with these primers positioned and showing the first three exons, 
Pax3 consensus binding site and IIR element can be seen in Figure 6.6A. 
ChIP assays were then performed using the Pax3 antibody described in Chapter 5 on 
three wild type embryos; the positive and negative controls were correct in each case. 
Figure 6.6B illustrates that the ChIP assay repeatably enriched for fragments carrying 
the IiR element and not the Pax7 proximal promoter or Pax3 consensus site. This 
confirms the mutagenesis result, and suggests that Pax3 is interacting with the Pax7 
locus via the I1 R silencer element in vivo. 
Whilst this result enables hypothesis three to be partially accepted this, and the work 
described in this thesis, does not fully resolve whether Pax3 is acting to repress as 
suggested by (Borycki et al., 1999), de- repress as suggested by Chapter 4's Luciferase 
data, or do nothing at all as suggested by (Relaix et al., 2004) the Pax7 gene. The 
occupancy of a site within a highly conserved element of apparent regulatory function 
would argue against Pax3 paying no role whatsoever in the transcription of Pax3. It is 
possible that the de- repression observed in Chapter 4 reflects an artefact of the 
Luciferase assay whereby the absence of Pax3 co- factors, usually present in vivo, 
enables the Pax3 transcription factor to mediate an unusual effect. Since Pax3 carries 
domains for both transcriptional activation and repression of target genes (Chalepakis 
and Gruss, 1995; Lang, 2005)) an observation of this nature in vitro would not be 
entirely unsurprising. This would not be in keeping with the clear up- regulation of 
Pax7 protein observed from C2C12 cells transfected with increasing quantities of 
Pax3, shown in Figure 4.15. Clearly further work, to resolve this issue in vivo and to 
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map the binding of Pax3 to the I1R element precisely, is needed. Given the role Pax7 
plays in both embryonic development and adult stem cell derived muscle regeneration 
in the adult, a greater understanding of Pax7 regulation may also be of therapeutic 
value. 
Conclusions 
In the above chapter a series of ChIP experiments, bringing together and testing the 
observations made in the Chapters 3 and 4 with the antibody designed and described 
in Chapter 5, are described. Pax3 has been shown to associate with the Wntl promoter 
and the Pax7 I1R silencer in vivo, via a defined and as yet undefined binding site, 
respectively. Msx2 may have some association with the Wntl locus in vivo, although 
the data presented here is inconclusive and much work remains to be done to 
complete this analysis. Importantly, the above data validates the use of the Pax3 
antibody with in vivo ChIP and paves the way for the use of these tools for a high 
level analysis of Pax3 function in development. 
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Chapter Seven: Discussion 
In this thesis a series of direct transcriptional interactions were postulated from 
published studies on Pax3. Methodologies to test these interactions were developed 
for in vitro and in vivo analyses. In the post -genomic era it is increasingly important 
to dissect precisely the genetic interactions involved in biological processes. 
Transcription is one of the first lines of regulation between the information encoded 
within the genome and the translation of that information into biochemically active 
material. It is essential that this process is studied in detail and that gene regulatory 
networks and relationships are reliably established. 
The process of transcription transfers coding sequences in DNA to an RNA format 
that is then translated into protein by the cellular ribosomal machinery. The RNA 
polymerases and factors constituting the general transcriptional holoenzyme are the 
same irrespective of gene, cell type, tissue, or even organism (Ayoubi and Van den 
Ven, 1996). The proteins that recruit the polymerases to the correct position on the 
genome are myriad and form one of the major regulatory points in this process. These 
transcription factors bind to specific sequences in the cis -regulatory regions of genes 
and mediate their upregulation (i.e. recruitment of the polymerase machinery and /or 
chromatin remodelling factors) or inhibition depending on their precise biological 
context. One of the problems faced in experimental biology is that the techniques 
used to examine such protein - DNA interactions precisely in vitro are often difficult 
to confirm in an in vivo context. A relationship observed with in vitro techniques will 
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not necessarily be borne out in an in vivo setting, nor is an in vivo approach always 
practical when examining relationships of this kind experimentally. 
In this thesis, the developing mouse embryo was used as a model system to examine 
transcriptional interactions between Pax3 and its targets. An in vitro approach was 
used in the first instance to map these interactions precisely. This was then followed 
by ChIP to confirm these interactions in vivo. It is hoped that this technique could 
then be applied to other Pax3 - target interactions, or even be scaled up to scan the 
mouse genome for equivalent sites demonstrating Pax3 binding in vivo to enable a 
fuller understanding of this important gene's function in development. 
Pax3 and Wntl 
Chapter 1 outlines some of the developmental roles Pax3 is known to have in the 
developing mouse embryo. One of the earliest post -gastrulation events is the 
induction of cells fated to become the nervous system from the ectoderm, known as 
neurulation (see (Copp, 2003) for review). Pax3 is intimately associated with this 
process, and the expression of this gene in the developing neuroectoderm is one of the 
earliest observable markers of the future spinal cord (Bang, 1997; Goulding et al., 
1991). The roles of Pax3 in the development of these tissues are varied, and much 
work has been done to characterise the effects of both Pax3 overexpression 
(Tremblay et al., 1996) and mutation (see (Epstein et al., 1991; Epstein, 1996) and 
references within Chapter 1 for overview). Assaying the direct targets of Pax3 is 
important when considering the role of this factor in development. This will also 
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enable the separation of direct and indirect effects of Pax3 when manipulating this 
factor in these systems. 
Wnt signalling is also fundamental to the patterning of the developing embryo, and 
several Wnt genes are expressed in the developing nervous system (Miller, 2001; 
Parr, 1993). Whilst Wnt8 has been shown to be one of the inductive factors 
establishing Pax3 expression in the developing neural folds (Bang et al., 1999) the 
expression of Wntl in the neural tube has been shown to be follow Pax3 temporally 
(Deardorff, 2001) and the expression of neural crest cell marker genes, such as slug, 
has been shown to depend upon a Pax3 mediated Wnt signal (Monsoro -Burq, 2004; 
Sato, 2005). The observation that Wntl expression levels are reduced on a Pax3 null 
background (Conway et al., 2000) but that Pax3 expression levels remain unchanged 
on a Wntl mutant background (Ikeya et al., 1997) suggest that Pax3 is genetically 
upstream of Wntl and led to the investigation of the following hypothesis: 
Hypothesis One 
Pax3 up regulates Wntl transcription directly, probably through the 3' distal 
enhancer region, in vivo during the development of the neural crest. 
This hypothesis was tested in Chapters 3 and 6. In Chapter 3 this problem was 
initially addressed by sub -cloning the 5.5kb 3' distal Wntl enhancer, first defined as 
necessary and sufficient to recreate the Wntl expression pattern in the developing 
mouse CNS by (Echelard et al., 1994) into a series of Luciferase reporter constructs. 
An interaction between the 3' distal Wntl enhancer and Pcr.r3 could not be detected. 
210 
Bioinformatic analysis had identified a Pax3 consensus within the Wntl 5' proximal 
promoter region. Despite the inability of the Wntl proximal promoter to drive reporter 
gene expression in a faithful reproduction of the Wntl expression pattern in the 
mouse, this region of DNA has been shown to be important in a regulatory context 
(Lagutin et al., 2003). The 5' proximal promoter was then also cloned into a 
Luciferase reporter construct and shown to be Pax3 responsive. Deletion studies 
confirmed that this interaction was mediated by a region of the Wntl promoter 
carrying the Pax3 consensus site. The specifity of this interaction was finally 
confirmed by site directed mutagenesis. 
These experiments illustrated that Pax3 was competent to up- regulate the 
transcription of a reporter gene under the control of the Wntl 5' proximal promoter. 
To confirm this interaction in vivo, ChIP was conducted using an antibody designed 
specifically for this purpose. This experiment confirmed the occupancy of Pax3 
specifically on this region of mouse genomic DNA, and not on the distal 3' enhancer. 
This enables hypothesis one to be concluded, with the modification that Pax3 is 
binding to the proximal promoter and not the distal enhancer element of this gene. 
This result sits well with previous studies examining the roles of these genes in the 
development of the neural tube and induction of neural crest. A model of the proposed 
interactions can be seen in Figure 7.1 (Brault et al., 2001; Dickinson et al., 1994; 
Ikeya et al., 1997; Monsoro -Burq, 2004; Sato, 2005; Serbedzija and McMahon, 
1997). Whilst other factors must clearly regulate the expression of Wntl in addition to 
Pax3 (i.e. Msxl (Lallemand, 2003; Monsoro -Burq, 2004), or WiF (St- Arnaud and 
Moir, 1993)), the above data in conjunction with the observed reduction of Wntl 
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expression by around 40 (Chapter 3) - 50% (Conway et al., 2000) on a Pax3 null 
background clearly implicates Pax3 as an important regulator of Wntl expression in 
vivo. 
Only one study to date, (Burstyn- Cohen, 2004), has cited evidence that Wntl may lie 
upstream of Pax3 in the chick. The data presented by this group does not differentiate 
between specific Wnt signals, however, and has only demonstrated that Pax3 is 
downstream of a canonical Wnt signal. Since Pax3 has been shown to be induced in 
the neural plate by Wnt8 in previous work in Xenopus (Bang et al., 1999), and given 
that the rostrocaudal wave of Pax3 expression is widely held to precede that of Wntl 
(see (Deardorff, 2001) for a time course analysis of dorsal neural tube markers in 
Xenopus), the role of Wntl as an inducer of Pax3 expression in the neural tube seems 
unlikely. 
When a Wnt/-LacZ transgene was crossed onto a Pax3 null background a clear loss 
of migrating LacZ positive neural crest cells was observed (Serbedzija and McMahon, 
1997). The possibility that a Pax3 - Wntl interaction may play a role in events after 
the induction of the neural crest population was also considered. Mice carrying a 
mutation in the Dv12 gene (Dv12 is a downstream component of both canonical and 
PCP Wnt signalling pathways) share an identical cardiac neural crest phenotype to 
Pax3 mutant mice (Briata, 2003; Clevers, 2002; Hamblet, 2002; Kioussi, 2002). This 
places Wntl in an attractive position to act as the Wnt signal in this process. This 
would also link the Pax3 and Dv12 cardiac outflow tract phenotypes with a common 
mechanism. A mutation in Pax3 would reduce the expression of Wntl in cardiac 
neural crest, thus inhibiting signalling through the Wnt /Dv12 /Pitx2 pathway and 
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generating a cardiac outflow tract phenotype. Another interesting feature of this 
pathway is the partially non -cell autonomous nature of the Sp'H cardiac phenotype 
(Chan et al., 2004; Conway et al., 1997a; Mansouri et al., 2001), again implicating a 
secreted signal such as Wntl in the development of these tissues. Finally, one group 
has noted in cardiac neural crest ablation experiments that defects in the developing 
chick heart actually begin to manifest whilst the migrating cells would still be 
populating the pharyngeal arches (i.e. before reaching the heart) (Waldo, 1999). One 
of these defects was in Ca' transients, a measure of excitation - contraction coupling, 
and is a phenotype also observed in Pax3 mutant embryos (Creazzo, 1998). Wntl , 
signalling via (3- catenin, has also been shown to regulate the expression of the 
connexin43 gene (critical in the formation of gap junctions in the heart which mediate 
the electronic coupling in cardiac tissues) (Zhaowei, 2000). Wnt1 -cre targeted 
inactivation of 13- catenin also generates defects in neural crest derived structures and 
cell survival (Brault et al., 2001). It is tempting to speculate that Wntl, as a target of 
Pax3 and signalling via (3- catenin, mediates these effects in vivo. 
Msx2 and Wntl 
To establish a role for Wntl as a possible effector of Pax3 function during cardiac 
development the findings of (Kwang et al., 2002) needed to be addressed. In this 
study Pax3 was shown to negatively regulate the Msx2 gene in the neural crest. In the 
Sp'H -I- mouse, the Pax3 null phenotype generates an expanded expression domain of 
Msx2 at the level of the post -otic neural tube (the area from which the cardiac neural 
crest originate (Chan et al., 2004)). This upregulation of Msx2 on a Pax3 null 
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background was shown to be causative in the development of the Splotch cardiac 
phenotype, since a double Msx2 /Pax3 homozygous mutant genotype rescues this 
defect specifically. It was reasoned that if Wntl is also an effector of Pax3 signalling 
in the development of the cardiac neural crest, Msx2 should act to downregulate Wntl 
expression. 
Therefore hypothesis two was also investigated: 
Hypothesis Two 
Wntl transcription is directly downregulated by Msx2, most probably by the distal 3' 
enhancer element, in vivo with implications for the normal development of the 
cardiac neural crest. 
To investigate this hypothesis the Msx2 protein was co- expressed in a series of 
Luciferase transfection experiments, and a responsive element mapped to a region of 
the Wntl enhancer containing a highly conserved 110bp sequence (first defined as 
necessary and sufficient for LacZ transgene expression in the Wntl domain of the 
mouse midbrain (Rowitch et al., 1998)) and an Msx2 binding site (Chapter 3). 
Unfortunately, mutational analysis of this site was not performed and the information 
obtained from a series of ChIP experiments using the DSHB Msxl /2 antibody was 
inconclusive (Chapter 6). It was tentatively concluded that Msx2 might associate with 
the Wntl locus in vivo, but more experiments are required to confirm this association. 
Also, ChIP experiments using both a specific Msx2 antibody and possibly using 
isolated neural crest cells would help to clarify this result. 
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The hypotheses outlined above were designed to identify and test possible direct 
interactions between Pax3 and target gene cis -regulatory sequences both in vitro and 
in vivo. The developmental systems outlined above and in Chapter 1 are presented as 
a relevant context for these interactions. To understand what the relationship between 
Pax3, Wntl and Msx2 may be functionally during development, the data described 
here can now be used to design specific transgenic experiments (for example the 
mutation of the Pax3 binding site in the Wntl promoter in a transgenic line, or 
assaying for a rescue phenotype if the Pax3 gene is expressed under the control of the 
Wntl regulatory elements on a Sp'" -I- background) to test these relationships further. 
Pax3 and Pax7 
Another developmental system was chosen for the second candidate target of Pax3 
regulation. The controversy over the role which Pax3 may play in the regulation of 
Pax7 is described in Chapter 1 (see (Borycki et al., 1999; Relaix et al., 2004)). To test 
any possible direct regulatory interaction between Pax3 and its sister Pax family 
member a similar approach to that outlined for Wntl was adopted, see Chapter 4. 
Beceause regulatory regions for the Pax7 gene had not been described for the mouse 
the identification of these regions formed the initial part of the investigation into this 
candidate target. 
Three techniques were used to try and position putative Pax7 promoter regions on the 
basis of the size and sequence of the Pax7 5'UTR. All techniques converged on a 
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5'UTR of around 100bp of upstream genomic sequence, which was consistent with a 
paper published subsequently on the mouse Pax7 promoter. This study evidenced a 
5'UTR of 73bp although the PEXT gel presented by this group does indicate faint 
bands at higher and lower molecular weights (Lang et al., 2003). One interesting 
exception in my data was the presence of consistently larger PEXT products, 
indicating a second transcriptional start site at a different location for the mouse Pax? 
gene. Studies in human (Syagailo et al., 2002) have also reported a larger 5'UTR 
(- 650bp), and the methods presented in (Lang et al., 2003) may have missed a larger 
PEXT product for technical reasons (running the PEXT products on a sequencing gel 
may mean larger ( >500bp) fragments do no resolve). 5'RACE may not have 
amplified these larger fragments due to technical issues with the PCR and cloning 
basis of this protocol and the CG and repeat rich nature of the genomic sequence in 
question. The lack of confirmation of these larger fragments by RPA is puzzling; this 
may indicate the presence of an upstream exon in the mouse Pax7 gene outside of the 
region covered by the RPA probe. It is interesting to note that, of the six studies to 
date characterising the mouse and human Pax7 5'UTR's, no definitive consensus on 
the transcriptional start has been reached. It is possible that a defined start site may 
not exist for this gene. The existence of promoters with multiple transcriptional start 
sites has long been accepted and may even be of regulatory importance (see (Ayoubi 
and Van den Ven, 1996) for review). Of the LacZ reporter transgenics reported in 
(Lang et al., 2003), even those containing 10kb of genomic sequence upstream of the 
Pax7 transcriptional start did not fully recreate the Pax7 binding pattern. This implies 
that additional regulatory elements to those reported here and in (Lang et al., 2003) 
must be involved in the regulation of this gene. It is possible the larger PEXT product 
observed here can be explained in this manner. Perhaps the PIPMaker alignment 
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output, shown in Appendix 3, could be used as a starting point to identify regions of 
putative regulatory importance. 
The I1R silencer within intron 1 was also reported by (Lang et al., 2003) although this 
element was not isolated and tested. Interestingly, they report that, in transgenic mice 
carrying both the I1R element and 4kb of proximal Pax7 genomic sequence, the I1R 
silencer seems to act as a pons- specific enhancer with respect to LacZ staining. 
Once candidate regulatory regions for the Pax7 gene had been described the 
following hypothesis was investigated: 
Hypothesis Three 
Pax7 is directly downregulated by Pax3, in vitro and in vivo, via defined regulatory 
elements and with implications for the development of both neural and mesodermal 
tissues. 
In this study we cloned a minimal Pax7 promoter, restricted to 1.5kb by activity in 
C2C12 cells, and the I1R element both individually and together in a series of 
Luciferase reporter constructs. These were co- transfected with Pax3 to test the above 
hypothesis. It was discovered that both elements were required on a reporter construct 
to elicit a response to Pax3. This response was a de- repression of the I1R silencing 
activity of the Pax7 promoter observed for these constructs in vitro. This relationship 
was unexpected since, if any regulatory interaction existed between Pax3 and Pax7 at 
all, it had been proposed to be negative (Borycki et al., 1999). Mutagenesis confirmed 
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that the Pax3 response was not via a Pax3 consensus in the Pax7 promoter region, 
and ChIP indicated that Pax3 bound the I1R element in vivo. These data confirm that 
Pax7 is a direct target of Pax3, but imply a positive relationship which is at odds with 
one published account of Pax7 expression on a Pax3 null genotype (Borycki et al., 
1999). Future work should map this Pax7 binding site on the I1R element precisely 
through mutagenesis, and then a transgenic approach should be adopted to interpret 
the developmental significance of this. QRTPCR was attempted for Pax7 between 
wild type and Sp2H -/- embryos, but a consistent result could not be obtained despite 
several attempts (data not shown). Recent work identifying a Pax3 and Pax7 
dependant population of skeletal muscle progenitor cells highlights the importance 
these genes have in adult muscle regeneration (Relaix, 2005). Establishing a 
regulatory interaction between these factors may therefore be significant in this 
context. 
Pax3 ChIP: future directions 
The establishment of direct vs. indirect targets for the action of Pax3 and other 
developmentally important transcription factors is essential in the interpretation and 
investigation of the function of these genes in vivo. Previous attempts have been made 
using a microarray approach (Mayanil et al., 2001) to screen for candidate targets of 
Pax3. The inability of these techniques to differentiate between primary and 
secondary effects of Pax3 function make the meaningful interpretation of these data 
difficult. 
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It is intended that the ChIP technique designed in this thesis may be used as a way of 
rapidly testing direct functional relationships between Pax3 and potential target genes 
in vivo. In addition to testing specific DNA - protein interactions, ChIP can be used in 
combination with genome wide arrays or CpG island arrays to screen for sites of 
direct transcription factor occupation (Buck, 2004; Hanlon, 2004; Weinmann, 2002). 
This approach, whilst relatively new in mammals due to limitations in the microarrays 
and bioinformatics available, has been used with great success in yeast (Lee, 2002; 
Lieb, 2001; Ren, 2000a). It is hoped that the validation of ChIP in mouse embryonic 
tissues described here will be used in future to screen for direct transcriptional targets 
of Pax3 during development. 
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Appendix 1: Constructs and cloning strategies 
Plasmid Name Cloning Strategy Outline 
pP3IRESEGFP / 
pP3IRES 
RTPCR from E10 RNA using Primers 3/5 
P3IRES, topo cloned and then shuttled using 
the Sacll -BamHl sites form the primers into 
pIRES -2 -EGFP (Clontech) 
pW1 ELuc 
Wnt -1 enhancer plasmid (McM -pWEXP3) 
Bglll fragment of 5.4kb using a Bglll / Sall 
double digest and then cloned into 
pGL3Promoter (Promega) BamHl site. 
pW1 PLuc 
pMT86 (JOM) digested with BamHl /Ncol to 
generate 4.89kb promoter fragment. This 
cloned into pGL3Basic BgIII /Ncol sites. 
pP7HYB 
PAC Library Pax -7 promoter screen. Human 
DNA amplified using P7HYB1L / 2R primers, 
520óp product topoisomerased into vector. 
pP7Probe 
PCR topo clone using P7RT1I /R primers to 
generate 770óp product (across the CpG 
island of Pax -7 5' proximal region) 
pCMV -Pax -3 pP3IRES 
(Sacll - BamHl) into pCMV- Script 
(stratagene) (Sacll - BamHl). 
p3.5TOPO 
Pax -7 promoter fragment TEPCR cloned 
from 14 PAC and crystal violet extracted 
before topoisomerasing into pCR -XL -TOPO 
(invitrogen). Hindlll screened to check 
orientation. 
pP7P -EGFP See Step 1, above. 
pP7RiboProbe 
Take pP7Probe and clone a 686óp Pax -7 
promoter fragment using Asp718 - Fspl and 
insert into pBSII(KS) with Asp718 - EcoRV. 
BamHl or Hindlll can be used to linearise at 
either end (or double to confirm fragment) to 
synth. riboprobe from with T3 or T7, 
depending on sense or antisense being 
required. 
p3.OLuc 
p3.5TOPO (BamHl- Fspl) -take 2.8kb frag 
into pBSII(KS) (BamHl- EcoRV) to create 
pintermediatel (below) and then digest 
pintermediatel with Sacl - Xhol - Fspl triple, 
extract the 2.9kb frag and insert into 
pGL3basic (promega) via Sac! - Xhol. NB. 
p3.0Luc called p3.5Luc in earlier notes, re- 
named to be more accurate. 
pintermediatel See above 
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p1.5Luc 
Take p3.0Luc, digest with Asp718, excise 
1.404kb frag of upstream promoter, re- ligate 
backbone to generate p1.5Luc with proximal 
1.5kb of Pax -7 promoter. 
p- 1.8Luc 
Take p3.0Luc, digest with BgIII, excise 
1.755kb of Pax -7 promoter proximal to ATG 
of Luciferase. Re- ligate backbone to 
generate Luciferase construct with distal 
1.8kb of Pax -7 promoter (deleted in pl .5Luc) 
controlling Luciferase. 
pl1 RLuc 
TEPCR PAC DNA using P7INT1 REGF /B, 
generate 546bp, digest frag with BamHl 
(sites in primers), clone into BamHl site of 
pGL3Promoter (both orientations, orientation 
screen performed by Sacl / Apal / Xbal triple 
digest) 
p1.511RLuc 
TEPCR PAC DNA using P7INT1 REGF /B, 
generate 546bp, digest frag with BamHI 
(sites in primers), clone into BamHl site of 
p1.5Luc (both orientations, orientation 
screen performed by Sac! / Apal / Xbal triple 
digest). 
pW1 P(1.2)Luc PW1 
PLuc, Asp718 digest to delete the distal 
3.5kb of Wnt -1 promoter 
pW1 P(- 1.8)Luc 
pW1 PLuc, Apal digest to delete the proximal 
3.0kb of Wnt -1 promoter (mis- named) 
KEEPS 250óp upstream of ATG so a better 
plasmid than p(- 1.8)Luc which only keeps 
50óp 
pP7SP6RiboProbe 
pP7RiboProbe, BamHl- Hindlll extraction of 
686bp frag and then cloning into pGEM -3ZF 
using BamHl- Hindlll. Linearise with BamHl 
later for SP6 transcription of riboprobe for 
RPA 
pCMV -MSx2 
Ordered from HGMP, seq to ensure full 
length cDNA and correct orientation wrt 
CMV prom (originally pCMV -Sport 
(Invitrogen ?) 
pW1 E(Bam)Luc 
pW1 ELucBF (BamHl) -fragment excised and 
vector re- ligated to make enhancer deletion 
construct 
pW1 E(Spe)Luc 
pw1 ELucBF (Spel) -fragment excised and 
vector re- ligated to make enhancer deletion 
construct 
pW1 E(Mbi)Luc 
pw1 ELucBF (Mbil), 816bp fragment carrying 
putative Msx2 response element excised 
and re- ligated into pGL3Promoter (Promega) 
Smal site and then screened for orientation 
using 
pW1 EPLuc 
pW1 P(1.2)Luc (Asp718 - Ncol), take 
1.236kb fragment, ligate into 
pW1E(Bam)Luc (Asp718 - Ncol) 7.937 
backbone fragment (loose 277bp containing 
the SV40 minimal promoter used in 
pGL3Promoter based vectors). 
pW1 PALuc 
Site directed mutagenesis of Pax -3 core 
consensus in the Wnt -1 promoter sequence 
on this plasmid. CTCGC - GATAA. 
pP7PALuc 
Site directed mutagenesis of Pax -3 core 
consensus in the Pax -7 promoter sequence 
on this plasmid. TCGC - ATAA. 
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Appendix 2: Primer List 
Primer Name Sequence (5' - 3') 
P3GENOF AAGCAGCGCAGGAGCAGAACC 
P3GENOR CCTCGGTAAGCTTCGCCCTCT 
W 1 LITEF CGCTCTCTTCCAGTTCTCAGACAC 
















CT - forward CTTTCAACCATCTCATTCCG 
W1 sub FWD 
CGGCAAGAGCCACAGCTTCGGATAACACTC 
- - ATTGTCTGTGGCCCTG 
W1 sub REV 
CAGGGCCACAGACAATGAGTGTTATCCG 




5'RACE (outer) CTGCCGAACCACATCCGTCACAAG 









P7 sub FWD 
AGTGTTTGTTTGTTTGAACTTCCTTGGATATACCTTC 
- - CACTCCTCCCGCCCC 
P7 sub REV 
GGGGCGGGAGGAGTGGAAGGTATATCCAAGGAA 
- - GTTCAAACAAACAAACACT 
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P7_PROM_CHIP_FWD CCCTCGCTTTTCCTCTTGTGTTC 
P7_ PROM_ CHIP_ REV GCCAAGAGGTTTATCCAGCCGA 
P7_I NTRO N_CH I P_FW D TTAGCCGCCCCTCTTGTCATTG 
P7_INTRON_CHIP_REV GAAAGTAAAGAGGGGGCGGTAG 
W1_ PROM _CHIP _FWD GGGACAGAGGAGACGGACTTC 
W1 PROM_ CHIP_ REV CATCACTGCCCTCACCGCT 
W1_ EN HAN_ CHIP_ FWD CGTCAGCCTGGATTAATCTTCG 
W1 EN HAN CHIP REV CGTTCACGTAGTGTCTCCCAA 
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Appendix 4: Luciferase Assay Data Treatment 
Luciferase transfections were performed as above using the Promega DLR Assay 
system and a TD -20/20 Luminometer (Turner Biosystems). There were two distinct 
types of Luciferase assay performed in this thesis. The nature and purpose of these, 
and the way in which the data has been processed in each case, are described here. 
Luciferase assays are transient transfection experiments where the expression of the 
Luciferase reporter gene can be used to infer the properties of various cis -regulatory 
elements in vitro. Whilst these methods generally involve plasmid DNA in secondary 
cell lines and are therefore not subject to all of the levels of gene regulation thought to 
occur in an in vivo context (i.e. chromatin remodelling, post -transcriptional 
modification, etc), the benefit of these methods is their rapid reproducibility and the 
chance to carefully dissect functional elements of non -coding DNA in much greater 
detail than would otherwise be practical. 
In this thesis all Luciferase assays were conducted as transfections in 24 well plates, 
using a final total of 1.51,1.g DNA in each well. This was to ensure no variability in 
transfection efficiency arose from different quantities of DNA in each experiment. 
Between two and four plasmids were simultaneously transfected into cells in any one 
transfection. In all cases a reporter vector, carrying the Firefly Luciferase ORF under 
the control of various pieces of DNA, was transfected simultaneously with an 
identical quantity of a second plasmid carrying a Renilla Luciferase ORF whose 
transcription is controlled by a known element (either the SV40 or Thymidine Kinase 
promoters). Both gene products are enzymes capable of metabolising specific 
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substrates with the concomitant production of light. In these assays the metabolite 
specific for the Firefly luciferase gene is added first, and the quantity of light 
produced over a fixed period of time (10 seconds) is measured by the Luminometer. 
The quantity of light produced is directly proportional to the quantity of enzyme 
produced, as predicted by Michaelis -Menten kinetics where rate, y, is related to 
concentration of enzyme by the relationship: 
V = Vmax[S] / Km+[S] 
where V,nax = k2.[Etotal], [S] = concentration of enzyme substrate, and k2 and K,,, 
represent kinetic constants. Where substrate is constant and in great excess (i.e. so 
O[S] --> 0 over the time course observed), increasing the concentration of enzyme 
([Etotai]) will increase the rate of reaction and therefore the quantity of light produced 
over a fixed period. A detailed derivation of this relationship can be found in (Price, 
2001). 
After the first measurement of light produced by the Firefly Luciferase has been 
made, the reaction in the sample is quenched chemically and a second substrate is 
added which is specific to the Renilla Luciferase enzyme. This activity is then 
measured in the same way. Since the first reaction is quenched before the second 
reading, two independent and specific Luciferase activity readings can be taken from 
the one sample. This is important since the second measurement of the Renilla 
Luciferase activity is made to control for the differences in transfection efficiency, 
cell lysis, etc which may vary. If the first reading increases by 50% between a treated 
and untreated sample, for example, and the second reading remains constant it is 
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assumed that the treatment has increased the transcription of the Firefly Luciferase 
gene by 50% through interacting with whichever DNA sequences are controlling its 
transcription. If both readings increase by 50 %, it is assumed that this change is due to 
differences in experimental conditions. 
The first Luciferase reading is therefore divided by the second reading to correct for 
this type of experimental variation and the resulting ratio, called normalised 
luminescence throughout, is taken as the real measure of variation between samples. 
Data is expressed as the mean value of several transfections. Each experimental run 
was performed in triplicate, to ensure each transfection was repeatable within a run, 
and then experimental runs repeated at least three times to generate data. Each reading 
on the Luminometer was also taken twice to ensure no variability in luminescence 
could be observed within the same sample over the time period assayed (i.e. that A[S] 
0 is true). 
In the first type of assay, the measurement of the basal activity of a putative promoter 
element is examined. In these assays normalised luminescence is measured for 
transfections where the Firefly Luciferase gene is placed under the control of a 
specific piece of DNA (such as the Wntl promoter). Two plasmids are co- transfected 
in each case (a test firefly Luciferase plasmid and a control Renilla Luciferase 
plasmid). Data is gathered for these transfections and expressed as fold induction. 
This is the number of times greater (or smaller) the normalised luminescence for these 
samples is over a baseline. In this case the baseline is defined as the normalised 
luminescence obtained for sample transfected with the Firefly Luciferase gene under 
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the control of the empty vector sequences (specifically the pGL3basic or 
pGL3promoter plasmids). 
In the second type of experiment the effect of co- transfecting an expression plasmid 
containing the ORF of a transcription factor of interest with plasmids containing the 
Firefly Luciferase gene under the control of specific regulatory element is performed. 
The normalised luminescence of samples transfected with differing ratios of 
expression construct to empty expression construct are compared. Three or four 
plasmids are transfected in each case; Firefly reporter, Renilla control, expression 
construct and /or empty expression construct to ensure the total quantity of DNA 
added remains constant (this is also to ensure a consistent amount of CMV promoter, 
driving expression of the transcription factor of interest, is added to prevent 
`squelching' or an expression data artefact due to competition of strong promoters for 
RNA polymerase machinery in the cell). In these experiments fold induction of 
normalised luminescence over baseline is generally reported. 
Occasionally, it was necessary to represent data as `indexed fold induction'. This was 
used to compare between samples where a direct comparison of fold induction was 
not possible. This was always for one of two reasons. Firstly, when considering the 
interaction of a transcription factor with either a promoter element or an enhancer 
element a meaningful comparison is impossible. This is because the two vectors used 
as baseline (pGL3basic or pGL3promoter, respectively) have very different inherent 
Luciferase activities. As a result, the actual numbers generated for fold induction are 
different. Secondly, when comparing effects of co- expression across a large data set 
or between different reporter plasmids of different sizes, the differences in absolute 
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value of fold induction was observed to vary, although the relative changes were 
similar. For example, one data set might generate a change in fold induction of 0.1 to 
10 whilst another might generate 10 to 1000. Clearly, the relative effect of treatment 
is identical, but an efficient comparison of the absolute values is impossible. Since all 
these experiments are concerned with the changes induced by co- expression of a 
particular cDNA, not the relationship to background observed in each separate 
experimental run, these data were indexed by setting the fold induction observed for 
the untreated sample (i.e., Ong pCMV -Pax3) at 1. In these cases, relative or indexed 
fold induction is reported (essentially the % change induced by a specific quantity of 
expression plasmid) to enable direct comparison. 
Finally, control experiments where pGL3basic and pGL3promoter empty reporter 
constructs were co- transfected with a range of quantities of pCMV- script, pCMV- 
Pax3 and pCMV -Msx2 expression constructs, using both pRL -TK and pRLSV40 
Renilla transfection control plasmids were performed. No change in baseline 
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